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Summary
The genomic integrity of a cell faces many challenges through various agents, that damage DNA
in many ways. Double-strand breaks (DSBs) are particularly serious as they can lead to gross
genome rearrangements, loss of heterozygosity and apoptosis. Depending on cell cycle stage and
availability of repair factors different ways exist in order to repair the breaks. One pathway is
homologous recombination, which uses sister chromatids as intact template for repair. In this
repair process the two homologous DNA strands are connected in a structure called Holliday
Junction (HJ), which has to be resolved before the cell divides. The resolution can be carried
out by structure-specific endonucleases, like SLX4-SLX1 and MUS81-EME1. These four proteins
form a complex (SM-complex) and resolve the HJ in a nick and counter-nick mechanism, where
SLX1 introduces the first cut and MUS81-EME1 introduces the second cut. SLX4 is a large
protein comprising several domains and serves as a platform protein interacting with several other
proteins involved in DNA repair or cell cycle control. So far it has not been fully understood,
how SLX4 coordinates the nucleases SLX1 and MUS81-EME1 on the HJ substrate. This study
presents a biochemical and structural characterization of the SM complex with a focus on the
SLX4SAP and MUS81 N-terminal domain. I could express and purify C. elegans SLX4SAP and
MUS81N from bacterial cells and by testing different DNA substrates, resembling intermediates in
double-stand break repair, I showed that both domains are promiscuous DNA binding domains.
DNA binding of ceSLX4SAP turned out to be in a cooperative mode, as has been reported also
for other SAP domains. Earlier studies showed that MUS81N and SLX4SAP interact with each
other. Here, the binding affinity between them could be quantified. The interaction with MUS81N
was abolished in a mutant of SLX4SAP, which also revealed a 3.5-fold reduced DNA binding. The
mutational analysis demonstrated that the interaction between the DNA-binding and the MUS81-
interaction area is only partially overlapping. The DNA binding site was further delimited by
shorter constructs. The systematical truncations revealed, that contrarily to expectations the
most conserved part of the SAP domain among several SLX4 orthologs was alone not sufficient
for DNA binding. In band shift assays with the SAP domain alone, residues from 467 to 560
were needed for DNA binding. Interestingly in complex with MUS81N the SLX4467-530 construct
showed stronger binding than the individual constructs. An NMR model of SLX4SAP could be
derived and was structurally compared to SAP domains from other proteins and displayed a high
flexibility at the C-terminus. Structural and biochemical comparison showed that SLX4SAP is a
typical SAP domain with hydrophobic residues between the helix-loop-helix fold and positively
charged residues with the invariant glycine in the loop region as well as cooperative DNA binding.
Based on the comparison with SAP domains from other proteins, the SLX4SAP is an important
component of the SM-complex for the stabilization of the interaction between SM-complex and
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DNA. Including the results in this thesis, the current model for HJ cleavage by the SM-complex
can be extended. While the first cut on the HJ is carried out by SLX1, SLX4SAP stabilizes the HJ
and interacts with the N-terminal domain of MUS81. This interaction and stabilization leads to
the second cleavage reaction carried out by MUS81-EME1. The involvement of two nuclease active
sites and several DNA-binding domains lead to the disentanglement of the HJ and contributes to
the genomic maintenance.
1. Introduction
1.1 DNA Damage and Repair
In every living organism, DNA with its four different nucleotides carries the genetic information
for the formation of proteins, cellular structures and whole organisms. It encloses the genetic code
for the development, functioning and survival of all known living organisms and many viruses.
Every time the cell divides, the DNA has to be duplicated in a process called replication and the
genetic information has to be preserved and passed on to the daughter cells. Defects in the genome
impair DNA metabolism, e.g. replication, transcription and recombination. Missing or defective
repair of the damage can lead to chromosomal rearrangements, fusion, deletion, mutations or
chromosomal loss. Various internal and external DNA damaging factors put the integrity of the
genome under pressure. This damage can sum up from 104 to 106 DNA damaging events per cell
per day [1]. Taken together, the stability of the cell’s genome faces many threats from endogenous
and exogenous sources and has to make sure each damage is repaired before the next cell division.
Endogenous sources for DNA damage can be reactive oxygen species or intermediate products
from metabolic processes (e.g. aldehydes), but also errors resulting from replication. Exogenous
sources are for example UV and X-ray radiation as well as chemotherapeutic drugs. The genomic
integrity is harmed on different levels by damage to the nucleobases of DNA (e.g. abasic sites,
mismatches, insertions / deletions, oxidative modifications, methylations), damage to the DNA
backbone (chemical adducts, single-strand breaks, double-strand breaks) and interstrand crosslinks
(ICLs) [1]. ICLs are characterized by covalent links between the bases on opposite strands, which
can lead to a blockage of replication. Additionally, protein adducts are another toxic DNA lesion,
which arise from the covalent linkage of proteins (e.g. topoisomerases) with DNA [3]. For each
type of DNA damage particular routes of repair have evolved, e.g. base excision repair, mismatch
repair, nucleotide excision repair, double-strand break repair (Figure 1.1 A) [1, 4, 5]. Multiple
pathways, dealing with a wide range of DNA lesions, have been characterized in the last decades
of DNA damage research and are reviewed in [1, 2, 4, 6].
The DNA repair pathways, forming the DNA damage response (DDR), are highly conserved
from bacteria to humans [7–9]. Together they prevent cell cycle arrest, apoptosis of cells and
uncontrollable cell growth (Figure 1.1 B). The cell cycle is divided in several stages, G1, S, G2
and M. The passage from one stage to the next stage is highly regulated and depends on cell
cycle checkpoints, which make sure that progression through the cycle is only occurring, when
certain conditions are fulfilled. Currently, three checkpoints are known, G1 checkpoint, G2/M
checkpoint and metaphase checkpoint, which all sense defects during the process, induce an arrest
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Figure 1.1: The complexity of DNA damage repair. (A) DNA damage is induced by various endogenous and
exogenous sources. Common exogenous DNA damaging agents are UV radiation, chemicals and chemothera-
peutic drugs. Endogenous damaging agents originate from the chemical instability of the nucleotides, cellular
metabolites and stalled replication forks. For the different lesions several pathways have evolved to counteract
the DNA lesions. For example base modifications, like 8-oxo-guanine arising from oxidation of guanine or uracil
emerging after cytosine deamination, are repaired by base excision repair. Stalled or collapsed replication forks
and ionizing radiation can generate strand breaks. (B) Adopted from [2]. Defects in the DNA can lead to a
halt at different cell cycle stages (G1, S, G2, M phases). Furthermore, DNA lesions defer DNA metabolism
and can lead to cell death, if replication and transcription can not be carried out in a timely manner due to
unresolved DNA lesion. Too many double-strand breaks can lead to apoptosis initiation. Increased apoptosis
can contribute to premature aging. On the other hand the development of cancerous cells is driven, if cells do
not undergo apoptosis and accumulate DNA errors. HR Homologous recombination; NHEJ Non-homologous
end joining; VDJ Variable diverse joining recombination during antibody diversification; BER Base excision
repair; SSBR Single-strand break repair; NER Nucleotide excision repair; TLS Translesion synthesis; MMR
Mismatch repair; ICL Interstrand crosslink
1.2 DNA Double-Strand Break Repair 5
and regulate the activity of cell cycle kinases, the cyclin-dependent kinases. Cyclin dependent
kinases ensure that all phases of the cell cycle are executed in the correct order. An erroneous
DNA repair can lead to a halt in cell cycle progression, which in turn means that the repair of DNA
lesions has to be carried out before the cell enters mitosis [10–12]. Cells have evolved complex
signaling pathways to arrest the progression of the cell cycle in presence of DNA damage, thereby
providing increased time for repair and tolerance mechanisms to operate [4, 7]. This has also an
effect on DNA metabolism and long-term DNA injuries lead to permanent changes in the DNA
sequence [2] (Figure 1.1 B).
To summarize, the DNA damage response is essential to prevent premature aging and the
development of cancer. Failures of the repair proteins can give rise to inherited disease, e.g.
Fanconi anemia (FA) [13, 14], Xeroderma pigmentosum [15] and Werner syndrome [16, 17]. In the
case of too many DNA lesions, cells in multi-cellular organisms initiate programmed cell death
and eliminate themselves from the population [4, 18].
1.2 DNA Double-Strand Break Repair
1.2.1 The Significance of Double-Strand Breaks
Double-strand breaks (DSBs) are one of the most deleterious type of DNA damage as they can
lead to disruption of genetic information and chromosomal aberrations, causing cancer. It was
demonstrated in yeast cells that even a single DSB left unrepaired could lead to cell death [19–
21]. DSBs can arise in various ways, including as a result of spontaneous acts like the collapse
of stalled replication forks during S phase, exposure to DNA damaging agents and repair of
incomplete telomeres after failure of telomerases [5]. DSB repair is important for the repair of
replication-associated damage [22] and as a subsequent step in the repair of interstrand crosslinks
[23]. In any way, the repair of DSBs is highly regulated as the cell has to ensure that repair starts
at the right time, place and in the right manner. Furthermore, double-strand breaks do not only
arise from erroneous acts, but can also be programmed by the cell [24]. Programmed DSBs are
carried out in order to generate genetic diversity, which plays a role in meiosis and in the immune
system. During prophase of meiosis I programmed DSBs are produced by the protein SPO-11 [25–
27]. In meiosis I chiasmata are formed, which result from the crossing-over between homologous
chromosomes [28]. These physical attachments between homologous chromosomes are essential for
the accurate separation in meiosis I [28]. Without the formation of the chiasmata the chromosomes
can not be segregated properly leading to infertility and miscarriages in humans as well as birth
defects in newborns [29]. Hence, homologous recombination fulfills two functions in meiosis, it
generates genetic diversity among the progeny derived from common parents and ensures proper
chromosome segregation [5]. The vertebrate immune system employs V(D)J recombination to
rearrange variable (V), diverse (D) and joining (J) gene segments leading to diversification of
antigen-binding regions in the immunoglobulins and T-cell receptors [30]. In this process, the
lymphoid specific RAG (recombination activating gene) proteins initiate the recombination and
introduce a double-strand break at specific recognition sequences [30–33]. Furthermore, DSBs
are created during immunoglobulin heavy chain class switching [34]. In this process the constant
region of the antibody is changed in order to generate antibodies with different effector function
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[34]. Thereby, the exons encoding the initially expressed IgH constant region is replaced by a set
of downstream exons, which changes the antibody class from e.g. IgM to IgG1 [34].
Eukaryotic cells possess two major repair pathways for DSBs, non-homologous end joining
(NHEJ) and homologous recombination (HR) (Figure 1.3 A, B) (NHEJ reviewed in [35–37] and
HR is reviewed in [8, 12, 26, 38, 39]). Under certain conditions, DSBs can also be repaired
by microhomology mediated end joining (MMEJ) and single-strand annealing (SSA) [40]. The
pathways are complementary and operate optimally under different circumstances [41]. The single
steps involved in the DSB repair were described firstly by Szostak et al. [42]. In the following
subsection the DNA double-strand break repair will be outlined.
1.2.2 The Sensing of DSBs
In order to protect the cell from genome instability, DNA damage has to be sensed first. The
recruitment of the different DDR factors to the DNA lesion is initiated by sensor proteins, which
recognize the lesion and activate the DDR [7, 16]. Several factors influence repair options, e.g.
cell cycle (availability of homologs), extend of damage and availability of factors. Thus, the choice
of repair options is provided by the order and the timing of the recruitment [16]. In general, the
assembly of the DDR response depends on a broad spectrum of posttranslational modifications,
e.g. phosphorylation, ubiquitination, poly(ADP-ribosylation) and others [16].
Double-strand breaks are detected by at least four independent sensors: Ku70/80, PARP
(poly(ADP-ribose) polymerase), RPA (replication protein A) and MRN (MRE11-RAD50-NBS1)
[16], which decide about the exact DSB repair pathway being taken and the outcome of the repair
process.
DSBs are rapidly bound by the Ku70/80 heterodimer, which loads onto the DNA ends [16].
Yeast Ku is proposed to counteract and prevent extensive DNA-end resection, which favors NHEJ
[36, 43]. There is evidence, that the DNA damage response protein p53-binding protein 1 (53BP1)
can work together with the replication timing regulator factor 1 (RIF1) and both block end
resection [36, 44]. Thus, in G1 phase, NHEJ is favored by more than 50-fold for the repair of DSBs
owing to the level of Ku and the suppression of extensive end resection by CtIP (CtBP-interacting
protein; CtBP C-terminal binding protein) and MRN [36]. Even during S- and G2 phase the
resection machinery has to overcome the presence of Ku at DNA ends either by outcompeting Ku
or by processing of DNA ends to a point at which Ku binding is less favored [36, 45].
Members of the PARP family are activated by the DSB and catalyze the addition of poly-ADP-
ribose chains on proteins to recruit DDR factors to chromatin at breaks [16]. PARP promotes the
microhomology mediated end joining pathway, which is a backup to the classical NHEJ pathway
[16]. PARP is thought to mediate the initial accumulation of the MRN complex [16]. Limited
DSB resection then leads to association of CtIP in the MMEJ pathway [16].
The MRN-complex is recruited to the DSB at the beginning of the repair process and consists
of three proteins, MRE11 (meiotic recombination 11), RAD50 (radiation sensitive) and NBS1
(Nijmegen breakage syndrome 1). [46, 47]. MRN localizes at the DSB ends via RAD50 [48] and
maintains the tethering of the DSB ends to each other via the coiled-coil tails of RAD50 [49]. In
association with CtIP and BRCA1 (breast cancer associated gene 1), MRN mediates initial stages
of DSB resection to promote HR in S and G2 phase [16]. Extensive resection and formation of 3’
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ssDNA ends leads to RPA accumulation, which stabilizes ssDNA regions [16]. The formation of
RPA-ssDNA complexes plays and important role in the activation of the kinase pathway.
Following the recognition of the DNA lesion by sensor molecules in HR, the master response
is then the activation of the ATM (ataxia telangiectasia mutated) and ATR (ATM and Rad3-
related) proteins [46], whereupon ATM is primarily activated by DSBs and ATR responds to a
broad spectrum of DNA damage [46]. ATR and its partner protein ATRIP (ATR interacting
protein) is activated following recruitment to RPA-coated ssDNA regions at stalled replication
forks and DSBs [16]. The activation of ATM is regulated by MRN, where the NBS1 subunit
associates with ATM [16, 46]. ATM is proposed to phosphorylate mediator proteins, like CHK2
(Checkpoint kinase 2) and p53 as well as several other DDR factors [7, 16]. In the chromatin,
flanking the DSB, ATM phosphorylates histone variant H2AX [46]. The phosphorylated H2AX is
required for the accumulation of more DNA repair proteins and chromatin-remodelling complexes
around the DSB [46]. After the recruitment of the first DNA damage sensors, the decision between
various possibilities has to be made, e.g. apoptosis, immune surveillance or DNA repair [16].
1.2.3 Non-Homologous End Joining
In the decision for a repair of the DSB, there are different options for the repair pathway possible.
One pathway is the non-homologous end joining pathway (NHEJ), which mediates the direct
ligation of broken DNA ends and usually involves minimal DNA end processing [41] (Figure 1.2
A). In a first step the DNA ends are bound by the Ku70/Ku80 heterodimer, which recruits
and activates the (DNA-PKcs) [51] forming the DNA-PK complex. DNA-PKs stabilize the DSB
ends and prevent end resection [52, 53]. Through sequential phosphorylation events DNA-PK
is stabilized at the DNA ends and gives access to end processing enzymes, like ARTEMIS [16].
ARTEMIS will cut DNA substrates at the boundaries between single-stranded and double-stranded
DNA [36, 54, 55]. Another nuclease, which might contribute to the repair of DSBs, is APLF
(aprataxin and PNKP (Polynucleotide kinase/phosphatase)-like factor) [36]. DNA Polymerases
λ and μ of Pol X-family polymerases interact with Ku and incorporate dNTPs [36]. The terminal
deoxynucleotidyltransferase (TdT) is another Pol X family member, but it is only expressed in early
B-lymphocytes and T lymphocytes during V(D)J recombination [36]. Ligation is then carried out
by the XLF (XRCC4-like factor)-XRCC4 (X-ray complementing chinese hamster gene 4)-Ligase
IV complex [56] (Figure 1.2 B). The alignment and the base pairing of the free DNA overhangs
are critical steps to initiate the ligation [35]. Additionally, PAXX (paralogue of XRCC4 and XLF)
interacts with Ku and it might be involved in the ligation of the NHEJ subpathway for blunt ends
[36]. NHEJ is flexible towards the modification of free DNA ends, which makes it susceptible for
small insertions and deletion [35, 36] (Figure 1.2 B). NHEJ does not need a template for repair and
can operate throughout the cell cycle [36]. However, the direct ligation of the DNA ends harbors
the risk of ligating the wrong ends and / or deleting DNA sequences [57]. Furthermore, NHEJ
during DNA replication can be deleterious because of the intrinsic increased incidence of breaks,
whose false joining could lead to chromosomal rearrangements [57–59]. When the HR machinery
is defective, the NHEJ-mediated mutagenic repair can turn into a major contributor to genomic
instabilities and tumorigenesis [57, 60, 61]. An alternate end-joining pathway comes into place,
when classical NHEJ is impeded, and relies on micro-homologies for the joining reaction, involving
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Figure 1.2: Pathways in double-strand break repair. Homologous recombination pathway steps from resec-
tion to D-loop formation (A), Non-homologous end joining (B) and different pathways choices of Homologous
recombination (C - E). (A) In the Homologous recombination (HR) pathway the 5’ ends of the broken ends
are resected in order to expose single-stranded DNA. ssDNA is covered by replication protein A (RPA), which
is replaced by RAD51 in the next step. Then RAD51-dependent homology search and strand invasion forms a
displacement loop (D-loop). Thereby DNA synthesis is primed from the 3’-OH end of the broken chromosome
on an intact template. The following process of second-end capture and HJ formation is described in Figure
1.3. (B) Non-homologous end joining (NHEJ) DNA protein kinase (DNA-PK) consists of the heterodimer
Ku70 and Ku80 and the DNA-PK catalytic subunit (DNA-PKcs). This pathway is alternative to homologous
recombination and does not require 5’ end resection. (C) The single-strand annealing pathway (SSA) uses
flanking homology regions to bridge the DNA lesion [50]. This causes a deletion between the repeats and leads
to mutagenesis. The ssDNA left over after annealing of the strands are being removed by the XPF/ERCC1
nuclease. (D) Synthesis-dependent strand annealing (SDSA) repairs the break by extending the D-loop and
subsequently disrupts and reanneals it to the second end. SDSA leads to a non-crossover outcome. This
process involves several DNA polymerases and helicases. (E) Break-induced replication (BIR) is employed after
a replication fork encountered a nick. Then a single-ended double-strand break is formed. A different way of
resolving the single-ended double-strand break is described in Figure 1.3. Overall, BIR can lead to a loss of
heterozygosity. Adopted from [39].
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MRN complex, PARP-1, DNA Polymerase θ [36], XRCC1 and DNA Ligase I or II [41, 62]. The
usage of micro-homologies at the lesion in the alternate NHEJ pathway increases errors [35].
1.2.4 Homologous Recombination and Its Subpathways
HR allows the accurate repair of DSBs by using a sister chromatid as a template. 5’ end resection
and formation of a D-loop are the intermediate steps leading to the formation of Holliday Junctions,
which have to be processed [42, 63]. As HR requires the presence of a homologous template and is
less error-prone compared to NHEJ, it is the preferred repair pathway in S and G2 phase [64]. A
prerequisite for the homologous recombination pathway is the resection of the broken DNA ends
[16, 61]. Extensive resection is regulated by the cell cycle through cyclin-dependent kinases (CDKs)
[36, 65]. These factors promoting end resection are more active during S and G2 phases, favoring
HR when a sister chromatid is present [16, 36, 65]. In G1 phase end resection is suppressed, in
order to give way for a DSB repair via NHEJ [50].
DSBs are sensed by the MRN complex, which promotes the activation of ATM and the prepa-
ration of DNA for HR or one of its subpathways [16] (Figure 1.2 A). MRN complex and CtIP
generate in an initial resection reaction 3’ ssDNA tails [36, 38]. For this, CtIP is phosphory-
lated by cyclin dependent kinases [44, 50, 66–68] and associates with BRCA1 [16]. Further end
resection to generate longer ssDNA stretches is carried out by the Bloom syndrome RecQ-like
helicase (BLM-helicase) together with Exonuclease 1 (EXO1) [16, 69]. Additionally, the DNA
replication helicase/nuclease 2 (DNA2) has been shown to extend the 3’ ssDNA tails [65, 69, 70].
The single-stranded DNA tails are covered by multiple copies of RPA complex [36, 71]. The
RPA-nucleofilament allows a protection of the ssDNA and prevents secondary structure formation
[36]. In the later course of HR, RPA will be replaced by the RecA homologue RAD51 to allow for
homology search and strand invasion [36, 72].
Single-Strand Annealing (SSA)
The single-strand annealing pathway (SSA) is a RAD51-independent pathway (Figure 1.2 C). ss-
DNA sequences generated during DSB processing contain regions of homology at both sides of the
DSB, which can be annealed and ligated [36, 73, 74]. First, extensive bidirectional resection re-
veals complementary ssDNA [73]. The complementary ssDNA tails are then annealed by mediation
of the strand annealing protein RAD52 [36, 73, 75]. For removal of unannealed non-homologous
portions of the 3’ ssDNA the nucleotide excision repair complex XPF-ERCC1 (xeroderma pigmen-
tosum group F - excision repair cross complementation group 1) and the mismatch repair complex
MSH2-MSH3 (MutS Homolog 2-MutS homolog 3) are employed [36, 65, 73, 76, 77]. In yeast, it
has been shown that Slx4 (synthetic lethal of unknown function 4) interacts with Rad1/Rad10, the
yeast ortholog of XPF-ERCC1 [78, 79]. By nuclease action the intervening region and one of the
repeats is deleted [73]. This pathway is error-prone and mutagenic as deletions and translocations
can be easily generated [36, 73].
Strand Exchange and D-loop Formation
After the first step in HR with the 5’ to 3’ resection of the DNA ends and the generation of
3’ single-stranded DNA [61, 65], the ssDNA is bound by the ssDNA-binding protein RPA [61]
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(Figure 1.2 A, second arrow). BRCA1 promotes the recruitment of BRCA2 to the DSBs via
the bridging protein PALB2 (partner and localizer of BRCA2) [61]. Next, BRCA1 and BRCA2
load the RAD51 recombinase onto the ssDNA to form a nucleoprotein filament [61]. BRCA2
thereby specifically promotes RAD51 filament assembly on ssDNA [5, 28, 61]. The interaction
between RAD51 and BRCA2 is limited to S and G2 phase of the cell cycle by CDK-dependent
phosphorylation of BRCA2 [16]. RAD51 belongs to a conserved class of recombinase enzymes,
which mediate DNA pairing and strand exchange [72, 80]. Different RAD51 complexes are formed,
which consists of various combinations of RAD51 paralogs [72, 80]. These pairs mediate RAD51
filament assembly [72, 80]. The displacement of RPA by RAD51 stimulates strand exchange
[61, 74]. RAD51-nucleofilament promotes strand invasion into a homologous duplex to initiate
repair synthesis [61, 74]. The homologous duplex is preferentially the identical sister chromatid
[61, 74]. In the intact strand a Displacement-loop (D-loop) is formed [5, 42].
Arising from the formation of the D-loop, different subpathways are possible: synthesis-
dependent strand annealing (SDSA), Break-induced repair (BIR) (Figure 1.2 D, E) or the for-
mation of double Holliday Junctions (HJs) (Figure 1.3 A) [12].
Synthesis-Dependent Strand Annealing (SDSA)
During SDSA the newly synthesized DNA dissociates to anneal to the other 3’ DNA end of the
broken chromosome and double-strand break repair is completed by ligation, resulting in a non-
crossing over product [73, 81, 82] (Figure 1.2 D). The Rad51 formed D-loop is extended by the
replicative DNA Polymerase δ with loaded PCNA (proliferative cell nuclear antigen) [83]. This
process is stimulated by the translesion polymerases Pol η and Pol κ [83]. SDSA is favored
by the displacement of the invading strand from the D-loop [73]. In higher eukaryotes several
helicases are involved in this process [73]. The BLM helicase along with TopIII α topoisomerase
promotes non-crossover formation [84]. The RecQ5 helicase was shown to promote SDSA by
disrupting RAD51-ssDNA filaments and thus counteracting the inhibitory effect of RAD51 on
strand annealing activity of RAD52 [73, 85]. Yeast Mph1, the ortholog of FANCM (Fanconi anemia
complementation group M) is proposed to dissociate the D-loop and promote the formation of the
non-crossover product independent of the yeast BLM ortholog Sgs1 (Slow growth suppressor 1)
[73, 86]. However, it has been suggested that another helicase, RTEL1 (regulator of telomere
length 1) disrupts D-loops and promotes SDSA in vivo after displacement of the RAD51 filament
and D loop dissociation [87]. The helicases involved, mediate the dissociation of the invading
strand from the D-loop in order to avoid crossover formation [82]. Following D-loop unwinding,
the nascent strand has also the opportunity to anneal with sequences other than those found at
the other end of the broken chromosome, which can contribute to the mutagenesis associated with
SDSA [88].
Break-Induced Repair (BIR)
The D-loop structure can assemble into a replication fork and copy the chromosome arm in a
process called break-induced replication (BIR) [73, 89–91] (Figure 1.2 E). BIR is carried out by a
migrating D-loop (bubble), where branch migration of an unresolved HJ promotes the displacement
of a newly synthesized strand and therefore leads to non-crossover repair [92–94]. The BIR repair
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Figure 1.3: Processing of Holliday Junctions Homologous recombination after D-loop formation (A) ssDNA
is covered by RAD51 and a RAD51 dependent homology search is performed. Upon strand invation a D-loop is
formed and DNA synthesis is primed on an intact template. After second-end capture the displaced strand of
the D-loop anneals to the other resected 3’ strand forming two nicked HJs and after ligation a double HJ. (B)
The double HJ can be dissolved by the BLM/TopIIIα/RMI1/2 complex leading to a non-crossover product. (C)
Another way to process dHJs is the resolution by structure-specific endonucleases. This cleavage is precisely
coordinated and leads to crossover or non-crossover products depending on the incision. During BIR the intact
strand can be displaced, wich has to be resolved, leading to a crossover or a non-crossover product. Adopted
from [39].
pathway is especially important in cases of one-ended chromosomal breaks caused by replication
fork collapse or shortening of telomeres [88, 91]. In telomerase-deficient cells BIR is an alternative
pathway to maintain the chromosome ends [91]. Because the BIR repair pathway is a kinetically
slow process it can be outcompeted by SDSA [73, 95]. However, as soon as BIR is initiated, the
synthesis rate becomes comparable with normal replication [73, 95]. In contrast to SDSA the
amount of DNA synthesis is much more extensive [88] and can proceed via a migrating bubble for
hundreds of kilobases [92]. To date, most mechanistic insight into BIR is derived from studies on
Saccharomyces cerevisiae. BIR has an additional need for replicative helicases (e.g. GINs complex,
CDC45 and the MCM complex) [88] and DNA Polymerase α , Pol32 and the 3’ to 5’ DNA helicase
PifI [93, 94, 96]. Pol32 is a non-essential subunit shared by Pol δ and the translesion polymerase
ζ [96]. So far, the exact functions of Pol32 and Pif1 are not well understood, but in the BIR model
of DSB repair Pol32 could act as a proccessivity factor of Pol δ and Pif1 might be important for
the progression of the mobile D-loop [93, 96]. BIR fully restores the integrity of the chromosome,
but it can lead to a loss of heterozygosity distal to the DSB [12, 97].
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Formation and Processing of Holliday Junctions
In order to accommodate the invading and the donor ssDNA strand in the D-loop RAD51-dsDNA
filaments are formed [28] (Figure 1.3 A). DNA synthesis is primed from the intact strand using the
invading 3’ end as primer [98]. Thereby, RAD51 dissociates from dsDNA to expose 3’-OH required
for DNA synthesis [28]. DNA synthesis during D-loop extension is carried out by translesion poly-
merase η [99] and κ as well as the replicative polymerase δ [83, 88]. Human polymerase δ together
with PCNA, a trimeric complex that encircles the DNA and prevents DNA polymerases from
dissociation, can extend the D-loop up to 2 kb [83]. In this process, DNA strands have to be
opened, where RAD54 is involved as a DNA translocase and as supercoiling motor [72]. RAD54
is an ATPase that is stimulated by RAD51 and generates positive supercoils ahead of protein
movement and negative supercoils trailing it [72]. Supercoiling facilitates the homologous pairing
reaction of the RAD51 nucleofilament and further DNA branch migration [72]. RAD54 has the
ability to remove RAD51 from dsDNA [5, 100] and to remodel chromatin [72]. A RAD54 paralog
has similar biological activities as RAD54 and plays a stronger role during meiosis [5].
After D-loop extension by Pol δ, Pol η and Pol κ [83], the current model proposes that the
D-loop is stabilized by capturing the second end of the DSB, leading to the formation of Holliday
Junctions (HJ) [42, 63] (Figure 1.3 A, lower part). The formation of HJ is important during
meiosis, when crossovers lead to divergence of the genetic pool [12]. However, in somatic cells
dHJs are an intermediate in recombinational DNA repair [101] and formation of dHJs can be
blocked by RAD51 suggesting an inherent bias towards SDSA [12]. SDSA is preferred in mitosis
leading to non-crossover products [28]. After D-loop formation, it is proposed that the displaced
DNA strand is extended towards the sequences that are homologous to the second processed DNA
end [102]. The displaced strand would then anneal to the ssDNA tail created by the resection at
the other end of the break [42, 63, 102]. Subsequent DNA synthesis from this captured second end,
branch migration and ligation generate two four-way structures composed of DNA strands base
paired with old and new partners simultaneously [102]. The occurrence of two four-way structures
is called double Holliday Junction (Figure 1.3 A).
So far, the whole process of the HJ formation, the involved proteins and their function is
not well understood. It is known, that Pol η, RAD52 and RPA collaborate to promote D-loop
extension, second-end capture and de novo DNA synthesis from the 3’ terminus of the captured
second DSB [103]. On the second resected end RPA is still bound to ssDNA and RAD52/RPA
mediated annealing leads to the capture of the second DNA end, which in turn serves as a template
for the initiation of DNA synthesis by Polη [103]. In total, RAD52 is involved in the process of
second-end capture [103–105]. The second-end capture forms one of the key intermediates of
homologous recombination: the four-way DNA (Holliday) Junction.
The formation of Holliday Junctions is the second-last step in DNA double-strand break re-
pair [42]. HJs were first proposed by Robin Holliday as four way branched DNA substrates
[63]. They can be formed as a result of regression of stalled replication forks [106] and can
be disentangled by two mechanisms. HJs can be either dissolved in a non-nucleolytic way by
the BLM-TopIIIα-RMI1/2 helicase-topoisomerase complex (Bloom - DNA Topoisomerase IIIα-
RecQ mediated genome instability protein 1/2; yeast: Sgs1-Top3-Rmi1/2) [84, 107] or resolved by
structure-selective endonucleases (MUS81-EME1, SLX1-SLX4, GEN1) [39, 108–115] (Figure 1.3
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B, C).
The dissolution is initiated by the migration of the HJs towards each other [116] (Figure 1.3 B).
The collapse / fusion of the two HJs forms a hemicatenated structure, whose decatenation leads to
the formation of a non-crossover product [116]. In somatic cells, the dissolution pathway is favored
for HJ removal as it prevents sister chromatid exchanges [84]. These sister chromatid exchanges
are to be prevented as they could lead to loss of heterozygosity, which in turn incites cancer
predisposition [108, 117–120]. Mutations in human BLM helicase give rise to Bloom’s syndrome,
a genetic disorder associated with genomic instability and early-onset cancer [17, 84, 121]. The
BLM helicase belongs to the family of RecQ helicases and forms an evolutionary conserved complex
with human topoisomerase IIIα [84, 122]. TopoIIIα, a type 1A topoisomerase [116], breaks and
rejoins DNA to alter its topology [84]. In the decatenation, TopoIIIα requires the ATPase activity
of the BLM helicase to execute the reaction [84, 107, 116]. Branch migration activity is exhibited
by the BLM helicase causing torsional stress [116]. This torsional stress is being alleviated by the
action of the topoisomerase [116]. Besides BLM-TOPO3, the cofactors RMI1 / RMI2 are needed
for efficient dissolution [116]. RMI1 interacts with BLM and TopoIIIα and strongly stimulates
the dissolution reaction, where it primarily functions in the decatenation step [107, 116]. RMI2
interacts with RMI1 and is important for the functionality of complex [116]. Interestingly, the
BLM helicase carries out different functions during DSB repair. BLM can act on various substrates
and dissolve various recombination intermediates. The ssDNA production after DNA damage is
carried out by BLM [70, 123]. Furthermore, BLM displaces RAD51 from ssDNA [105] and dissolves
in complex with a topoisomerase and RMI1/2 the HJ substrate as the last step of homologous
recombination [84, 107].
The resolution of HJs is carried out by an ubiquitous but diverse group of metal ion-dependent
endonucleases called Holliday Junction resolvases or structure-selective nucleases (see reviews [124–
126]) (Figure 1.3 C). In general the resolvases are characterized by their ability to 1) bind Holliday
Junctions in a structure-specific manner; 2) introduce a pair of symmetric nicks across the junction
point; 3) generate nicks with 5’-phosphate and 3’ hydroxyl termini that are readily ligatable [127].
In most cases junction binding is associated with a distortion of the stacked-X conformation of
the HJ to a more open structure [127–130]. The HJ resolution mechanism is very well studied
for bacterial and bacteriophage resolvases [124, 131]. For some HJ resolvases, like bacteriophage
T4 endonuclease VII and T7 endonuclease, simply the binding to the stacked X-conformation
of the HJ is sufficient to trigger cleavage [125]. Some resolvases, e.g. E. coli RuvC (resistance
to UV light), are not only structure selective, but the cleavage is specific and prefers a cognate
sequence at the junction point [132, 133]. The RuvC resolvase might depend on the relocation of
the Holliday Junction by branch migration so that the required sequence can be localized at the
junction point [127]. The ATP dependent branch migration of the HJ is catalyzed by RuvAB,
which associates with RuvC [127, 134].
In eukaryotes the resolution is more complex and involves different resolvases, which are struc-
turally not related to each other. The human GEN1 (gap endonuclease 1) protein and the S.
cerevisiae ortholog Yen1 were identified by mass spectrometry following fractionation of HeLa cell
extracts and screening a yeast gene fusion library for HJ resolution activity, respectively [111].
GEN1 is a member of the Rad2/XPG (Xeroderma pigmentosum complementation group G) fam-
ily of structure specific nucleases, characterized by an N-terminal and an internal XPG nuclease
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domain and a helix-hairpin-helix domain [111]. HJs are cleaved by GEN1 in a symmetrical way
leading to a ligatable product [111]. This cleavage mechanism is contrast to the asymmetric HJ
cleavage seen for MUS81-EME1 (methyl methanesulfonate UV sensitive, clone 81 - essential mei-
otic endonuclease) [135], but it is functionally conserved with the bacterial HJ resolvase RuvC
[111]. GEN1 activity is regulated by nuclear exclusion [117]. Thus, the cell makes sure, that
GEN1 has access to recombination intermediates and cleaves them, when the nuclear membrane
breaks down at mitosis [117, 136]. Mutations of GEN1 have been found in breast cancer patients,
classifying GEN1 as a cancer gene [111, 137]. GEN1 and SLX4 (synthetic lethal of unknown func-
tion 4) are synthetically lethal in human cells as a consequence of dysfunctional mitosis proceeding
in the presence of unprocessed HJs [112]. In yeast, flies and humans GEN1 and MUS81-EME1
could be shown to work in redundant pathways [109, 138–140]. A knockout of them in a cellular
background of BLM syndrome leads to severe chromosomal abnormalities [140]. In C. elegans this
genetic interaction could not be detected [25].
The nuclease complex SLX4-SLX1-MUS81-EME1 (SM-complex) has activity on HJs [113–
115, 141, 142]. The nucleases work in a nick and counter-nick mechanism with SLX1 (synthetic
lethal of unknown function 1) introducing the first cut and MUS81-EME1 the second cut [141].
Recently, Wyatt et al. proposed that the complex forms a multi-nuclease complex consisting of
SLX4-SLX1-MUS81-EME1-XPF-ERCC1 (SMX-complex) [143]. The cleavage mechanism of the
SM-complex is unique among the Holliday Junction resolvases as the cleavage is carried out by two
different nucleases. Usually, HJ resolution proteins bind four-way junctions in dimeric form and
introduce symmetrical nicks [144]. For example, bacterial RuvC (Resistance to UV light) binds
as a dimer on opposite faces of the junction [145, 146]. T4 endonuclease VII also forms a dimer
in order to cleave the HJ [147–149]. The SM complex supplements the BLM-dependent double
HJ dissolvase activity [112]. But even with an active BLM complex HJ resolution is essential and
depends on SLX4 and GEN1 function [112]. The resolvases are responsible for the generation of
crossovers as resolvase deficient cells exhibit reduced frequency of sister-chromatid exchange [150].
The following section will explain the properties of the SM complex and the domain architecture
in more detail.
1.3 The SLX4-SLX1-MUS81-EME1-Complex
Originally, Slx4 was first discovered together with Slx1 in yeast synthetic lethal screens in absence
of the dissolution complex Sgs1/Top3 (yeast ortholog to human BLM/TopoIII) [151]. The het-
eromeric complex was then functionally characterized as a structure specific endonuclease redun-
dant to Sgs-Top3 [152]. Slx1-Slx4 form a complex and are involved in the replication of rDNA in
yeast [152, 153]. The eukaryotic orthologs of yeast Slx4 were identified through several approaches
[113–115, 154]. Two groups scanned for human SLX4 in a BLAST search using either a potential
DNA binding domain or a conserved C-terminal domain as query [113, 115]. Another group’s
attention was drawn towards SLX4 as it was identified as a target of the ATM/ATR protein ki-
nase [114]. The Drosophila SLX4 ortholog, MUS312, was also found by sequence comparison with
other proteins containing a C-terminal conserved domain [154]. A rough domain assignment was
carried out by sequence alignments with SLX4 orthologs from other species [113, 115], identifying
five domains at the beginning (Figure 1.4 A).
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Interaction partners were identified and their interaction site was roughly mapped by Yeast-
two-hybrid screen [113–115, 154], immunoprecipitation [113–115] and proteomic analysis of SLX4
complexes [114]. These analysis revealed that SLX4 is a scaffold protein and through the assembly
and coordination of several nucleases it is involved in diverse pathways of genome maintenance, in-
cluding ICL repair, DNA replication, nucleolytic processing of HR intermediates, replication stress
management and telomere maintenance [155] (Figure 1.4 B). Furthermore, a crystal structure of
a yeast Slx1-Slx4 complex suggested how Slx1 is activated and it revealed how Slx1 binds on its
interaction site in Slx4 [156] (Figure 1.5 A). The following subsections will give an overview of the
domain architecture of SLX4 and its interaction partners as well as structural and biochemical
information available about the heterodimers, SLX1-SLX4 and MUS81-EME1, which are the four
constituents of the SM-complex.
1.3.1 Domain Architecture of SLX4
The 200 kDa human SLX4 protein, also called BTBD12, has a multi-domain structure, which
allows binding of a wide range of interacting proteins and thereby controlling the activity at the
target site. The initial domain organization was found by sequence alignments with other SLX4
orhologs by various groups [113–115] and was refined by interaction studies later on [157, 158].
At the N-terminus are two ubiquitin binding domains localized, UBZ-1 and UBZ-2 (Figure
1.4 A). These domains are important for recruitment of SLX4 to sites of replication-dependent
interstrand crosslinks [14, 159–161]. UBZ-1 is required for the SLX4-dependent repair of ICLs and
binds poly-ubiquitin chains with a preference for K63- over K48-linkages [14, 158–160]. Both UBZ
domains are required for the resolution of Holliday Junctions under BLM depletion [160].
The MLR region was detected as a conserved motif required for the interaction between the
Drosophila SLX4 ortholog MUS312 and the Drosophila XPF ortholog MEI9 [113]. It was thus
named as MLR (MUS312-MEI9 interaction-like region) [113]. MEI9 (meiotic protein 9) is essential
for meiotic recombination in Drosophila melanogaster [162]. The sequence in MUS312, which is
known to associate with MEI9, is conserved among SLX4 orthologs and may serve as a general
binding site for XPF [78, 113].
The BTB domain (Bric-a-brac, Tramtrack, Broad complex), sometimes also referred as POZ
domain (pox virus and zinc finger) was originally identified in Drosophila melanogaster transcrip-
tion regulators and pox virus zinc finger proteins [163]. BTB domains are in general responsible for
protein dimerization or interaction with non-BTB-proteins [163]. SLX4BTB might play a role in
ICL repair, but its exact role remains elusive [158]. The dimer formation of SLX4BTB is proposed
to be important for the localization of SLX4 at genomic sites such as telomeres, the assembly and
regulation of the nucleases and the foci formation of SLX4 at common fragile sites [157]. Another
study showed by immunoprecipitation that SLX4BTB mutants are deficient for SLX4 dimerization
[164].
SIMs (SUMO-interacting motifs) in SLX4 are short stretches of hydrophobic residues flanked
by acidic residues [164–166]. In general, they mediate noncovalent interaction with the small
ubiquitin-like modifier (SUMO) and presence of multiple SIMs in a protein enables the protein to
bind to poly-SUMO2/3 chains [166], which has been shown also for SLX4 [164, 165]. The SIMs
promote the sumoylation of XPF and SLX4 itself and are important for managing replication
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Figure 1.4: The SLX4 scaffold protein and its interaction partners. (A) Diagram showing the domain
architecture of the human and Caenorhabditis elegans SLX4 and SLX1 proteins. UBZ: ubiquitin-binding zinc
finger domain; MLR: MUS312-MEI9 interaction-like region; BTB: Bric a brac, Tramtrack, Broad-Complex
domain; SIM: SUMO-interacting motif; SAP: SAF-A/B, Acinus and PIAS domain; CCD: conserved C-terminal
domain; GIY: nuclease domain; RING: really interesting new gene (B) Interaction partners of SLX4 and their
relative interaction site. MSH2/3 (MutS homologs 2/3) are involved in DNA mismatch repair. FANCD2
(Fanconi anemia complementation group D2) is involved in the repair of interstrand crosslinks. The so far
uncharacterized SLX4 interacting protein (SLX4IP or C20orf94) interacts with the N-terminus of SLX4. The
nuclease XPF-ERCC1 (xeroderma pigmentosum group F - excision repair cross complementation group 1)
interacts via the MLR domain. The interacting kinase ATM / ATR (ataxia telangiectasia mutated / ataxia
telangiectasia mutated and Rad3-related) is involved in sensing of DNA damage. SLX4 is involved in telomere
maintenance through TRF2/TRF2IP (telomeric repeat-binding factor 2 / TRF2-interacting protein). The
interaction with TOPBP1 is conferred via a single phosphorylation site at T1260. PLK1 (Polo-like kinase
1) is involved in cell cycle regulation. Through the C-terminal domains, SLX4 coordinates the activity of the
Holliday Junction resolvases MUS81-EME1 (methyl methanesulfonate UV sensitive, clone 81 - essential meiotic
endonuclease 1) and SLX1 (synthetic lethal of unknown function 1).
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stress at genomic common fragile sites [164, 165]. However, the SUMOylation function of SLX4
does not solely depend on the SIMs, but also on the BTB domain [164]. Thus, SLX4 is not only
a scaffold protein but it is also proposed to harbor a SUMO-E3-ligase activity [164]. So far, the
functional impact of XPF sumoylation is unknown, but it has been described that sumoylation of
the yeast XPF-ortholog Rad1 reduces its DNA-binding ability [126, 167]. Furthermore, the SIMs
contribute to the localization of SLX4 at telomeres [165].
SLX4 contains an area at the C-terminal region that resembles a SAP motif (named after SAF-
A/B, Acinus and PIAS) [168] (Figure 1.4 A). The SAP motif is characterized by two amphiphatic
helices containing hydrophobic, polar and bulky residues separated by a conserved glycine in the
loop region [168]. SAP proteins are found in a number of chromatin-associated proteins, such as the
scaffold attachment factors SAF-A and SAF-B, PIAS family members and Acinus [168]. Further-
more the SAP motif is also found in other DNA repair proteins, including the non-homologous end
joining protein Ku70, plant poly-ADP-ribose polymerase, and the post-replicational repair protein
Rad18 [168]. Direct evidence that the SAP motif binds DNA has come from studies of SAF-A
and Ku70 [169, 170]. The SAP domain can either be used as the main DNA binding component
of a protein (e.g. SAF-A) [169] or as an additional stabilizing element (e.g. Ku70 and SpCCE1)
[127, 170, 171].
The extreme C-terminal domain is the CCD domain (conserved carboxy-terminal domain) or
referred to as SBD (SLX1 binding domain) [158]. This domain confers the interaction with the
structure specific endonuclease SLX1 [113, 158]. The CCD and the SAP domain contain the highest
degree of sequence similarity across SLX4 orthologs from fungi to mammals [78, 113–115, 154].
Taken together, the domains comprise a large area, where the different interaction partners of
SLX4 are associated. This allows SLX4 to take part in different DNA repair pathways and other
cellular pathways.
1.3.2 The Interaction Partners of SLX4
SLX4 has been described as a scaffold protein [113–115]. In general, scaffold proteins serve as
a binding platform for proteins, thereby tethering them into complexes and helping to localize
pathway components to the target cell compartments. The various domains in SLX4 serve as
interaction sites with structure-selective endonucleases, but also with proteins involved in sev-
eral cellular pathways [113–115, 154] (Figure 1.4 B). SLX4 helps in the successful recruitment of
the endonucleases SLX1, MUS81-EME1 and XPF-ERCC1 to DNA and coordinates their action
[126]. The interaction partners have been uncovered by several methods, like yeast-two hybrid or
proteomic analysis and will be described in this subsection [113–115, 154].
Proteomic analysis identified MSH2/3 as interaction partners of SLX4 [114, 115]. The MSH2/3
proteins are involved in DNA mismatch repair and recognize insertions, deletions and mismatches
[172]. So, far it is only known that MSH2/3 interact at the N-terminus of SLX4 between the
residues 1 to 669 [114]. Neither the exact interaction site nor the function of this interaction has
been characterized.
The Fanconi anemia complementation group D 2 (FANCD2) has been shown to interact with
SLX4UBZ in co-localization and immunoprecipitation studies [159]. Ubiquitylated FANCD2 re-
cruits SLX4 to ICL sites [159]. FANCD2 is part of the Fanconi anemia (FA) pathway for the
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repair of ICL and is ubiquitylated by the FA core complex, an E3 ubiquitin ligase. FANCD2
and its interaction partner FANCI constitute a central axis to connect the FA core complex with
downstream functional units of the FA pathway [13].
SLX4IP (previously referred to as C20orf94) was identified as an N-terminal interaction partner
of SLX4 [114]. The protein was shown to be deleted in childhood acute lymphoblastic leukemia
[173]. To date, there is neither functional nor structural information about SLX4IP or its interplay
with SLX4 available. Interestingly, SLX4IP appeared in the evolution of vertebrates and it is
absent in invertebrates, but lacks any known protein interaction domains [114].
XPF-ERCC1 (xeroderma pigmentosum group F - excision repair cross complementation group
1) is one of the three interacting nucleases of SLX4 and belongs to the XPF/MUS81 nuclease
family member [113–115, 174]. XPF-ERCC1 (Rad1-Rad10 in yeast) plays important roles in ICL
repair, single-strand annealing, telomere maintenance and nucleotide excision repair [174–179].
The interaction with SLX4 is conferred via the MLR domain and the BTB domain [113, 158, 175].
Only a portion of cellular XPF interacts with SLX4 [115], the non-SLX4 bound XPF participates in
other DNA repair pathways, such as nucleotide excision repair [158, 180]. Through the interaction
with XPF-ERCC1, SLX4 is involved in ICL repair, specifically in the unhooking step [161, 175,
179]. The recruitment of the first UBZ domain in SLX4 to ICL sites depends on ubiquitylated
FANCD2 and subsequently SLX4 recruits XPF-ERCC1 via the MLR domain [14, 160, 161, 179].
Leucine 230 in the hsXPF helicase domain is essential for the interaction with SLX4 and the
recruitment to the damage site [175]. This interaction has high binding affinity [175]. A second
interaction site between XPF and SLX4 is conferred transiently via SLX4BTB and activates the
ICL incision [175]. Finally, the nuclease domain in XPF recognizes and processes the ICL substrate
[175]. Another study could show, that a truncated form of SLX4, comprising SLX4 UBZ, MLR
and BTB domain, stimulates XPF-ERCC1 nuclease activity towards the processing of forked or
flap containing DNA and is thus accelerating XPF-ERCC1 unhooking of crosslinked DNA [179].
Human cells with low levels of XPF or ERCC1 are sensitive towards UV irradiation and DNA
cross-linking agents [158, 181, 182]. XPF-ERCC1 mutations are found in various genetic disorders,
e.g. the autosomal recessive skin disorder Xeroderma pigmentosum, which is characterized by UV
sensitivity and high predisposition to skin cancer [15, 183].
ATM / ATR kinases (ataxia telangiectasia mutated / ataxia telangiectasia mutated and Rad3-
related) interact with SLX4 [79, 114, 184, 185]. Mammalian SLX4 is a key substrate of ATM
in the germ line, playing a role in the spermatogonial stages of gametogenesis and in the entry
and progression through prophase I [186]. The localization of SLX4 onto meiotic chromosomes is
dependent on ATM [186]. In yeast, Slx4 is phosphorylated by the yeast ATM / ATR orthologs,
Mec1 and Tel1, and is required for repair of DNA alkylation damage and single-strand annealing
[79, 184]. ATM and ATR are both members of the phosphatidylinositol-3’-OH-kinase-like protein
kinase family and are important for the sensing of DNA damage [46, 187, 188]. ATM is responding
to DNA DSBs arising throughout the cell cycle and is regulated by the MRN complex, which
prepares the DNA for HR [16, 45, 185, 188]. ATR responds to perturbations of the cellular DNA
replication exposing ssDNA and is regulated by the ATR-interacting protein [45, 185, 188]. ATM
and ATR initially phosphorylate mediator proteins, which amplify the DNA damage response by
recruiting ATM / ATR substrates [16]. ATM / ATR either phosphorylate the substrates directly
or by other kinases, like the CHK2 kinase, leading to a phosphorylation cascade and in the end
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to cell cycle arrest [16, 187, 188]. Further, they are known to cross talk with each other and
their function can also be redundant [46]. However, ATM / ATR are not only involved in DNA
damage response, but coordinate a variety of cellular activities, from DNA replication and repair
to transcription, metabolic signaling and RNA splicing [16, 185]. Mutations in the atm gene
were first connected with the autosomal recessive disorder Ataxia-telangiectasia, characterized by
cerebellar ataxia, telangiectases and lymphoid tumors [189]. ATR is mutated in Seckel syndrome,
characterized by ’bird-headed’ facial appearance and hematological abnormalities [188].
Through the interaction of SLX4 with TRF2/TRF2IP (telomeric repeat-binding factor 2 -
TRF2 interacting protein), SLX4 is involved in telomere maintenance [114, 177, 178]. Telomeres
are regions of repetitive DNA sequences at chromosome ends, which protect the ends from degra-
dation. Because of the alternate and secondary DNA structures in telomeres, they pose a challenge
in DNA metabolism [190]. TRF2 is a negative regulator of telomere length and key component in
the control of nucleases at telomeres [126, 155]. It is required to shield telomeres from uncontrolled
activity of structure specific endonucleases and it is required for recruitment of SLX4 and its as-
sociated nucleases to telomeres [126, 155, 178]. Thereby TRF2 interacts via a TRF2-binding-like
motif (aa 1014 - 1028) in SLX4 [177, 178]. The interaction of TRF2 with SLX4 is reinforced by the
SIMs [165]. It is proposed that SLX4 and its three associated nucleases localize at the telomeres
[177, 178]. Thereby, SLX4 and TRF2 form a scaffold and assemble a telomere maintenance kit
containing XPF-ERCC1, MUS81-EME1 and SLX1, whereas SLX4-SLX1 regulates the telomere
length [177, 178, 191].
Interaction between SLX4 and TOPBP1 (DNA topoisomerase 2 binding protein 1) is conferred
via the phosphorylation of Thr 1260 in SLX4 (in yeast Slx4 Ser 486) by CDK, which is conserved
between yeast and humans [192–194]. Additionally, the interaction between SLX4 and TOPBP1
(yeast: Dpb11) requires the kinase ATR (yeast ortholog Mec1) [57, 195]. The complex Slx4-Dpb11
integrates two cellular signals in yeast. First, the cell cycle state is implied through Slx4 phospho-
rylation by Cdk1 and second, the presence of DNA damage is signaled through checkpoint kinase
phosphorylation [194]. TOPBP1 is an essential scaffolding protein involved in DNA replication,
DNA repair, transcriptional regulation and DNA damage checkpoint signaling [57, 192, 196, 197].
In yeast, the Slx4-Dpb11 complex acts as an regulator of joint molecule removal pathway by in-
teracting with the structure-selective endonuclease Mus81-Mms4, in which Dpb11 acts as a bridge
between Slx4 and Mus81-Mms4 (methyl methane sulfonate sensitive 4; yeast ortholog of MUS81-
EME1) [194].
Proteomic analysis found the polo-like kinase 1 (PLK1) as an interaction partner of SLX4
[114, 115] (Figure 1.4 B). PLK1 is a conserved eukaryotic kinase, controlling multiple essential
steps of mitosis and meiosis [198]. It is implicated for example in the activation of Cdk1-Cyclin
B at mitotic entry and activation of the anaphase promoting complex [198]. PLK1 associates
with SLX4 in part through a candidate polo-box binding motif centered on S1453 in SLX4 [114].
Furthermore, it has been demonstrated that PLK1 also interacts with SLX4IP and ERCC4 [114].
Depletion of SLX4 reduced the interaction between PLK1 and ERCC4, suggesting that SLX4
bridges the interaction between PLK1 and ERCC4 [114]. PLK1 regulates MUS81-EME1 activity
in yeast and human [117, 199]. Furthermore, PLK1 phosphorylates SLX4 and its activity is
required for the association between SLX4 and MUS81 [114, 200].
The human MUS81-EME1 complex interacts via the MUS81-N-terminus with SLX4SAP [158,
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201, 202]. In human cells SLX4 binds directly to MUS81-EME1, whereas in budding yeast the
interaction needs the TOPBP1 ortholog Dpb11 as a bridge between the two partners [194]. The
MUS81-SLX4 interaction plays a role in the resolution of HJs and in the processing of stalled
replication forks [141, 158]. Mus81 was first discovered by Interthal and Heyer in a yeast two-
hybrid screen with the recombinational repair protein Rad54B as bait [203]. Eme1 was identified
as an interaction partner of Mus81 in a tandem affinity purification coupled to mass spectrometry
approach in fission yeast [135]. The following subsection will cover MUS81-EME1.
SLX1 (synthetic lethal of unknown function (X)-1) interacts with the CCD domain in SLX4
[113–115, 158] (Figure 1.4 B). slx1 was first discovered in a synthetic lethal screen for genes in
absence of the budding yeast RecQ helicase homolog Sgs1 [151, 152, 204]. The BLM homolog Sgs1
unwinds recombination intermediates [69]. In higher eukaryotes SLX1 was identified by homology
searches [113–115, 154].
SLX1 contains an N-terminal GIY-YIG nuclease domain (also called Uri nuclease), named
after the conserved active site residues (Figure 1.4 A, 1.5) [153]. The GIY-YIG nuclease domain is
found in all kingdoms of life, e.g. as UvrC in prokaryotic nucleotide excision repair or as homing
endonuclease I-TevI in bacteriophage T4 [205]. The typical GIY-YIG nuclease conserved core
contains a conserved Y in the first motif, an almost universal Y and a strongly conserved G in the
second motif [205, 206]. Those residues are also shown in SLX1 proteins from different organisms
(see Appendix for GIY-YIG domain 4.2). A mechanism of substrate binding and cleavage has
been proposed for Slx1 based on the restriction enzyme Hpy188I [206] (Figure 1.5 B). A single
metal ion is bound in the GIY-YIG active site and the metal ion is proposed to destabilize the
substrate and stabilize the transition state [156]. The metal ion is located on the opposite side of
the scissile phosphate, which is the target of a nucleophilic attack by a water molecule [156]. This
water molecule on the other hand is likely being coordinated by the active site residues Tyr 14 and
Arg 36 in Slx1 [156]. Further residues are involved in the stabilization of the transition state [156].
The C-terminal domain of SLX1 was designated as RING (really interesting new gene)-finger like
domain after structural comparisons [153, 156, 207] (Figure 1.4). The RING finger Zn-binding
domain is postulated to mediate protein-protein or protein-DNA interactions [205, 208].
Until now, there is only sparse structural information available about SLX1 and its interaction
site with SLX4 [156, 207]. Crystal structures of Slx1 from two yeast homologs (Candida glabrata
and Schizosaccharomyces pombe) have been solved [156, 207]. The Slx1 monomer consisted of the
two domains, the N-terminal GIY-YIG nuclease domain and the C-terminal zinc finger domain
[156] (Figure 1.5 A). These two domains interact with each other and are stabilized by a long
α helix, which spans the entire molecule and provides a scaffold [156]. In the center of the nuclease
is a β -sheet containing five strands, which are flanked by six α -helices [156]. The GIY-YIG
nuclease structure is highly conserved with other GIY-YIG nucleases [156]. Mutation of either of
the residues R34 and E74 in fission yeast, corresponding to the residues E82 and R41 in human
SLX1 lead to inactivity of the nuclease [113, 114, 141, 153]. The C-terminal part of Slx1 showed the
zinc finger domain, which is related to RING finger domains, like those found in E3 ubiquitin ligases
or FANCL [156, 207]. Slx1 is proposed to form a dimer [156]. The dimerization of Slx1 is suggested
to block its activity as the active site of each subunit would be partially blocked by the RING
domain of the other subunit [156]. The crystal structure of Slx1 and Slx4CCD showed a change in
the RING domain compared to Slx1 alone and the CCD domain was positioned in the cleft between
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Figure 1.5: The structure of SLX4-SLX1 (A) Crystal structure of the yeast Slx1 dimer and the yeast Slx1-
Slx4CCD complex (PDB codes: 4XM5, 4XLG). Slx1 is proposed to form a homodimer, which blocks the active
site. Slx1 is suggested to be activated by conversion of the homodimer into the SLX1-SLX4CCD. (B) Schematic
illustration of the proposed catalytic mechanism based on the restriction nuclease Hpy188I. Adopted from [156]
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the nuclease and RING domain [156] (Figure 1.5 A). Slx4CCD is folded as a helix-turn-helix domain
with a four-helix bundle [207]. The complex formation of SLX1-SLX4 is conferred by hydrophobic
interactions and hydrogen bonding [207] and ablated when residue C1805 in hsSLX4 is mutated
or C1536R in murine SLX4 [178, 202]. The structure of Candida glabrata Slx4CCD shows that a
mutation to arginine at the same position leads to steric clashes and thus abrogating the interaction
with Slx1 [156]. Several residues are giving a possible explanation why Slx1 homodimerization
and interaction with Slx4 are mutually exclusive [156]. SLX1 in complex with SLX4 is involved in
the processing of Holliday Junctions during homologous recombination [113–115, 141] as well as
in telomere maintenance by preventing telomere lengthening [177, 178, 191]. Furthermore SLX1
could also be involved in the repair of ICLs as a 5’ endonuclease [126]. SLX1 as part of the
SMX-complex is involved in the cleavage of replication forks [143].
1.3.3 The MUS81-EME1 Nuclease
The first discovered eukaryotic Holliday Junction resolvases were the fission yeast and human
MUS81-EME1 endonucleases [135, 203, 209]. They belong to the XPF-ERCC1 endonuclease
family, which is only present in archaea and eukaryotes and conserved among them [142, 174].
This family can be structurally and functionally divided into catalytic and non-catalytic family
members [174]. Catalytic family members share a common characteristic core of an ERCC4
endonuclease domain and a tandem helix-hairpin-helix (HhH)2 domain [174] (Figure 1.6 A, B).
The ERRC4 domain is distantly related to prokaryotic type II restriction enzymes [210, 211].
The nucleases containing an ERCC4 domain like XPF, MUS81 and FANCM form heterodimers
with a non-functional catalytic domain subunit (ERCC4, EME1, EME2, FAAP24 (FA-associated
protein 24 kDa)) [212]. In the non-functional subunits the key residues have been diverged to
leave the subunit inactive [174, 210]. In humans, four heterodimeric complexes containing XPF
family members have been identified, including XPF-ERCC1, MUS81-EME1, MUS81-EME2 and
FANCM-FAAP24 [174]. The signature motif GDXnERKX3D is being proposed for the active site
of XPF family members (see also Figure 1.6 A orange dots) [174, 212]. MUS81 and EME1 dimerize
via their C-terminal (HhH)2 domains [135, 213]. XPF-ERCC1 complex, a classical member of the
described endonuclease family, processes splayed-arms, bubbles and stem-loop structures [174]. In
contrast to XPF-ERCC1, MUS81-EME1 possesses the ability to process higher branched DNA
structures, like HJs [126, 135, 209].
The human MUS81 protein has two more domains at the N-terminus in comparison to EME1,
an additional HhH2 domain and a winged helix(WH) domain (Figure 1.6 B). The first 86 amino
acids in MUS81 contain the N-terminal HhH motif, which is responsible for the interaction with
the SLX4SAP domain and can in addition bind to DNA [112, 113, 143, 158, 201, 202]. In general,
HhH motifs bind DNA in a non-sequence specific manner [218]. The binding takes place via the
formation of hydrogen bonds between protein backbone nitrogens and DNA phosphate groups
[218]. Here, as the same domain in MUS81 interacts with DNA and the interaction partner SLX4,
it is so far not known how the interactions are regulated. A possible mechanisms was proposed
by Wyatt et al., that upon formation of the SMX complex the HhH domain is prevented to
bind DNA substrate as the interaction between SLX4 and MUS81HhH induces a conformational
change, relaxes substrate specificity and activates its nuclease functions [143]. Recently, a nuclear
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Figure 1.6: Sequence similarities, domain architecture and crystal structure of MUS81-EME1. (A)
Sequence similarities between the ERCC4 domains of MUS81 and EME1 orthologs from different organisms.
Dark blue indicates strictly conserved residues, white indicates variable residues. The orange dots indicate
the key residues of the ERCC4 motif [214]. The orthologs were aligned with MUSCLE [215] and displayed
using Jalview [216]. The alignment shows the sequences of Homo sapiens (hs), and Caenorhabditis elegans
(ce). Uniprot accession numbers [217] from top to down: Q96NY9, P91153, Q96AY2, Q9GZG5, Q92889 and
G5EBZ1. (B) Schematic representation of MUS81-EME1 domain organization for human and Caenorhabditis
elegans proteins. Light grey boxes indicate the Helix-hairpin-helix (HhH) domains at the N- and C-terminus.
The cyan box at MUS81-N-terminus depicts the winged helix (WH) domain. The dark purple boxes in the
MUS81 proteins indicate the ERCC4 (excision repair cross-complementation group 4) domains with nucleic acid
cleavage activity. The light purple boxes in the EME1 represent the ERCC4 domains, where important active
site residues have been rendered to leave the protein inactive. Amino acid boundaries are shown as numbers.
(C) Crystal structure of hsMUS81245-551-hsEME1177-570 in complex with 32-bp dsDNA with 3-nt 3’flap (green)
(PDB code: 4P0R). The black dotted circle marks the cleavage site. The colors correspond to the domain
organization laid out in (B).
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magnetic resonance (NMR) structure of MUS81HhH has been published, showing a stable folded
domain comprised of a pair of anti-parallel α-helices that pack against in each other in an angle of
110◦ [143]. The second helix connects via a loop to the third and fourth helix, which then forms
the HhH motif [143].
The WH domain in human MUS81 was structurally characterized by NMR as well [219]. The
residues 128-230 fold into a helical domain that adopts a WH tertiary fold [219]. In general,
the WH domains are a subclass of helix-turn helix DNA binding domains that are found in
DNA-processing enzymes and many transcription factors [126]. The human MUS81 WH domain
contains two functionally important elements of WH proteins, the recognition helix alpha3 and
the beta-hairpin ’wing’ motif [220]. The WH domain is highly basic with 12 Arg/Lys side chains,
whereas two arginines are within the recognition helix, suggesting a possible charge complementary
appropriate for binding DNA [219]. The winged helix domain has been shown to alter the DNA
binding specificity of MUS81-EME1 complexes [219]. Furthermore, it has been suggested that
both the amino-terminus and the recognition helix of the WH domain have a role in DNA binding
[219]. Deletion of the WH domain reduces cleavage activity of MUS81-EME1, mutations in the
WH domain reduce binding of the isolated domain to DNA in vitro and show a sensitivity towards
DNA damaging agents in S. pombe [219]. The WH domain is essential for both meiosis and DNA
damage tolerance in S. pombe [219].
Apart from the NMR structures of the N-terminal domains of MUS81, there are two crystal
structures published containing the nuclease-(HhH)2 core of the heterodimer MUS81-EME1 [213,
214]. The first structure of a DNA-free human-zebrafish hybrid MUS81-EME1 sheds light on
the nuclease domain of MUS81, the nuclease-like domain of EME1 as well as on the two C-
terminal Helix-hairpin-Helix ((HhH)2) domains of each protein [213]. The nuclease core is shared
with the PD-(D/E)XK superfamily and consists of a central β-sheet that is flanked by α-helices
[213, 221]. The active site of the MUS81 contains carboxylate residues that coordinate divalent
metal ions [213, 214, 222]. The metal-ions are essential for DNA hydrolysis in a two-metal ion
mechanism [223]. Another structural study by the Cho lab showed at low resolution, how the
nuclease recognized and cleaved several DNA flap-substrate [214]. Figure 1.6 C shows the overall
structure of MUS81 (dark purple)-EME1 (light purple) in complex with 3’flap DNA adapted from
[214]. The flap DNA substrate is being kinked by the N-terminal (HhH)2 domains of MUS81
and EME1 together with the nuclease domain and the 3’ end of the incision strand is guided
to the active site [214]. DNA bending is achieved by conformational changes in MUS81-EME1
from a closed to an open form (Figure 1.6 C) [214]. Comparison of the structures with and
without DNA substrate showed substantial differences as the relative orientation varies between
the different crystal structures [213, 214]. DNA binding induces significant conformational change
in the linkers, which transforms the MUS81-EME1 structure from a compact to an open state
[214]. In pre-nick state, the DNA is packed between the EME1-HhH-C-terminal domain and the
MUS81 nuclease domain, whereas after cleavage the DNA is bound to the EME1-ERCC4 like
domain and the MUS81-(HhH)2-C-terminal domain [214, 221].
So far, only low resolution structural information about XPF family members is available and
further structural data is needed to understand how the N-terminal domain of MUS81 interacts
with DNA substrates and positions in respect to the catalytic domain. The structural characteri-
zation of MUS81-EME1 has revealed a distinctive orientation of its nuclease and (HhH)2 domains
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toward DNA junction binding [213, 214]. However, both studies lacked the amino-terminal exten-
sion of MUS81 and EME1. The NMR studies of the N-terminal domains show the overall fold,
but it still remains elusive how the N-terminal domains will interact with the DNA substrate.
For other XPF family members a structure of the archaeal XPF homodimer in complex with a
dsDNA fragment has been published, but the DNA is not interacting with the active site [224].
Structural information of the eukaryotic XPF-ERCC1 is available for the ERCC1 nuclease-like
domain [225] and the HhH heterodimer [225, 226]. Furthermore, some structural information of
FANCM-FAAP24 is available [227]. However, until now no structural information is available
about the catalytic complex of XPF-ERCC1.
MUS81-EME1 can cleave diverse DNA substrates due to the active site with the DNA binding
pocket and the differences in linker and location of the (HhH)2 domain compared to XPF family
members [214]. Therefore, MUS81-EME1 is involved in different DNA repair pathways. It plays
a critical role in the genome maintenance, e.g. in the repair of internal cross-links and replication
fork collapse in mitotic cells and in meiotic cross-overs [135, 209, 228]. Its role in the recovery
of stalled or collapsed replication forks is evolutionary conserved [221]. Problematic replication
forks can arise in regions of the genome that are inherently difficult to replicate, in response
to replisome-blocking agents (ICLs) or when dNTP pools are dimished [221]. Thereby, MUS81
collaborates with BLM and ATR to convert the replication forks into transient DSBs that are
rapidly repaired [126, 229]. Additionally, MUS81 can associate with and stimulate FEN1 (flap
endonuclease 1) activity [230]. This interaction is dependent on the N-terminal winged helix of
MUS81 [219]. MUS81-EME1 is involved in ICL repair and carries out the unhooking process of the
DNA cross-link [228], thus creating a one-ended double-strand break. In murine cells is the role
of MUS81 in ICL repair independent of its interaction with SLX4 [201]. Interestingly, in human
cells, MUS81-EME1 mutants incapable of interaction with SLX4 are also defective in ICL repair
[201]. Furthermore, MUS81-EME1 is upregulated at mitosis and it has been found in yeast, that
Mus81 limits the error-prone process of break-induced replication [126].
1.3.4 Cleavage Properties of the SM-Complex
Through DNA replication and the different types of DNA damage occurring at molecular level [1],
a huge variety of DNA substrates with distinct secondary structures arises. Therefore, the various
nucleases have evolved to resolve the different DNA structures, each nuclease having its own
cleavage range and specificity. The cleavage activity of the nucleases can be tested experimentally
in vitro by labeled substrates. These substrates correspond to the different intermediates during
DNA repair. Therefore, a short overview will be given about the cleavage properties of the
nucleases associated with SLX4 in Figure 1.7.
First, SLX4 was described to form a complex with the GIY-YIG type endonuclease SLX1
in fission yeast for ribosomal DNA maintenance [153]. Biochemical data suggested then that
the complex plays a role in the processing of stalled replication forks [231] and later Holliday
Junction resolution activity was reported [113–115, 141]. The S. cerevisiae Slx4-Slx1 complex
cleaves splayed arms, 5’flaps, replication forks (RF) and HJs [152]. The major cleavage site for the
5’ flap lies in the 5’ single-stranded arm at the junction between the single- and double-stranded
DNA [152]. The fission yeast Slx1-Slx4 cleaves stem loops and HJs [153]. The human SLX4-SLX1
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Figure 1.7: DNA substrates and cleavage properties of nucleases associated with SLX4 Cleavage activities
of human XPF-ERCC1, its Saccharomyces cerevisiae ortholog Rad1-Rad10, the human MUS81-EME1 complex
and its Saccharomyces cerevisiae ortholog Mus81-Mms4 as well as the SLX4-SLX1 complexes from human,
Caenorhabditis elegans, Shizosaccharomyces pombe and Saccharomyces cerevisiae nuclease complexes. The
XPF-ERCC1 / Rad1-Rad10 and the MUS81-EME1 / Mus81-Mms4 complexes belong to the XPF endonuclease
family. SLX1 is a GIY-YIG nuclease.
shows activity towards Y forks, 3’- and 5’-flaps, RFs, stem loops and HJs [113–115, 141]. Both,
yeast Slx1 and human SLX1 alone have only very weak nuclease activity, but in complex with
Slx4 and SLX4 the cleavage rate is increased tremendously [114, 141, 153]. For the C. elegans
SLX1-SLX4 complex, endonucleolytic activity could be detected for RFs, 3’ flaps, 5’flaps and
HJs [25]. However, the ceSLX1-SLX4 complex is not a bona fide HJ resolvase as it does not
cleave HJ substrates with perfect symmetry as the human complex does [25]. The ceSLX1-SLX4
endonuclease is more reminiscent to the baker’s yeast and the fission yeast complexes [25, 152, 153].
The difference in the cleavage activity is based on the different function C. elegans SLX1-SLX4
has, as it is involved in the resolution of meiotic crossovers [25]. Comparing the nuclease activities
from different organisms, it shows that subtle differences between the orthologs of one nuclease
complex exist.
In association with EME1 the MUS81 endonuclease is able to cleave different three- and four-
way junctions containing a duplex downstream from a nick in vitro [232]. Human and yeast
MUS81-EME1 / Mus81-Mms4 cleave nicked HJs, replication forks and 3’flaps [141, 174] (Figure
1.7). In addition to these substrates yeast Mus81-Mms4 cleaves also D-loops [213, 233]. These sub-
strates for MUS81-EME1 form during mitosis and fission yeast meiosis, but also during processing
of damaged replication forks.
When cleavage activity of SLX4 in complex with SLX1 and MUS81-EME1 was tested in vitro,
a unique cleavage mechanism was detected: SLX4 brings the SLX1 and MUS81-EME1 nucleases
during HJ resolution together giving rise to a coordinated nick and counter-nick mechanism [141,
143]. In the setting of the two active sites SLX1 introduces the first cut on Holliday junction
and MUS81-EME1 introduces the second cut [141]. Both incisions occur within the lifetime of
the SM-HJ DNA complex and the cleavage is faster than compared to the activity of the proteins
1.3 The SLX4-SLX1-MUS81-EME1-Complex 27
alone [141, 143]. Thus, SLX4 scaffold tethers MUS81-EME1 and SLX1 and thereby coordinates
the activity of the nucleases on HJs [141, 202]. Recently, it has been shown that the N-terminal
HhH domain in MUS81 regulates substrate specificity in MUS81-EME1 [143]. Interaction of SLX4
with MUS81 HhH domain, which can also bind DNA, relaxes nuclease specificity, thus activating
nuclease functions [143]. Deletion of this N-terminal domain led to preferential cleavage of 3’flaps,
but also showing weak activity on intact HJs [143]. In contrast to the wild-type enzyme MUS81-
EME1 lacking the HhH domain showed decreased activity on RF and nHJs, but increased activity
towards the unusual substrates 5’flap and splayed arms [143]. Thus, the N-terminus of MUS81
plays a critical role in the regulation of cleavage preference of the nuclease domain, when in complex
with SLX4.
Furthermore, when the third SLX4-interacting nuclease, XPF-ERCC1, was tested in the con-
text of the SMX-complex, it was shown that it does not take part in the cleavage reaction directly
[143, 234]. The XPF-ERCC1 nuclease alone processes splayed-arms, bubbles and stem-loop struc-
tures [174]. But in the context of the trinuclease SMX complex XPF-ERCC1 increases HJ resolu-
tion activity compared to SM complex, thus playing a role in stabilizing the complex [143, 234].
HJ cleavage activity has been reported for the SM complex, but the general RuvC paradigm for
HJ resolution cannot be applied [136, 146]. The Escherichia coli RuvC protein forms a homodimer
and coordinates the two active sites to introduce a pair of symmetrical nicks into strands that
are diametrically opposed across the junction [136, 146]. The reaction products are then a pair
of nicked duplexes that can readily be ligated [136, 146]. The resolvase GEN1 shows comparable
cleavage behavior as the prototypic HJ resolvase RuvC and cleaves 5’flaps, replication forks and
HJs [111, 235]. In contrast, the SM-complex has been shown so far to work with a unique cleavage
mechanism as it contains a pair of heterodimeric flap endonucleases, each contributing one active
site to the cleavage [136]. The majority of the cleavage products can not be ligated, contains
flaps and requires further processing [136]. Furthermore, human SLX4 provides a scaffold for the
tri-nuclease complex [143] and has been shown to be the only example so far for a tri-nuclease
complex [236]. Taken together, SLX4 is a context-dependent nuclease scaffold, that requires the
activation of different modules depending on the lesion [158].
1.3.5 Regulation of the SM-Complex
The structure-selective endonucleases are an inherent threat to genome integrity because bro-
ken DNA ends can facilitate chromosome rearrangements and genome alterations, which are po-
tentially tumorigenic [156]. Thus, the endonucleases have to be tightly regulated to make sure
that the correct DNA substrate is cleaved at the right time [156]. The regulatory mechanisms
are suggested to work at several levels [156]: protein expression, post-translational modification
(Mus81-Mms4/Eme1, Yen1) [117, 118, 139], nuclear localization (Gen1) [237], conformational
changes (FEN1), protein-protein interactions (XPG, XPF-ERCC1, SLX-MUS) [141] and dimeri-
sation (SLX1) [156, 221]. Several studies carried out in yeast have been shown how the nucleases
are regulated throughout the cell cycle [117–119, 136, 139]. Thereby, cell cycle stage specific phos-
phorylation of the nucleases and their interaction partners ensure temporal and spatial control as
well as sequential activation [136]. During S phase, the HJ resolution activity of Mus81-Mms4
is low, but at mitosis onset it becomes elevated due to phosphorylation of Mms4 by cell cycles
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kinases Cdc28/Cdk and Cdc5 [117–119, 136, 194, 238]. This temporal regulation of Mus81 chan-
nels a large proportion of joint molecules into the dissolution pathway [117, 238]. The dissolution
leads to non-crossover outcome and is beneficial for mitotic cells [84, 194]. Additionally, the
restriction of Mus81 activity may be necessary to achieve temporal separation of lesion bypass
reaction and joint molecule resolution [120]. Mus81 could impede the bypass reaction, given its
relatively broad substrate specificity to a range of DNA substrates (RF, D-loops, HJs) [194]. The
regulation of the nucleases in human cells is in detail different from the regulation in yeast cells
[136]. The EME1 subunit in the MUS81-EME1 complex becomes phosphorylated by cell cycle
kinase CDK1 and PLK1 at the onset of mitosis [117, 136, 199]. SLX4 becomes phosphorylated
by CDK1 and PLK1 [200]. These phosphorylations promote the association of MUS81-EME1
with SLX4-SLX1 to form the SM-complex [136, 141]. This direct interaction between SLX4 and
MUS81 occur at prometaphase in response to the phosphorylations of MUS81-EME1 and SLX4
[114, 141, 200, 202, 234]. Hence, the two nucleases are combined to form a highly active HJ
resolvase [136, 141].
1.3.6 Comparison Between the Human and the C. elegans SM-Complex
In this thesis the human and Caenorhabditis elegans proteins of the SM-complex were investigated.
Therefore, this subsection will give a short comparison between the proteins of the SM complex
from the different organisms. The nematode Caenorhabditis elegans is a well-established model
organism, which has been used in a wide array of research questions, e.g. apoptosis, development
and meiosis. During meiosis double-strand breaks occur and are easy to investigate as C. elegans
follows a strict lineage of each larval cell [239]. Furthermore, C. elegans proteins are in general
to 80% conserved to vertebrates [240]. The SLX4 ortholog in C. elegans is named HIM-18 (high
incidence of males) which is characterized by an increased X chromosome loss [24]. For simplicity
reasons HIM-18 is referred to herein as ceSLX4. ceSLX4 was discovered through a functional
genomics approach in C. elegans. It has been shown to be essential for normal meiotic progression
[24]. ceSLX4 facilitates processing of HR intermediates, which result from stalled replication forks
and programmed meiotic DSBs [24].
Direct comparison of the domain organization between the human and worm proteins shows
that the C. elegans proteins are in general shorter than the human proteins (Figures 1.4 A and 1.6
B), except for the SLX1 protein. ceSLX4 has only 40% size of the human ortholog and is much
more compact as it lacks the long uncharacterized and disordered stretches between the domains.
It shares 16% identity and 56% similarity with the human SLX4 [24]. Especially, the C-terminal
SAP and CCD domains are highly conserved [113–115]. Interestingly, the C. elegans SLX1 protein
contains a 168 amino acid N-terminal extension before the GIY-YIG nuclease domain (Figure 1.4
A), which can not be found in other SLX1 orthologs. Moreover, a bioinformatics analysis could not
find a related sequence in any other protein, except for other nematode species or ascaris species.
The C. elegans MUS81-EME1 proteins are shorter by approximately 100 amino acids (Figure 1.6
A). ceMUS81 does not contain a WH domain as human MUS81. So far, the WH domain has not
be found in any nematode species [219]. An alignment between MUS81 orthologs from different
organisms does not show any hints towards the domain in C. elegans (see Appendix 4.3).
The interaction between ceSLX4 and ceSLX1 has been shown by yeast two-hybrid assay [24,
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241] and co-immunoprecipitation [25]. The interaction is based on both domains of ceSLX1, the
RING finger domain and the nuclease domain, and the CCD domain of ceSLX4 [25]. In the
nematode C. elegans, previous work found that ceSLX1 and the ceSLX4 are required for the
resolution of some meiotic crossovers [25]. Studies showed that in C. elegans are two parallel,
partially redundant pathways responsible for crossover formation - one is dependent on MUS81
and the other on XPF1 [176, 241, 242].
C.elegans SLX4 is required for HR-mediated repair at stalled replication forks and has a role
in converting HR intermediates into crossover products [24]. ceSLX4 facilitates processing of
HR intermediates resulting from replication fork collapse and programmed meiotic double-strand
breaks in the C. elegans germline [24]. ceSLX1 is required for the repair of stalled/collapsed
replication forks and meiotic DSBs [25]. The involvement of ceSLX1 in the repair of meiotic DSBs
is not based on the resolution of the HJ itself, but it is involved in the regulation of the meiotic
crossover distribution [25]. SLX1 is required for the suppression of crossovers at the center region
of chromosomes [25]. For this, SLX1 could either act as a non-crossover specific HJ resolvase at
the center region of chromosome V or the RING finger could act as an epigenetic reader [25, 241].
In C. elegans, SLX1 is involved in several genome maintenance pathways: replication support,
re-establishment of a normal fork, ICL repair and nucleotide excision repair [25]. ceMUS81-EME1
is regulating the crossovers during meiosis together with SLX1 [241]. ceMUS81 and ceSLX1 have
overlapping roles for DNA repair with HIM-6, the C. elegans ortholog of BLM [241]. In C. elegans
meiosis XPF1 acts redundantly with MUS81 and SLX1 to resolve HJs into crossover products on
chromosome arms, which are epigenetically marked by histone H3K9me [176, 241, 242]. Through
the interplay between the structure-specific endonucleases they are able to have either positive or
negative control on meiotic crossovers depending on the chromosome region [241].
1.3.7 Involvement of the SM-Complex in Genome Integrity and Disease
For mammalian cells Holliday Junction processing is of great importance. Cells depleted for BLM
and SLX4, thus blocking the dissolution pathway and one resolution pathway, are synthetic lethal
[112, 136, 141]. The same holds true for the depletion of SLX4 and GEN1, when blocking both
resolution pathways [112, 136, 141]. Chromosomal abnormalities and mitotic defects lead to this
mortality [112, 140, 141, 243]. Unresolved recombination intermediates fail to elicit checkpoint
response, the resolvase-deficient cells enter mitosis with their sister chromatid bridges intact [234].
At anaphase the cells display ultrafine bridges, coated with RPA, which indicates ssDNA presence
[150]. At mitotic division these bridges are broken, result in DNA breaks at G1 and repair by
NHEJ, but they lead ultimately to cell cycle arrest and cell death [150]. These kind of resolvase
deficient system is somewhat artificial, but provides a model for the study of recombination inter-
mediates [234]. The cellular defects caused by resolvase deficiency show that the resolvases are not
simply a backup for the dissolution pathway, but are essential factors in chromosome segregation
[234].
In budding and fission yeast, the deletion of slx1 does not exhibit lethality or DNA damage
sensitivity. The cells exhibit only defects in completion of rDNA replication [153, 204]. In human
cells, siRNA based depletion of SLX1 increases DNA damage after treatment with ionizing radi-
ation, camptothecin and DNA interstrand cross-linking agents [113–115, 154]. Knockout mice for
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SLX1 did not exhibit any morphological, developmental or hematological defects and were fertile
[202].
Fission yeast lacking either mus81 or eme1 produce spores that are inviable because of the
defects in chromosome segregation during meiosis I [78, 135]. In contrast, deletion of mus81 in
budding yeast leads to a modest decrease in meitotic survival as budding yeast Mus81 is only
responsible for a small subset of crossovers during meiosis [78]. So far, MUS81 has not been
reported to be mutated in any human disorder [158]. However, knockout mice and cells are
sensitive to cross-linking agents [158, 244, 245]. Two MUS81 mouse models have been generated
[244, 245], but only one of them showed cancer predisposition [245]. Depletion of MUS81 from
human cells leads to CPT sensitivity [114, 158]. In prostate cancer cells MUS81 has been detected
as an alerter for the immune system to the presence of transformed cells [246]. MUS81 cleaves
genomic DNA, which accumulates in the cytosol triggering the activity of the immune system
[246].
Although, EME1 -/- mouse embryonic stem cells do not show changes in viability or growth
rate, they exhibit aneuploidy, increased sister chromatid exchange upon DNA damage and in-
creased levels of spontaneous chromosomal abnormalities [247].
S. cerevisiae cells lacking Slx4 are highly sensitive to the DNA alkylating agent MMS, leading
to a blockage of replication and induction of the damage checkpoint signaling pathway [152]. SLX4
has been found to play a role in the Fanconi anemia pathway as FA complementation group P
(FANCP) [14, 248, 249]. The FA pathway repairs ICLs and SLX4 with its associated nucleases
has been found to play not only a role in the repair of double-strand breaks but also in the repair
of DNA interstrand crosslinks (ICLs) [14, 161, 179, 249]. The rare recessive genetic disease FA is
characterized by progressive pancytopenia, congenital and skeletal malformations, predisposition
to hematologic and solid cancer [250]. Furthermore, sensitivity towards DNA crosslinking agents is
a hallmark for diagnosis of FA [250]. Individuals carrying mutations in SLX4 manifest symptoms of
FA by showing hypersensitivity towards the DNA damaging agents camptothecin and mitomycin
C [14, 249]. So, far 22 FA genes have been identified and FA signaling is crucial in the DNA damage
response [13]. In FA patients relies the in vivo activity of XPF-ERCC1, MUS81-EME1 and SLX1
during DNA repair strictly on their association with SLX4 and the nucleases are important for
DNA repair of distinct DNA lesion [112, 158]. Mice lacking SLX4 exhibit chromosomal instability
with symptoms similar to Fanconi anemia [248]. So far, FA patients with different mutations in
SLX4 have been described [14, 158, 249]. For example, siblings with deletions in the UBZ domain
of SLX4 showed symptoms of FA and mutated SLX4 derived from this patients was not recruited
to DNA damage [160]. Patients lacking SLX4 show a more severe developmental phenotype, e.g.
bone marrow failure and death in the early twenties [14, 158, 249].
Mutations or knockouts in the genes encoding the nucleases lead to viable cells and organisms.
This is in contrast with the rather strong phenotypes of SLX4 mutation or deletion. The nucleases
are assumed to be redundant in the processing of DNA damage [159]. For the nucleases involved
in HJ resolution, disease phenotypes have not been described as HJ resolution is a highly backed
up process. If there is a mutation in e.g. SLX1, then HJ resolution can still be carried out by
GEN1 [243]. However, as SLX4 is involved in several pathways and forms a platform for various
proteins involved in different cellular processes, a deletion or a knockout has severe consequences
for the integrity of the genome.
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1.4 Aim of the Thesis
SLX4 is a scaffold protein and fulfills several roles in DNA damage repair and other cellular pro-
cesses trough its interactions with partner proteins. It has the remarkable ability to bind several
DNA repair nucleases and is not a passive scaffold, but can act as a nuclease stimulating factor
[179]. This versatility, its broad role in DNA damage response and the importance as a tumor
suppressor makes SLX4 a very interesting object of study. So far, not much is known about how
these nucleases interact with each other and in the context of a Holliday Junction. This thesis is
focused on the C-terminal domains of SLX4 and the Holliday Junction resolvases, MUS81-EME1
and SLX1. In this context, it was of interest, how the individual DNA-binding modules are co-
operating in order to recognize and lead to a cleavage of the substrate. The initial goal was the
structural elucidation of the SM complex binding Holliday Junction by crystallography as so far
only a low resolution structure of MUS81-EME1 in complex with flap DNA and a structure of
SLX1 and SLX4CCD without DNA are available [156, 214]. Therefore, expression of human and
C. elegans orthologs in E. coli and mammalian suspension culture was established and purifi-
cation protocols were installed. Expression and purification of a SLX4 C-terminal construct in
mammalian cells resulted in a highly phosphorylated protein and the phosphorylation pattern
of SLX4 in presence and absence of SLX1 was analyzed. Also the influence of DNA damag-
ing agents was evaluated towards changes in phosphorylation pattern. The interaction between
SLX4SAP and the N-terminus of MUS81 was measured and quantified by several methods, e.g.
analytical ultracentrifugation and thermofluor, as earlier studies demonstrated the interaction by
co-immuniprecipitation and yeast-two-hybrid assay [201, 202]. Furthermore, it was known that
the N-terminus of MUS81 can bind DNA [143, 219], thus DNA binding of C. elegans MUS81
N-terminus was further characterized. The SAP domain of SLX4 is referred to as a putative DNA
binding domain because of its comparison to other SAP domains. However, this ability of SLX4
has not been demonstrated in vitro yet. Here, band-shift assays and fluorescence anisotropy show
that SLX4SAP indeed binds DNA with a slight preference for intact Holliday Junction. Further-
more, DNA binding of a complex of SLX4SAP and MUS81N showed higher DNA binding affinity
than of the proteins alone with a clear preference of HJ and nicked HJ over dsDNA. Moreover,
the area in SLX4SAP was determined, which is responsible for DNA binding. In collaboration the
NMR structure of SLX4SAP was determined and compared with SAP domains from other pro-
teins. A model how the SAP domain could bind DNA was discussed. Structural and biochemical
information will help to answer the following questions: how is the complex of SLX4 and MUS81
differentiating the cleavage substrate? Which area in SLX4SAP is involved in DNA binding? Fi-
nally, the results and conclusions from the experiments were discussed in the context of Holliday
Junction resolution and the coordinated cleavage reaction by the four proteins.
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2. Results
2.1 Expression and Purification of the Human SM-Complex
To obtain structural and biochemical information on the Holliday-Junction cleavage complex con-
sisting of SLX4-SLX1-MUS81-EME1 (SM-complex), I tested expression of Homo sapiens proteins
in E. coli and in mammalian cell expression system. The human proteins are particular interesting
as human SLX4 is found to be mutated in the rare genetic disease Fanconi anemia [14, 248, 249].
The first part of this chapter will describe the purification and crystallization process for the hu-
man proteins and in a later section the expression and purification of the C. elegans orthologous
proteins will be described. As a general screening outline, it was always first tested, whether full
length proteins could be expressed and purified and then shorter constructs were designed based
on limited proteolysis and secondary structure prediction. Especially, for the human SLX4 protein
the regions in the middle of the protein were intrinsically disordered.
2.1.1 Purification of hsMUS81-EME1
The structure-selective endonuclease MUS81-EME1 complex belongs to the XPF-ERCC4 family of
nucleases and MUS81 contains the functional catalytically active ERCC4 domain whereas EME1
harbors the catalytically inactive domain [174]. MUS81-EME1 interact with each other via their
C-terminal HhH domains [135, 213]. Previous publications about MUS81-EME1 showed that
recombinant MUS81-EME1 are poorly expressed individually, but co-expression gave good yields
[142, 251]. In order to overproduce full-length hsMUS81-EME1 (construct 1, Figure 2.3) I used
a codon optimized synthetic gene, in which the codons are optimized for the codon bias and
for an even distribution of GC content. The two proteins were cloned as a bicistronic construct
with N-terminally His8-SUMO (small-ubiquitin related modifier)-tagged hsEME1 and untagged
hsMUS81. The proteins were solubly expressed in E. coli BL21 gold cells and purified using
IMAC (immobilized metal affinity chromatography), heparin affinity chromatography and SEC
(size-exclusion chromatography) (Figure 2.1). SEC or gel filtration is a chromatographic method,
which separates proteins according their size and so, it can be used for purification as well as
analytical purposes. Larger proteins elute at shorter retention times and smaller proteins at
longer retention times. Proteins forming a complex, are expected to elute together in one peak.
Size exclusion chromatography of hsMUS81-EME1 showed one main peak and few smaller peaks.
SDS-PAGE analysis revealed that the peaks, that elute at later time points, contained either
degradation products or contaminants and the last peak was composed of the His8-SUMO tag.
The main peak was analyzed by total mass spectrometry and showed to contain the FL protein of
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Figure 2.1: SEC analysis of hsEME1-MUS81 using a Superdex 200 16/600 column. (A) Size exclusion
chromatogram of purified hsEME1-MUS81 showing an elution profile with a major peak and few smaller peaks
visualized by UV absorbance at 280 nm and 260 nm. The major peak eluted at 66 ml containing the full length
EME1 and slightly degraded MUS81. The other peaks eluted at 88.5 ml, 97.1 ml and 103.0 ml consisting of
either various degradation products or contaminants. The last peak eluted at 127.0 ml and contained His8-
SUMO tag. (B) SDS-PAGE shows the fractions of the main peak and the other peaks. The pooled fractions
are marked by a line. (M) Protein marker in kDa. (In) Input protein sample injected on gel-filtration column.
EME1. Full length MUS81 was not detected, however, there were two slightly degraded fragments
each lacking 11 kDa either at N- or C-terminus. They correspond to a MUS81 fragment lacking
the N-terminal HhH domain and another MUS81 fragment lacking the C-terminal HhH domain.
Despite the degradation issues, a limited crystallization screening was performed with various
DNA substrates but did not yield any crystals.
In order to obtain constructs with a higher possibility to crystallize, I engineered several trun-
cated constructs and tested them for expression and purification. For this especially the MUS81
construct was split up into two parts. Based on the already published structure of human MUS81-
EME1 (PDB: 4P0P and 4P0Q) and secondary structure prediction more constructs containing the
ERCC4 domain with the active site and the C-terminal HhH domains were designed and tested
for purification (Figure 2.3). The published NMR structures of the human MUS81 N-terminal
HhH and WH domain [143, 219] lead to the design of the hsMUS812-225 construct combining the
two domains (see below). To tackle the degradation problem of MUS81, the proteins were cloned
into a bicistronic vector with N-terminal His8-SUMO tag (Figure 2.2 A) for hsEME1 and C-
terminal CPD (cysteine protease domain)-TwinStrep tag for hsMUS81 (Figure 2.2 C). In general,
a C-terminal tag on MUS81 should prevent C-terminal degradation and increase the yield of full
length protein. The CPD tag is an inducible autocleaving protease tag [252, 253] (Figure 2.2 C)
adapted from a Vibrio cholerae MARTX toxin. The addition of inositol-6-phosphate leads to an
activation of the CPD protease and CPD cleaves at the target protein-CPD junction. The protease
domain recognizes the amino acid sequence XXXL—AGGK and cleaves between the leucine and
alanine residue leaving only a leucine residue left at the C-terminus of the target protein. After
binding the target protein to an affinity column, tag cleavage allows a very convenient separation
between target protein and the remaining tag. Furthermore, it has been shown before, that the
CPD tag increases expression, solubility and stability of target proteins [253].
The constructs hsEME1233-570-MUS81256-551, hsEME1210-570-MUS81133-551 and hsEME1178-570-
MUS81241-551 were purified using IMAC, followed by affinity chromatography with Strep-Tag. The
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Figure 2.2: Fusion protein purification systems. (A) The small-ubiqutin related modifier (SUMO)-tag
serves as a solubility enhancer for recombinant protein and is a protease recognition site for the protease Senp2
[254]. (B) For expression in mammalian expression system the SUMO tag was modified to prevent cleavage by
endogenous Senp2 protease [255]. (C) Cysteine protease domain tag (PDB 3eeb [256]) is covalently linked to
the target protein. Upon addition of inositol hexakisphosphate (IP6) the CPD protein undergoes cleavage at
the P1 Leu site. The residues termed X are the C-terminal residues of the target protein. At P2 position the
most common residues are A, G, S or W [252]. The auto cleavage site is marked by the black line between P1
and P1’.
proteins were eluted from the Strep column by activation of the CPD self-cleavage property with
IP6 (Inositol-hexakisphosphate). However, in all four tested constructs, the cleavage activity was
not sufficient as large amounts of CPD-Strep-tagged protein remained on the column and were
eluted when the Strep-tag was displaced from the column material by desthiobiotin. Additionally,
the removal of the SUMO-tag lead to decreased stability and solubility of the proteins. Taken to-
gether, all constructs had either precipitation issues after tag cleavage under the tested conditions
or the CPD cleavage was not efficient and separation between tag and protein after cleavage was
not possible.
Next, expression and purification of truncated constructs of hsMUS81-EME1 were tested only
with N-terminal His8-SUMO tag on hsEME1 in the bicistronic vector and untagged hsMUS81.
The published construct hsEME1178-570-MUS81241-551 (Construct 2) was tested as a starting point
[214]. The protein was purified by a combination of IMAC, weak cation exchanger and SEC and
resulted in pure protein as judged by SDS-PAGE (Figure 2.4). The sample was subjected to
crystallization with the published DNA substrates and our own designed DNA substrates. The
goal of this reproduction was to evaluate whether the sample quality was high enough in order to
produce crystals. hsEME1178-570-MUS81241-551 in complex with one of the published substrates
(17bp 5’flap) gave rise to crystals in 0.1 M MES pH 6.5, 5% Ethanol, 5 mM DTT. The crystal
diffracted to 3.1 A˚. The structure of this construct could be solved by molecular replacement with
the published coordinates of 4P0P using PHASER. But our structure did not show additional
details than the already published structure. Other nHJ and HJ substrates, which were used for
crystallization as well, did not give any crystal hits. Taken together these experiments show that
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Figure 2.3: Schematic representation of hsEME1-MUS81 constructs the constructs were tested for ex-
pression (exp), solubility (sol) and degradation (deg) in E. coli. Success of the experiment is indicated by
plus (positive) and minus (negative). Most of the constructs could be soluble expressed and did not show
much degradation. All bicistronic constructs except for hsEME1246-570-MUS81241-551 were tested in two different
vectors with different tags, N-terminal-His8-SUMO (pCB-bax04) and N-terminal-His8-SUMO-C-terminal-CPD-
Twinstrep (pCB-bax25). The MUS812-225 construct was expressed with N-terminal-His8-SUMO (pCB-bax04)
and C-terminal-CPD-His8 (pCB-bax10) tag. However, the tested constructs did not yield any crystals with the
DNA substrates. HhH helix-hairpin-helix (light grey); ERCC4 excision repair cross complementation group 4
(dark purple: catalytic active domain; light purple: catalytic inactive domain); WH winged helix (cyan).
the quality of the purified protein was suitable for crystallization but DNA substrates other than
the published ones did not gave rise to crystals.
As mentioned before, a construct from aa 2 to aa 225 was designed based on the already
published NMR structures of hsMUS81 WH and HhH domain [143, 219] and secondary structural
prediction (Figure 2.3, Construct 6). These two N-terminal domains of MUS81 were not included
in the structural studies by Gwon et al. [214] as their cloned construct contained hsMUS81246-551
and hsEME1178-570. The WH domain has been found to interact with DNA and has an influence on
positioning as well as on cleavage activity of MUS81-EME1 and MUS81-EME2 complexes [219].
Moreover, the HhH domain in human MUS81 is involved in DNA interaction, which has been
shown by fluorescence anisotropy and NMR chemical shift titration [143]. However, both NMR
structures do not contain a DNA substrate and there is so far no information of how these N-
terminal domains interact with DNA substrates and how they assist in orienting DNA with respect
to the active site domain of MUS81. Therefore, the next approach was to purify the N-terminal
hsMUS812-225 construct and crystallize it alone and in complex with DNA. The hsMUS812-225
construct was very well expressed in E. coli and turned out to be highly soluble in E. coli using
a His8-SUMO tag. The protein construct eluted as single peak with some tailing in gel filtration
(Figure 2.4 B). Analysis of the protein identity by mass spectrometry analysis applying ESI-TOF
mass spectrometry (electrospray ionisation - time-of-flight) showed the correct size of the protein
construct. hsMUS812-225 alone and in complex with various DNA substrates was subjected to
crystallization trials.
The N-terminal DNA binding domains in the construct hsMUS812-225 and the bicistronically
expressed C-terminal constructs of MUS81-EME1 containing the ERCC4 domain were combined.
Through the combination, a nearly full-length MUS81 was assembled on the DNA substrate with
reduced degradation issues compared to the full-length expressed protein. By mixing the proteins
and the DNA substrates in 1.0:1.0:1.1 molar ratio, the DNA binding domains and the active site
would together bind the DNA substrate and were subjected to crystallization. However, none of
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Figure 2.4: SEC analysis of hsMUS81 constructs based on limited proteolysis using a Superdex 75
16/600 column. (A) Size exclusion chromatogram of purified hsEME1178-570-MUS81241-551 showing an elution
profile with a major peak and few smaller peaks visualized by UV absorbance at 280 nm and 260 nm. The
major peak elutes at 50.5 ml, the other peaks elute at 73.6 ml and 88.3 ml. The SDS-PAGE next to it shows
the fractions of the main peak and the other peaks. (B) Size exclusion chromatogram of purified hsMUS812-225
showing elution profile with a major peak visualized by UV absorbance at 280 nm and 260 nm. The major peak
elutes at 63.8 ml. Right side, the SDS-PAGE shows the fractions of the main peak. The pooled fractions are
marked by a line. (M) Protein marker in kDa. (Hep) Protein sample after Heparin column. (Hep cut) Protein
sample after Senp2 cleavage. (In) Input protein sample injected on gel-filtration column.
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Figure 2.5: Expression test of different hsSLX4 constructs in HEK293 suspension culture. N-terminal
His8-eGFP-SUMO tagged hsSLX41-1834, hsSLX4667-1834 and hsSLX41300-1834 were expressed at 3:1 PEI:DNA
ratio in FreestyleTM expression media supplemented with 1% FCS. Expression duration was one, two and three
days. Samples of 0.2x106 cells/ml were applied to 10% SDS-PAGE and analyzed by in gel fluorescence (left)
and Coomassie stain (right).
the trials containing hsMUS812-225 lead to crystallization hits.
2.1.2 Expression and Purification of hsSLX4 and hsSLX1
SLX4 interacts as a platform protein with other proteins involved in DNA repair, especially
structure-specific endonucleases like MUS81-EME1 and SLX1 [113–115]. The human 200 kDa
SLX4 protein consists of six domains (Figure 1.4 A) [113–115, 158]. The C-terminus harbors the
SAP domain, which interacts with the MUS81-EME1 nuclease complex [201, 202], and the CCD
domain, which confers interaction with the GIY-YIG nuclease SLX1. Earlier biochemical studies
described a nick and counter-nick mechanism for the four-protein complex on Holliday Junction
substrate [141]. The expression of the full-length SLX4 protein was first attempted in E. coli, but
did not yield any protein in pull down experiments, suggesting that the protein is not produced
or insoluble. Secondary structure and disorder prediction indicated large unstructured regions.
Therefore, expression of the full-length protein was tested in a mammalian expression system with
HEK293 suspension culture. Expression of the full-length SLX4 and truncated SLX4 constructs,
derived from secondary structure prediction, were tested with an N-terminal His8-eGFP-SUMO
tag in small scale (Figure 2.5). For this, a small volume of cell culture was transiently transfected
with the respective construct at different transfectant:DNA ratios and whole cell samples were
taken after one, two and three days of expression. The samples were subjected to SDS gel elec-
trophoresis and expression levels were detected by in gel fluorescence of the GFP tag. GFP was
detected due to its stability towards SDS concentrations of up to 0.5% and omitting the boiling
step for SDS-PAGE sample preparation [257]. For the full-length hsSLX4 only a weak signal was
detectable at the respective molecular weight. Furthermore, after two or three days of expression,
degradation of the protein was observed by SDS-PAGE. The N-terminally truncated constructs
showed higher expression levels than the full-length protein, but with increasing duration of ex-
pression, a stronger breakdown of the protein occurred. The strongest expression level of the tested
constructs was reached with hsSLX41300-1834, which was used for further large scale expression in
HEK cells and for purification.
Recombinant expression of hsSLX1 was attempted in E. coli but lead to the accumulation of
insoluble protein in inclusion bodies. A common strategy to enhance protein solubility is the co-
expression with an interaction partner. Therefore, co-expression with SLX4 as interaction partner
2.1 Expression and Purification of the Human SM-Complex 39
A
Ab
sor
ba
nce
	(m
AU
)
Elu�on	Volume	(ml)
M In S200	Pool
116
66
45
35
25
18
14
hsSLX11‐275	
hsSLX41300‐1834	
0 20 40 60 80 100 120 140
0
50
100
150
200
280nm
260nm
B
Figure 2.6: SEC analysis of hsSLX41300-1834 co-expressed with hsSLX111-275 using a Superdex 200 16/600
column. (A) Size exclusion chromatogram of purified hsSLX41300-1834 + hsSLX111-275 showing an elution profile
with a major peak visualized by UV absorbance at 280nm and 260nm. The major peak elutes at 63 ml. The
second peak elutes at 95.2 ml and contains the proteases. (B) SDS-PAGE shows the fractions of the main
peak. The pooled fractions are marked by a line. (M) Protein marker in kDa. (In) Input protein sample injected
on gel-filtration column.
was tested in HEK cells. Co-expression of hsSLX1 with hsSLX41300-1834 construct resulted in
soluble protein in small scale expression tests and in large scale expression. However, the yield of
the expressed proteins was limited and a lot of expressed protein was still found in the insoluble
fraction after lysis. In order to increase the amount of soluble protein, different methods of cell
lysis (detergents, beads, sonication) were tested and assessed by fluorescence measurements. In
the end, best lysis conditions were found with high salt lysis buffer containing the detergent NP-40
and sonication. hsSLX41300-1834 and hsSLX111-275 were applied to a GFP-binder column (single
domain anti-GFP fragment derived from heavy chain antibodies VHH of Canelidae [258]) and
after tag cleavage the eluted proteins were applied to gel filtration (Figure 2.6). SEC analysis
showed one main peak at 63.0 ml and two smaller peaks at 95.2 and 126.9 ml. The smaller peak
at 95.2 ml contained the proteases used for tag cleavage and the last peak could not be resolved
by SDS-PAGE. The SDS gel showed slight degradation bands for both proteins.
The activity of the purified proteins was investigated in a cleavage assay testing different DNA
substrates (Figure 2.7 A). The protein complex showed very weak cleavage on ssDNA substrate,
medium activity on flap substrates and intact Holliday Junction. The strongest activity under
the tested conditions was observed for a nicked HJ substrate. As the activity tests indicated
that the purified proteins are active, I purified hsSLX41300-1834 and hsSLX111-275 complex for
crystallization trials. Crystallization with different DNA substrates was attempted with the active
hsSLX1 protein and a construct with mutated active site residue Y17F, which was introduced based
on the proposed cleavage mechanism and sequence alignments of SLX1 proteins from different
organisms (Figures 1.5 B and 4.2). However, despite testing different protein concentrations and
DNA substrates no condition yielded crystals.
As the hsSLX41300-1834 construct was prone to degradation as seen in the SDS-PAGE (Figure
2.6), limited proteolysis was carried out for the complex with hsSLX111-275 in search for a more sta-
ble and compact construct. Limited proteolysis applies different proteases, which digest unfolded
protein regions in a non-specific manner. Chain segments in regular secondary structures will be
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Figure 2.7: Activity test and limited proteolysis of hsSLX41300-1834-hsSLX111-275. (A) Nuclease activity
of hsSLX41300-1834-hsSLX111-275 with different 5’ FAM-labeled DNA substrates. 640 nM protein complex was
incubated for 30 min at 37◦C with 40 nM DNA substrate. The cleavage products were separated by native
TB-PAGE and analyzed using a PhosphorImager. Bands marked with a asterisk indicate artifacts. (B) Time
course of limited proteolysis for hsSLX41300-1834-hsSLX111-275 with Chymotrypsin at 0.02 mg/ml concentration.
Samples were taken after 1, 5, 10, 15, 30, 45, 60, 90 and 120 min. (In) Input protein sample used for proteolytic
analysis. (M) Protein marker in kDa. Bands marked with a diamond on the right indicate stable hsSLX41300-1834-
hsSLX111-275 fragments and were sent for peptide fingerprinting.
less accessible to the active site of the protease as flexible loop regions. After testing five different
proteases at three different concentrations, a time course with Chymotrypsin at 0.05 mg/ml was
performed (Figure 2.7 B). The bands, which were analyzed by peptide mass fingerprinting for
identification, are marked with a diamond at the side.
All bands sent to identification solely contained peptides of hsSLX4. hsSLX1 did not get further
truncated in limited proteolysis experiments. Based on the results from limited proteolysis, new
constructs were designed for hsSLX4 and tested for expression in E. coli with either N-terminal
SUMO-tag or C-terminal CPD-tag (cysteine-protease domain) and in HEK293 culture with C-
terminal mVenus-tag (Figure 2.8). The CPD-tag is an inducible auto-cleaving protease tag, which
also enhances protein solubility (see section 2.1.1 and Figure 2.2). Different constructs were
designed containing only the SAP, only the CCD domain or both of them together at different
length (Figure 2.8).
Several hsSLX4 constructs showed medium expression levels with the CPD tag in bacterial
expression (Constructs 8 - 13), especially the large hsSLX41300-1834 construct could be expressed
(Construct 8). Thus, hsSLX4 constructs 8 - 13 in vectors with C-terminal CPD tag were purified
by Ni affinity column with subsequent IP6 cleavage. The cleavage mix was loaded on ion exchange
column, eluted by increasing salt concentration and subjected to size exclusion chromatography.
However, in CPD-tagged hsSLX41300-1834 (Construct 8) and smaller constructs (hsSLX41706-1824
(Construct 12), hsSLX41748-1824 (Construct 13)) the protease recognized not only its target site
but also other sites containing nonpolar residues. This resulted in a strong degradation pattern
after induction of CPD-cleavage (see Appendix Figure 4.5). To check for this additional CPD
recognition sites, Leu residues in hsSLX41300-1834 were counted to 39 and then checked whether
the sequence around the Leu resembled similarity to the CPD recognition site [252] (see Appendix
Figure 4.6). In total, nine sites in the hsSLX41300-1834 construct were found, which contained
either Ala, Gly, Ser or Trp in P2 site and might therefore be recognized by the activated cysteine
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Figure 2.8: Schematic representation of hsSLX4 and hsSLX1 constructs. The constructs were tested for
expression (exp), solubility (sol) and degradation (deg) in E. coli and HEK293 cell culture. Bacterial expression
was tested with either N-terminal His8-SUMO-tag or C-terminal CPD tag (upper part) and expression in
mammalian suspension cells was carried out with C-terminal 3C-mVENUS-1d4 tag and / or with N-terminal
His8-eGFP-SUMO (lower part). The success is indicated by + (positive) and - (negative). Most of the
constructs were soluble, but especially the constructs in bacterial expression system were prone for degradation.
The shorter constructs showed higher expression levels, but were also degradation prone.
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protease. This creation of unwanted degradation products lead to the conclusion, that the CPD-
tag was not applicable for hsSLX4 constructs.
Expression of constructs 14 - 16 comprising the SAP domain of hsSLX4 was carried out with
a N-terminal His8-SUMO tag and in addition with C-terminal CDP-tag. Purification of the
SUMO-tagged proteins using Ni column, anion exchange column and gel filtration lead up to
2 mg of protein with few degradation bands per l of expression culture. However, the tested
protein constructs degraded over time, which can be potentially hindering for crystallization.
Purification of the CPD-tagged SAP constructs (Construct 14 and 15) was carried out but lead
to few degradation bands. In comparison the SUMO-tagged constructs had still less degradation
bands. Crystallization trials were set up for the SAP domain constructs alone and in complex
with DNA substrates, but they showed mainly precipitation and protein crystals could not be
achieved. Hence, the strategy regarding the human proteins was shifted towards the expression of
hsSLX1 and hsSLX4CCD constructs in HEK cells.
hsSLX4 constructs containing the CCD domain were co-expressed in various combinations
of hsSLX1 protein in mammalian cell culture (Figure 2.8 lower part, constructs 24 - 30) and
reached low amounts of 0.2 mg per liter of expression culture after purification. Typically, purified
protein amounts of 1 mg/ml can be reached in HEK suspension culture [259, 260]. Despite
trying different tags the purified constructs showed strong degradation. Furthermore, the purified
proteins were subjected to ESI-TOF mass spectrometry to assess the purity and it was found
that the MS spectrum showed many peaks indicating heterogeneity. The peak differences in the
spectrogram showed shifts of 80 Da post-translational modification, most likely phosphorylation.
Further analysis of the phosphorylation of hsSLX41300-1834 was performed and will be described in
the following section 2.2. In summary, due to low expression level, degradation and heterogeneity
of the different tested constructs, the hsSLX4 constructs did not gave hits in crystallization.
2.2 Phosphorylation Site Mapping of hsSLX41300-1834
A construct comprising the C-terminal domains, hsSLX41300-1834, could be expressed alone and
together with hsSLX111-275 in HEK cells. Interestingly, the purified protein showed a peak series
with differences of 80Da in ESI-TOF MS, indicating phosphorylation of the protein sample. As
SLX4 is a platform protein and due to its interaction partners involved in different cellular path-
ways, its action is most likely regulated via post-translational modification. From literature it is
known that phosphorylation of SLX4 has an influence on its association with its interaction part-
ners [114, 141, 194, 195, 200, 261]. Wyatt et al. proposed a model in which CDK1-phosphorylation
of SLX4 controls MUS81 association [141]. This could be underlined in a later study under the
inhibition of Wee1 kinase interacting with CDK1 [200]. SLX4 is also a target of ATM / ATR
kinases [79, 185]. However, the relevance of this phosphorylation remains elusive in mammalian
cells. In yeast, Slx4 phosphorylation depends on Mec1 and Tel1 (ATR and ATM orthologs) in cells
exposed to genotoxins [184, 195]. This phosphorylation was observed in cells arrested either in G1
or G2. [184]. Furthermore, PLK1 associates with SLX4 through a possible polo-box binding motif
on Ser1453 [114]. Another example, showing the importance of phosphorylation, is the interaction
between SLX4 and TOPBP1, which is conferred via phosphorylation at Thr 1260 by CDK [194].
This interaction has been also investigated with the yeast ortholog Dpb11 of TOPBP1 [193–195].
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Figure 2.9: Electrophoretic shift analysis of hsSLX41300-1834-hsSLX111-275 after phosphatase treatment.
The dephosphorylation of purified hsSLX41300-1834-hsSLX111-275 by various phosphatases causes limited elec-
trophoretic shift in SDS-PAGE. hsSLX41300-1834-hsSLX111-275 was incubated with λ phosphatase (λ), Antarctic
phosphatase (A), shrimp phosphatase (S) and fast alkaline phosphatase (F). λ phosphatase (λ), Antarctic phos-
phatase (A) and fast alkaline phosphatase (F) ran at approximately 30 kDa and their labeling is summarized
by ”Phosphatases” on the right site of the gel.
This interaction is mediated by multiple phosphorylation sites in yeast Slx4 [193, 195] and cell
cycle regulated as well as dependent of the CDK site Ser 486 in Slx4 [193, 194]. In yeast cells
arrested in G1 or G2, Slx4 and the scaffold protein Rtt107 are heavily phosphorylated by Mec1,
a DNA damage signaling kinase (ATR in humans) [184]. This phosphorylation by Mec1 is only
carried out when each of the interaction partners is present [195]. The phosphorylation-regulated
complex Rtt107-Slx4-Dpb11 plays an important role in the response to replication stress [261].
Furthermore, yeast Slx4 is not only involved in the resolution of HJs during mitosis, but plays a
role in the resection of the 5’ DNA ends by counteracting Rad9 and subsequent resection [261].
Thus Slx4 controls signaling events in order to facilitate HR [261]. As the yeast ortholog of Slx4
shows important phosphorylation sites, it was reasoned that the human SLX4 might also show
prominent phosphorylation sites.
As a first and rapid experiment, the electrophoretic mobility shift of purified hsSLX41300-1834
and hsSLX111-275 before and after phosphatase treatment was analyzed (Figure 2.9). The analysis
of the electrophoretic mobility shift is a simple method to determine the ratio between phos-
phorylated and unphosphorylated protein. Same amounts of protein were treated with different
phosphatases and their height on a SDS-PAGE was compared to an untreated protein sample.
Four different phosphatases were applied, λ phosphatase, Antarctic phosphatase, shrimp alkaline
phosphatase and fast alkaline phosphatase. The enzymes differ in their reactivities towards ser-
ine/threonine and tyrosine phosphorylation. λ phosphatase has dual specificity on serine/threonine
and tyrosine phosphates [262]. Antarctic phosphatase shows similar activity on both types of phos-
phorylation sites [263]. Fast alkaline phosphatase has a preference for phosphotyrosine residues
[263]. Shrimp alkaline phosphatase can be applied for dephosphorylation of DNA ends and pro-
teins [263]. For each phosphatase the respective protocol was applied in order to have maximum
enzyme activity. After phosphatase treatment only a limited shift between the samples could be
observed (Figure 2.9). Treatment with λ phosphatase (λ) and shrimp phosphatase (S) did not
show a shift in electrophoretic mobility. Treatment with Antarctic phosphatase (A) and fast alka-
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line phosphatase (F) showed a marginal increase in electrophoretic shift and the protein bands for
the dephosphorylated hsSLX4 construct ran few millimeters lower than the control band for the
hsSLX4 construct. In summary, analysis of electrophoretic shift with a SDS-PAGE did not gave
an unambiguous result for the phosphatase of choice and the extent of dephosphorylation. These
results hit the limitation of the method. Literature reported that phosphorylation-induced shifts
in electrophoretic mobility are most likely due to local context-dependent effects on the flexibility
of the protein chain rather than to changes in molecular weight [264]. Furthermore, the decrease
in charge and the increase in SDS-binding after de-phosphorylation might not have been strong
enough to induce the shift in electrophoretic mobility. Thus, the approach for the examination of
phosphorylation sites was changed and will be described in the next subsection.
2.2.1 Phosphorylation sites of hsSLX41300-1834
First the bioinformatic analysis tool GPS 3.0 [265] was applied for the prediction of phospho-
rylation sites in hsSLX41300-1834 taking the kinases CDK1, PLK1 and ATM/ATR into account
and showed in total 47 predicted phosphorylation sites for CDK1, PLK1 and ATM/ATR (Figure
2.10 A). The GPS 3.0 online prediction tool searched for minimal CDK1 consensus sites (S / TP)
and found 25 phosphorylation sites. For PLK1 and its consensus sequence (D / E - X - S / T -
hydrophobic aa - X - D / E) the software found 11 phosphorylation sites and for ATM / ATR
(T / SQ) 11 sites. The search for kinase consensus sequences shows that there is the theoreti-
cal possibility that SLX4 can be heavily phosphorylated. Furthermore, literature suggests that
SLX4 is phosphorylated and we also found it heavily phosphorylated. Therefore, it is likely that
heterogeneity of SLX4 originates from phosphorylation. A reason for the inability to crystallize
the constructs is caused by the presence of these post-translational modifications. In order to
examine the amount of phosphorylation of SLX4 and to assess the influence of phosphatases re-
garding de-phosphorylation a proteomic approach was applied. Different phosphatases were tested
in order to find a condition with low or missing phosphorylation. The phosphorylation sites of
hsSLX41300-1834 in absence and presence of hsSLX1 were examined subsequently. Furthermore
the phosphorylation sites of hsSLX41300-1834 in presence of hsSLX1 treated with different DNA
damaging agents were investigated.
hsSLX41300-1834 was expressed alone and co-expressed with hsSLX111-275 in transiently trans-
fected HEK293 suspension culture, purified by GFP-binder affinity chromatography and peptide
finger printing as well as mapping of phosphorylation sites was carried out by Dr. Nagarjuna Na-
garaj in the Biochemistry Core Facility at the Max-Planck Institute of Biochemistry (Martinsried,
Germany).
For the solely expressed SLX4 construct six phosphorylation sites could be identified (4x Ser,
2x Thr), whereof four were located close to the SIM 3 motif and two were between the SAP and
the CCD domain (Figure 2.10 B upper panel). Comparison with the predicted phosphorylation
sites showed that all six phosphorylations are located in CDK1 consensus sequences and thus
likely been introduced by CDK1. In co-expression with hsSLX111-275 SLX4 was much stronger
phosphorylated with 18 detected sites, 5x Thr and 13x Ser (Figure 2.10 C upper panel). Most of
phosphorylation sites were located between the domains, except for one site (S1567), which was in
the SAP domain. Phosphorylation of S1453 for PLK1 interaction [114] was not detected, however
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Figure 2.10: Phosphorylation site mapping of hsSLX41300-1834 alone and co-expressed with hsSLX111-275.
(A) Phosphorylation sites based on phosphorylation site prediction by GPS 3.0 (http://gps.biocuckoo.org)
specific for CDK1, PLK1 and ATM / ATR phosphorylation. (B) hsSLX41300-1834 was expressed alone in asyn-
chronous HEK cell culture, purified and phosphorylation sites were analyzed by MS fingerprinting. Different
phosphatases (see below) were used in order to remove the phosphorylation sites. (C) hsSLX41300-1834 was co-
expressed with hsSLX111-275 in asynchronous HEK cell culture, purified and phosphorylation sites were analyzed
by peptide fingerprinting. For removal of phosphorylation sites different phosphatase were used for treatment:
shrimp phosphatase (Shrimp PPT), antarctic phosphatase (Antarctic-PPT), fast alkaline phosphatase (Fast AP)
and λ phosphatase (λ PPT). For peptide fingerprinting a protein amount of 40 μg for control and phosphatase
treated samples was digested in solution with GluC and Trypsin to increase peptide coverage. For analysis only
peptide intensities above 1 x 107 and phosphosites above 75% probability showing up in all triplicates were
taken into account. Magenta residues indicate phosphorylation sites found in the database Phosphosite Plus
[266]. The analysis of phosphorylation sites is based on triplicate measurements.
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the adjacent residues T1446 and S1469 were phosphorylated in presence of SLX1. Peptides for
hsSLX111-275 were identified in the peptide mass analysis but phosphorylations were not detected.
Furthermore, phosphorylation of the CCD domain, the interaction site between SLX4 and SLX1,
was not observed. AIn the course of this study, another investigation was published on the effect
of the mutation of predicted CDK consensus sites around the SAP domain (S1469, T1476, T1524,
T1544, T1561, T1571) [200]. Duda et al. used stably expressed SLX4 full length protein, mutated
the sites to alanine and the interaction with MUS81 was abolished [200]. The SLX4-MUS81
association is controlled by CDK1-mediated phosphorylation of SLX4 and this phosphorylation is
coupled to mitotic entry [200]. The mentioned phosphorylation sites except for S1469 and T1476
were not detected in the presented phosphorylation screen.
Comparing the experimentally detected phosphorylation sites with the predicted sites showed
that one third of them were not shown in the prediction. The other sites were mostly predicted
to be phosphorylated by CDK1, with the exemption of S1412, which could be both a CDK1 and
a PLK1 site, two ATM / ATR sites (S1617 and S1699) and S1743, which could be either a PLK1
or an ATM / ATR site.
Next, the found phosphorylation sites were compared with the database Phosphosite Plus [266].
This database is a resource for experimentally observed post-translational modifications and com-
prises data from journal articles and cell signaling technologyTMscientists. This database served
as a resource for the recovery rate of our analysis but also as comparison of the conditions in which
the sites were identified. The here presented analysis identified 19 unique phosphorylation sites
found in hsSLX41300-1834 from expression conditions alone and in co-expression with SLX111-275.
Only eight of these sites were also retrieved from the Phosphosite Plus database (Figure 2.10
B, C magenta residues and Table 2.1). When hsSLX41300-1834 was expressed alone five of the six
detected phosphorylation sites were also listed in the database. Interestingly, when the phosphory-
lation sites of the co-expressed hsSLX41300-1834 with its 18 detected sites was searched, only seven
of them could be found. The phosphorylation site mapping revealed under the conditions of the
co-expression with hsSLX111-275 not only a different phosphorylation pattern compared to before
listed phosphorylation sites, but also new sites were identified under the influence of hsSLX111-275
co-expression. When the phosphorylation sites from Phosphosite Plus database were retrieved,
most of the sites were detected in tissues derived from leukemia or breast cancer. This is an inter-
esting finding as leukemia as well as breast cancer are associated with defects in HR. Especially
phosphorylations at T1315 and S1329 were detected in many proteomic studies and are the most
commonly found phosphorylation sites of hsSLX4 in in vivo studies (Table 2.1). But so far, there
are no further investigations reported, what the role of those specific phosphorylations sites is.
For the yeast ortholog of Slx4 eight phosphorylations sites have been identified [195, 261].
Most of the phosphorylation sites are located at the C-terminal part of the yeast protein and are
introduced upon DNA damage by the Mec1 / Tel1 kinases (see also Appendix 4.7). However,
upon comparison with the used hsSLX41300-1834 construct, four of the eight sites were located
in the human construct. Three of the yeast sites were not found phosphorylated in the human
ortholog. Only S627 in scSLX4 could be identified as phosphorylation site S1567 in hsSLX4,
which is located in both proteins in the SAP domain. In yeast Slx4 this site is together with
six other phosphorylation sites important for the interaction with the TOPBP1 ortholog Dpb11
[195]. Mutation of this site together with six more residues abolishes phosphorylation by Mec1
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Table 2.1: Comparison of experimentally found phosphorylation sites in hsSLX41300-1834 with the Database
Phosphosite Plus [266] (site group ID). The table gives only a selection of the references given for each
phosphorylation site. Only the tissues and cell lines with the most frequent references are depicted. MS mass
spectrometry, Jurkat T lymphocyte cells, HEK293 human embryonic kidney cells, HeLa cervix carcinoma cells
Phosphory-
lation
Site
Site
Group
ID
Method of
characteri-
zation
Disease Tissue Cell Line Number
of ref-
erences
T1315 472085 MS breast cancer, leukemia, acute
myelogenous leukemia
bone marrow, Jurkat,
HeLa
50
S1329 472088 MS breast cancer, leukemia, acute
myelogenous leukemia
HEK293, bone mar-
row, HeLa, Jurkat
43
S1342 8110962 MS n.a. Jurkat 1
T1446 34352045 MS n.a. Jurkat 1
S1469 3225800 MS various breast cancer types, lung
cancer
HeLa, breast cell lines,
pulmonary cell lines
19
T1476 4738110 MS n.a. n.a. 1
T1676 31082723 MS breast cancer HeLa, HEK293 5
S1681 31081478 MS n.a. HeLa, erythroid cell
line
1
and interaction with Dpb11 [195]. In a recent study with human SLX4, mutation of all predicted
CDK phosphorylation sites in the SAP domain to alanine abolished interaction with MUS81 [200].
Mutation of the residues to aspartic acid or glutamic acid has not been tested so far. The SAP
domain as a phosphorylation site might be involved in important protein-protein interactions.
The detection of the phosphorylation sites showed the reason for the heterogeneity of the pro-
tein sample. In order to obtain a uniform sample with reduced post-translational modification
for crystallization, I co-expressed and purified hsSLX41300-1834-hsSLX111-275 and solely expressed
hsSLX41300-1834, which were treated with four different phosphatases after purification. The same
phosphatases as for electrophoretic mobility shift assay were applied to use their different reactiv-
ities towards serine/threonine and tyrosine phosphorylation. For each phosphatase the respective
protocol was applied in order to have maximum enzyme activity. For treatment of hsSLX41300-1834
expressed alone, a strong reduction in phosphorylation was achieved. The best results were ob-
served when applying either λ-phosphatase or fast alkaline phosphatase resulting in only one
phosphorylated residue (T1315) (Figure 2.10 B lower panel). In co-expression with hsSLX1, the
phosphatases removing most phosphate groups were λ-phosphatase and Fast-AP (Figure 2.10 C
lower panel). Antarctic phosphatase removed a few phosphates, but shrimp phosphatase removed
nearly no phosphate group, which made it not suitable for protein dephosphorylation. Interest-
ingly, the phosphorylation of T1315 could never be removed, which suggests a location within
a non-accessible region. Furthermore, this site has the most references found for hsSLX4 in the
database Phosphosite Plus [266].
In subsequent purifications, hsSLX4 protein constructs expressed in HEK cells were de-phosphorylated
with either λ-PPT or FastAP and were submitted to crystallization: However, despite the reduced
phosphorylation they did not gave rise to crystals.
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Figure 2.11: Heat Map cluster of hsSLX41300-1834 phosphopeptides in co-expression with hsSLX111-275
under influence of different DNA damaging agents. Each column of phosphosite intensities represents the
average of triplicate measurements. Numbers on the site indicate the position of the detected phosphorylation
site in hsSLX41300-1834. The bar on the left site refers to domain organization of the construct. The heat
map depicts log2 to of the localization probability of the phosphorylation of a certain amino acid. Dark pink
rectangles indicate high intensity and thus localization probabilty of the respective phosphorylation site. Dark
green rectangles indicate low intensity of appearance. Grey spots refer to phosphorylation sites which could
not be detected (n.d.). Control: co-expression of hsSLX41300-1834 and hsSLX111-275 without addition of DNA
damaging agents; Eto: incubation for 1 h with 5 μM Etoposide; HU: incubation with 2 mM hydroxyurea
for 3 h; MMC: incubation for 1 h with 0.1 μg/ml with mitomycin C; MMS: incubation for 1 h with 2 mM
methylmethanesulfonate.
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2.2.2 Phosphorylation Site Mapping under the Influence of DNA Dam-
age
In a next step, the expression of hsSLX41300-1834 under the influence of different DNA damaging
agents was tested in order to find a condition with a distinct distribution of phosphorylation sites.
The strategy behind this screening was to detect whether the addition of different DNA damaging
agents could lead to a more homogenous phosphorylation pattern and in addition to higher protein
yield in expression. The focus of this approach goes beyond the mapping, it was also anticipated to
find a damaging agent, which would induce the phosphorylation of a site, which is not detected in
untreated cells. In this aproach, based on the mapping further experiments would be carried out.
The hypothesis is that upon DNA damage SLX4 will be recruited to the damage site and change
its conformation to bind its interaction partners. Earlier publications noted that scSlx4 becomes
phosphorylated in response to DNA damage at all cell-cycles stages [184]. In electrophoretic
mobility shift experiments of scSlx4 from cells treated with different DNA damaging agents the
most pronounced shift was caused by MMS (methyl methanesulfonate) [184]. After exposure of
cells to MMS, yeast Slx4 is phosphorylated in vivo at Thr72, Ser289 and Ser329 [79]. Replication
stress induced by MMS leads in yeast cells to phosphorylation of Slx4 by Mec1 (human ATR) and
upon phosphorylation to interaction with Dpb11 (human TOPBP1) [57].
The tested DNA damaging agents induce different kind of DNA damage, which are processed
differently in the cells and involve SLX4 in the repair process. Hydroxyurea (HU) is depleting the
dNTP pool in the cell, leading to stalled replication forks and subsequent double-strand breaks
[267]. The crosslinking agent mitomycin C (MMC) introduces covalent links within one strand or
between two DNA strands and leads ultimately to the formation of sister chromatid exchanges
[16, 112]. The application of the alkylating agent methyl methanesulfonate (MMS) blocks the
progression of the replication forks [113]. The topoisomerase II inhibitor etoposide causes double-
strand breaks due to blockage of the re-ligation in DNA unwinding [268, 269]. Any of the DNA
damage induced by the different agents might be enough to trigger a certain phosphorylation
pattern.
For the phosphosite analysis under DNA damage influence, hsSLX41300-1834 was coexpressed
with hsSLX111-275. After over night expression, the DNA damaging agents were added and in-
cubated for the respective time indicated in Materials & Methods Table 4.25. Afterwards, the
proteins were purified in a one-step purification with GFP-binder beads and subjected to phos-
phorylation site analysis, carried out by Dr. Nagarjuna Nagaraj (MPIB).
Overall, strong differences between the phosphorylated sites in SLX4 from untreated cells and
cells treated with different DNA damaging agents could not be detected in the sense of switching
phosphorylation on and off (Figure 2.11). In comparison to the untreated cells, most sites were
still phosphorylated under the influence of the agents but with slight changes in intensity. Small
differences in phosphorylation intensity was seen between untreated and treated cells. T1315 is
always phosphorylated at high intensity under any condition. The same is true for S1434 (low
intensity), S1450 (low intensity), S1453 (high intensity), S1617 (high intensity) and S1743 (high
intensity). This indicates that the phosphorylation of these sites is not regulated by any tested
DNA damage. Under the influence of MMS T1326 is phosphorylated, while phosphorylation of
this residue is absent in the other conditions. Thr on position 1326 is followed by Pro, which
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indicates a CDK1 phosphorylation site. Another striking difference is the absence of phosphoryla-
tion on S1716 in MMC and MMS, a ATM/ATR predicted phosphorylation site. Treatment with
hydroxyurea shows the lowest differences compared to control cells. This is quite surprising as
one would have expected that the treatment with the ICL-inducing agent hydroxyurea leads to a
high phosphorylation of SLX4. ICLs are being repaired in the FA pathway and SLX4 is involved
in subsequent steps of the ICL repair pathway. Published results showed furthermore that Slx4
from yeast cells treated with HU has a decreased electrophoretic mobility compared to untreated
cells and thus a higher phosphorylation level [184].
In general many phosphorylation sites were still found and there was no condition tested, which
showed extreme reduction or increase in phosphorylation (Figure 2.11). The heat map compares
the relative appearance of each phosphorylation site towards a baseline (see Figure 2.11). The
dark pink rectangles refer to an increased intensity of this phosphorylation site, whereas the dark
green rectangles indicate a weak intensity. In general no big differences between the control sample
and the treated samples could be detected.
With the detection of the phosphorylation sites the different peaks in ESI-TOF MS after pu-
rification could be explained. Some of the phosphorylation sites could be removed by phosphatase
treatment, but especially when co-expressed with SLX1 many phosphates could not be removed.
Due to the heterogeneity of the proteins and the degradation problems, crystallization with the hu-
man proteins was not further attempted. As another strategy the Caenorhabditis elegans proteins
were tested for crystallization.
2.3 Purification of the C. elegans SM-Complex and Crys-
tallization Attempts
Additionally to the human proteins, Caenorhabditis elegans homologs of SLX1, SLX4 and MUS81-
EME1 were investigated. The C. elegans homologs are in general shorter than the human proteins,
especially the SLX4 protein (see Figures 1.4 and 1.6 B). However, the SAP and the CCD of SLX4,
the GIY-YIG nuclease and RING domain in SLX1 as well as the ERCC4 domains in MUS81-
EME1 are conserved between the orthologs [113, 115]. The C. elegans SLX4 ortholog is involved
in meiotic chromosome segregation and is named HIM-18, high incidence of males, characterized
by an increased X chromosome loss [24]. Herein HIM-18 is referred to as ceSLX4. C. elegans is
a model organism to study the DNA damage response as many orthologs of human DNA repair
factors are found in nematodes with an reduced complexity of the system. Furthermore, C. elegans
is a well known target to study germ cell development and meiosis [239] and lots of information
about the four proteins is available [24, 241, 242].
2.3.1 Purification of the Full-Length C. elegans Proteins
The respective genes were cloned by PCR from a C. elegans cDNA library (a kind gift of Karsten
Klage). Initial small scale expression tests of the C. elegans proteins were carried out and all full-
length constructs of the four proteins showed expression (Figure 2.12). The large scale purification
was carried out in a three-step process using IMAC, ion exchange chromatography and SEC. Figure
2.13 shows the gel filtration elution profiles and the respective SDS gels.
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exp sol deg
45		ceEME1-MUS81 ERCC4 HhHHhH HhH ERCC4 HhHHhH ++ ++ ++
ceSLX4
31		ceSLX41-718 UBZ MLR BTB SAP CCD1 718 ++ ++ ++
BTB SAP CCD32		ceSLX4225-718 + + +++
BTB SAP CCD33		ceSLX4277-718 ++ + ++
SAP CCD34		ceSLX4467-718 +++ +++ -
CCD35		ceSLX4535-718 +++ +++ -
36		ceSLX4443-606 +++ +++ -SAP
SAP37		ceSLX4467-606 +++ +++ -
40		ceSLX41-718-ceSLX11-443 UBZ MLR BTB SAP CCD +/-RINGGIY
41		ceSLX41-718-ceSLX1168-443 UBZ MLR BTB SAP CCD +/-RINGGIY
38		ceSLX11-443 RINGGIY 4431 ++ + ++
43		ceMUS81191-445-ceEME11-454 ERCC4 HhHHhHERCC4 HhHHhH +++ +++ +ceMUS81 ceEME1
42		ceMUS811-445-ceEME11-454 1 ERCC4 HhHHhH 4541 445HhH ERCC4 HhHHhH ++ ++ +++
44		ceMUS811-445-ceEME1161-454 ERCC4 HhHHhHHhH ERCC4 HhHHhH ++ ++ -
46		ceEME1161-454-MUS811-445 ERCC4 HhHHhH HhH ERCC4 HhHHhH ++ ++ +
47		ceEME1231-454-MUS81198-445 ERCC4 HhHHhH ERCC4 HhHHhH + + -
48		ceMUS811-157 +++ +++ -HhH
39		ceSLX1168-443 RINGGIY ++ + ++
ceSLX1
Figure 2.12: Schematic representation of ceSLX4, ceSLX1 and ceEME1-MUS81 constructs. The
different constructs were designed based on limited proteolysis experiments and tested for expression (exp),
solubility (sol) and degradation (deg) in E. coli with N-terminal His8-SUMO-tag. The success is indicated by
+ (positive) and - (negative). Most of the designed constructs were expressed very well and soluble. Few of
them showed strong degradation.
The 81.1k Da full-length C. elegans SLX4 or HIM-18 (hereafter referred to as ceSLX4) could be
solubly expressed in E. coli cells and was purified with Ni affinity, cation exchange chromatography
with subsequent gel filtration (Figure 2.13 A). In comparison to the human SLX4 protein, the
ceSLX4 protein could be purified to yields of 2 mg protein per liter of bacterial culture and
showed only few degradation bands.
ceSLX1 contains a 168 amino acid N-terminal extension in front of the GIY-YIG nuclease do-
main, which is not present in most other SLX1 orthologs and was predicted to be disordered by the
globular domain prediction tool GlobPlot [270]. In a bioinformatical search the 168 aa N-terminal
extension was only found in SLX1 orthologs from other nematodes (e.g. Caenorhabditis brenneri
Uniprot ID EGT50705) and some Ascaris species (e.g. Ascaris suum F1KVZ3). However, the As-
caris SLX1 orthologs were not present after a Blast search, but searching SLX1 for Ascaris species
in the Uniprot database revealed the similarity to the nematode SLX1. The N-terminal extension
is a special hallmark of SLX1 orthologs from worms and initially two constructs were designed
comprising the full-length ceSLX1 (Figure 2.12 Construct 39) and a truncated version lacking
the N-terminal extension (Figure 2.12 Construct 40). Both constructs could be solubly expressed
and were purified by Ni affinity step and Heparin column. The shorter ceSLX1 construct showed
aggregation after Heparin column, which could be seen from visual inspection by white precipita-
tion, and showed degradation analyzed on SDS-PAGE. In the last step of purification using SEC
(Superdex 75 10/300 GL, GE Healthcare) ceSLX1 full-length construct eluted at 8.3 ml corre-
sponding to the void volume of the column (Figure 2.13 B). As the theoretical molecular weight
of full-length ceSLX1 is 50.5 kDa, the volume of 8.3 ml indicates a state of soluble aggregates. As
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the SLX1 protein forms a dimer in solution [156], it was already expected that SLX1 will elute
in a lower elution volume then the monomer size. Next, cleavage activity was tested by mixing
ceSLX1 and ceSLX4 in a 1:1 ratio, but activity could not be detected. To increase the stability
of the ceSLX1 constructs, expression of ceSLX1 constructs was attempted in a bicistronic vector
containing the N-terminally tagged interaction partner ceSLX4. Two different ceSLX1 constructs
were cloned and tested for solubility (Figure 2.12 Constructs 41 and 42). After Ni Pulldown only
ceSLX4 could be identified in the soluble fraction but not the ceSLX1 constructs (indicated by +/-
in Figure 2.12). As another strategy to increase stability of the proteins, ceSLX1168-443, ceSLX4
and ceMUS81-EME1 were co-purified. In the course of the purification, the four proteins showed
even stronger degradation compared to the purification alone. Additionally, the four proteins
did not show complex formation in size exclusion chromatography. Because of lacking enzymatic
activity and long term protein stability issues, no further experiments with ceSLX1 were carried
out. Additional reasons will be discussed in section 3.1.
Individual expression and purification of ceMUS81 and ceEME1 was only possible for ceMUS81,
but not for ceEME1. The purified ceMUS81 alone did not show any cleavage activity towards
tested substrates (Appendix Figure 4.8). Earlier it has been shown that for fission and bakers yeast
the formation of a complex of MUS81 and EME1 is essential for cleavage of DNA substrate [135,
271]. The cleavage mechanism applied by the heterodimer seems to be conserved. Furthermore,
the stability of the MUS81-EME1 complex is as suggested by their intertwined structure [214].
The inability of ceMUS81 to cleave DNA substrate is consistent with the before published results
that MUS81 needs EME1 as co-factor for activity. Furthermore, in regard to the expression yield
it has been shown earlier that recombinant MUS81-EME1 are poorly expressed individually, but
co-expression gave good yields [142, 251]. Hence, they were expressed from a bicistronic vector in
E. coli cells. The full-length proteins were purified and showed only few degradation bands and
a mixture of SUMO-tagged EME1 as well as cleaved EME1 (Figure 2.13) C). Crystallization was
attempted in presence and absence of DNA substrates, but did not yield any hits. Additionally,
crystallization of the full-length constructs of ceSLX4 alone and ceMUS81-ceEME1 alone and
bound to different DNA substrates was attempted but did not gave rise to any hits.
2.3.2 Limited Proteolysis of ceSLX4 and ceMUS81-EME1 and Crystal-
lization Trials
As the full-length proteins of ceSLX4 and ceEME1-MUS81 showed degradation, limited proteol-
ysis was used to search for a more stable construct (Figure 2.14). First, the proteases Trypsin,
Chymotrypsin, Elastase, Subtilisin and GluC with broad substrate specificity were applied to the
ceSLX4 construct at three different concentrations (0.1, 0.01 and 0.001 mg/ml). The first cleavage
test is performed in order to find the most useful protease and the optimal substrate:protease ratio.
Based on the preliminary result a time course with Elastase at 0.02 mg/ml and Chymotrypsin
at 0.01 mg/ml was carried out (Figure 2.14 A). The limited proteolysis experiment with SLX4
was performed in the absence of DNA, as the protein is suggested to work as a protein-protein
interaction hub but does not bind DNA on its own [141, 143, 156]. Based on the results of limited
proteolysis considering structural domain and disorder prediction several N-terminally truncated
constructs were designed (Figure 2.13). A detailed description of the constructs and the rationale
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Figure 2.13: SEC analysis of full-length ceSLX4, ceSLX1 and ceEME1-MUS81 proteins. (A) Size
exclusion chromatogram of full-length ceSLX4 using a Superose 6 16/600 column showing an elution profile
with one major peak at 39.3 ml, containing the full-length ceSLX4 protein and smaller peak at 88.6 ml & 122.6
ml, corresponding to degradation products. The SDS-PAGE shows the fractions of the main peak and the
other peaks. (B) SEC analysis of ceSLX1 using a Superdex75 10/300 column showing the elution profile with
one major peak at 8.3 ml and two smaller peaks at 12.2 ml and 28.9 ml. The SDS-PAGE shows the fractions
of the first two peaks. (C) Gel filtration profile of bicistronically expressed ceEME-MUS81 using a Superdex
200 16/600 size exclusion column. The SDS-PAGE shows the fractions of the main peak (69.4 ml) and the
smaller peaks (101.7 ml and 114.1 ml). All chromatograms are visualized by absorption at 280 nm and 260
nm. Pooled fractions are marked by a line. (M) Protein marker in kDa. (In) Input protein sample injected on
gel-filtration column. (D) Degradation products (C) Contaminant band (SUMO) cleaved off SUMO tag.
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Figure 2.14: Limited proteolysis experiments for ceSLX4 and ceEME1161-445-ceMUS81. (A) Time course
of limited proteolysis for ceSLX4 with Elastase at 0.02 mg/ml and Chymotrypsin at 0.01mg/ml concentration.
(B) Time course of limited proteolysis for ceEME1161-445-ceMUS81 in complex with nicked Holliday Junction
substrate 4w4x16n3 with Chymotrypsin at 0.02 mg/ml and in complex with nicked HJ substrate 4w4x15n3
with Subtilisin at 0.002 mg/ml concentration. Samples were taken after 5, 10, 15, 30, 45, 60, 90, 120 and 180
min. (In) Input protein sample used for proteolytic analysis. (M) Protein marker in kDa. Bands marked with
an asterisk on the right indicate stable fragments and were sent for peptide fingerprinting.
will be given in the next paragraphs.
Similarly, the construct ceEME1161-454-ceMUS811-445, which was designed according to align-
ment with truncated hsEME1 from Gwon et al [214], was subjected to limited proteolysis. The
proteolytic experiment was performed in presence and absence of nicked Holliday Junction DNA
substrate to gain structural information about the mode how MUS81-EME1 complex binds the
DNA substrate. In the first proteolysis experiments with the five different proteases at three
concentrations, slight differences in the bands appearing could be seen. The truncated EME1
construct stayed stable in every condition, except for subtilisin at the highest concentration. The
most differences between substrate-bound and free proteins was seen for the band pattern at low
molecular weight (lower than 17 kDa). However, as the aim was laid on larger constructs, analysis
of limited proteolysis experiments was more focused on the large discrete bands of the DNA-bound
proteins. Next, a proteolytic time course was carried out in presence of nicked Holliday Junction
with Chymotrypsin at 0.02 mg/ml and with Subtilisin at 0.002 mg/ml (Figure 2.14). Again, the
EME1 construct stayed stable during the course of the experiment. The marked bands in figure
2.14 were sent to identification by protein fingerprinting. Analysis of the peptide fragments from
each band revealed that only MUS81 was cleaved by the tested proteases. According to the results
of the limited proteolysis experiments and in silico structural prediction, different constructs of
MUS81-EME1 were designed. In addition, the position of the two proteins was also switched in
the expression vector (Figure 2.12).
The new constructs containing different versions of truncated and full-length MUS81 and EME1
in the bicistronic vector. Mainly, they were truncated from the N-terminus, where a large unstruc-
tured region is predicted between the HhH domain and the ERCC4 domain. The constructs were
expressed very well and were purified by Ni-affinity chromatography, weak cation exchanger (Hep-
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Figure 2.15: SEC analysis of ceMUS811-157 and ceSLX4443-606. (A) Size exclusion chromatogram of the
N-terminal construct of ceMUS81 (1 - 157) using Superdex 75 16/600 column. The elution profile shows a
main peak and a small pre-peak. The main peak elutes at 67.8 ml and contains ceMUS811-157. The small
pre-peak elutes at 59 ml and contains a contaminant protein. The SDS-PAGE shows the fractions of the pre-
peak and the main peak. (B) SEC analysis of ceSLX4443-606 using a Superdex 75 16/600 column. The protein
elutes as symmetric main peak at 59.6 ml with a smaller peak afterwards at 74.7 ml. The SDS-PAGE shows
the fractions of the main peak containing ceSLX4443-606 and of the peak afterwards containing degradation
products. Chromatograms are visuallized by absorption at 280nm (straight line) and 260nm (dashed line).
Pooled fractions are marked with a line. (M) Protein marker in kDa, (In) Protein sample injected on gel
filtration column.
arin column) and size exclusion chromatography. For crystallization, active site mutations of
MUS81 were used to form complexes with DNA substrates. They were submitted to crystalliza-
tion trials in presence and absence of DNA substrates (HJ, nHJ), but did not gave rise to any
hits.
In literature it was reported that MUS81 N-terminus can bind DNA [143, 219]. Limited
proteolysis gave also rise to a construct containing only the N-terminus of ceMUS81 (Figure 2.12
Construct 49). Purification was carried out with NiNTA chromatography, Heparin column and size
exclusion chromatography (Figure 2.15 A). The N-terminal construct of ceMUS81 could be purified
to 20 mg of protein per liter of bacterial expression and did not show degradation after SDS-PAGE
analysis. ceMUS811-157, later on referred to as ceMUS81N, was subjected to crystallization with
and without DNA substrate, but did not gave rise to any crystals.
After the new design of the ceSLX4 constructs based on limited proteolysis results and domain
prediction, the new constructs were tested for expression, purification and degradation. Two
constructs of ceSLX4, ceSLX4225-718 and ceSLX4277-718 (Figure 2.12 Constructs 33, 34), lacked
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the first two domains and showed some degradation after purification as the unstructured part
between the BTB domain and the SAP domain was still a target for proteases during purification.
Then constructs 35 to 38, containing both or one of the C-terminal domains, were tested for
expression. Construct 35, ceSLX4467-718, expressed very well, did not show degradation bands in
SDS-PAGE and was submitted for crystallization. It gave rise to initial microcrystals and phase
separation at 20 mg/ml in 50 mM Tris pH 8.0, 20 mM Sodium oxalate and 2.2 M Sodium malonate
(Figure 2.17 A). The micro crystals were harvested, crushed and used for matrix seeding. After two
days a large crystal appeared in 50 mM Tris pH 8.0, 0.2 M Calcium acetate and 26% PEG 8000
(Figure 2.17 B). The crystal was measured with synchrotron radiation and did not show any
diffraction. An analysis of the crystal by SDS-PAGE failed, as it completely dissolved during
preparation of the sample. As the protein was highly soluble, it could be highly concentrated,
which lead to high viscosity of the sample. This made setting up crystallization trials challenging
as the protein solution could not been pipetted precisely.
Therefore, the strategy to induce crystal growth was changed to search for a different for-
mulation buffer, which increases protein stability. In order to do so, nanoDSF (nano differential
scanning fluorimetry) was used to screen different buffers and find the buffer exhibiting the highest
melting temperature. nanoDSF allows ta sensitive and practical way to monitor the thermally
induced unfolding of protein samples [272, 273]. Here, internal Trp fluorescence was used to moni-
tor the increase in fluorescence upon unfolding. The transition occurs at the melting temperature
(Tm) and depends on the thermostability of the protein under the tested conditions. The Tm
can shift under different buffer conditions, like in the case of hsSLX4443-718 (Figure 2.16 A). The
buffer containing Bis-Tris-Propane at pH 7.5 leads to a higher melting temperature than the Hepes
buffer at pH 8.0. The melting curve thus shows a condition, which is beneficial for protein sta-
bility. Here, different salt concentrations and pH values have been tested (Figure 2.16 B). Low
salt concentration (50 - 100 mM) decreased the thermal stability a lot and a pH of 8.0 showed
lowest melting temperature and therefore lowest protein stability. In addition to sodium chloride,
potassium chloride and potassium acetate were tested for stability studies, but did gave rise to
higher melting temperatures (data not shown). The highest thermal stability with highest melting
temperature was seen at pH 7.5 with Bis-Tris-Propane buffer and 200 mM NaCl (Figure 2.16).
This buffer condition was used in subsequent crystallization experiments for the formulation of
the protein construct. Although the protein construct was tested extensively, the shown crystal
(Figure 2.17 B) could neither be reproduced nor could other crystal forms be obtained.
The construct ceSLX4535-718 containing only the CCD domain, which interacts with SLX1,
expressed to large amounts (13 mg protein per liter of bacterial cell culture). It was tested in
crystallization trials, but did not gave any hits or nucleation starting points which could have
been used for further optimization.
2.3.3 Crystallization Trials of ceSLX4SAP
The SAP domain of ceSLX4 is the interaction site for MUS81 [201, 202] and other proteins,
containing SAP domains, were shown to bind DNA [127, 274, 275]. DNA binding of the ceSLX4
SAP domain will be discussed in section 2.5.3. Two different constructs of the ceSLX4 SAP domain
were initially designed and could be purified in large amounts (> 30 mg protein per liter of bacterial
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Figure 2.16: Stability test of ceSLX4443-718. (A) The melting curves for ceSLX4443-718 were measured by
nano differential scanning fluorimetry with a temperature range from 20◦ to 90◦. For clarity the x-axis was cut
at 70◦. (B) The table summarizes different conditions tested for optimal stability of the protein. Shown are
three buffer systems at different pH values tried each with three different NaCl concentrations.
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Figure 2.17: Crystallization of different ceSLX4 constructs. (A + B) Crystallization of ceSLX4467-718.
Initial microcrystals appeared after 2 days in 50 mM Tris pH 8.0, 20 mM Sodium oxalate and 2.2 M Sodium
malonate (A). One crystal (B) appeared after 2 days in 50 mM Tris pH 8.0, 0.2 M Calcium acetate, 26% (w/v)
PEG 8000 after matrix seeding with microcrystals shown in (A). (C) Crystallization of ceSLX4443-606 at 34.7
mg/ml in 0.1 M Sodium citrate pH 5.5, 20% (w/v) PEG 3000. The left picture shows amorphous crystals,
which appeared after 2 days, and spherulites, which appeared after 13 days. The UV fluorescence picture of
the same drop (right) shows strong fluorescence for the spherullites and weak fluorescence for the amorphous
crystals. (D) Crystallization of birefringent ceSLX4467-606 in complex with ceMUS81K270M-ceEME1161-454 at in
20% (w/v) PEG 3350, 0.2 M Magnesium chloride. (E) + (F) Crystallization of ceSLX4467-606-ceMUS81K270M-
ceEME1161-454-nHJ substrate (4w4x16n1) in 18% (w/v) PEG 3350 and 0.2 M Calcium acetate (E) Crystals
viewed under polarized white-light illumination showed birefringence. (F) Crystals viewed under UV light showed
absorption of the UV light.
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culture) and without any degradation (Figure 2.15 B). These constructs posed to be also very
stable and highly soluble. They could be concentrated easily up to 50 mg/ml. Crystallization
trials of the protein alone (Figure 2.17 C) and in complex with DNA were attempted. The
crystallization of the protein alone lead to the formation of amorphous crystals and spherulites
(Figure 2.17 C left). They were tested for protein content with a UV microscope for crystal
inspection (Figure 2.17 C right). The spherulites appeared bright white under UV light like
protein crystals would appear. The amorphous crystals showed weak UV fluorescence. In the
first crystallization trials amorphous crystals formed latest after 2 days. The fast growth of
amorphous crystals indicates that nucleation is induced very fast and then proteins enter the
phase of supersaturation. Frequently, drops containing either one of the SAP constructs showed
skin formation. In order to slow down the nucleation and to prevent formation of amorphous
crystals, a vapor diffusion rate control experiment with a mixture of different oils was attempted.
In the sitting drop vapor diffusion setup the reservoir was covered with a paraffin oil: silicon
oil ratio of 80:20, which allowed only limited drop evaporation as high paraffin oil percentages
allow a slower rate of drop evaporation. The diffusion between drop and reservoir is slowed
down, thus decreasing crystal growth. A crystallization plate was set up, where the reservoir
was covered with 80% paraffin oil and 20% silicone oil, which resulted in a strong decrease of
nucleation and only precipitation was visible but no microcrystals. In another trial to slow down
growth of amorphous crystals, 5% glycerol was added to the protein solution, which increased the
solubility of the protein and lead to crystallization drops with precipitation and phase separation.
The amorphous crystals and the spherulites depicted in Figure 2.17 C were used for microseed
matrix seeding. However, only precipitation and amorphous crystals were detected in subsequent
crystallization trials with the applied seeding technique. Additionally, nanoDSF measurements
were carried out for the construct ceSLX4443-606 as well. NanoDSF measurements rely on the
intrinsic fluorescence mainly of tryptophane and tyrosine residues at 330 and 350 nm. The SAP
construct contains only one tyrosine residue and fluorescence was therefore too weak for recording
of thermal unfolding curves. Then buffer conditions with the low salt concentrations and high
pH were adopted from the screening with the ceSLX4467-718 construct. Crystallization of the
ceSLX4SAP constructs in complex with DNA substrates lead to very thin feather-like, long and
fragile crystals. They were attached strongly to the bottom of the drop and detaching lead to
fragmentation of the crystal. Mostly, when analyzing the crystals under the UV-microscope, they
absorbed the UV fluorescence, which indicates DNA crystals (similar to Figure 2.17 F). Seeding,
addition of various DNA substrates and different protein:DNA ratios did not gave any hits. In
summary crystallization of ceSLX4SAP alone as well as with DNA did not lead to diffraction
quality crystals.
2.3.4 Crystallization Trials of ceSLX4SAP in Complex with Interaction
Partners
As the SAP domain and the MUS81-EME1 constructs alone or with DNA did not lead to any
crystallization hits, another crystallization strategy was applied, which combines ceSLX4SAP with
ceMUS81N and DNA substrates. The rationale behind was to stabilize unstructured regions in the
proteins by their substrate and their interaction partner. This setup did not yield any crystals,
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even though various DNA substrates were tested.
In another approach the before mentioned strategy was extended by crystallization trials of
ceSLX4SAP, full-length MUS81 (wild type and active site mutants) and different EME1 truncations
with various DNA substrates. Using full-length MUS81 was important here, as the N-terminus
of MUS81 interacts with SLX4SAP and the C-terminal HhH domains are the interaction site with
EME1 (Figures 1.4 B, 1.6 B)[135, 201]. In this way, a complex of MUS81 interacting with EME1,
the DNA substrate in the active site of MUS81ERCC4 and SLX4SAP stabilizing the interaction
would be achieved. Three dimensional crystals were obtained (Figure 2.17 D) and conditions
around 20% PEG 3350 and 0.2 M Magnesium chloride were tested with different cations in ad-
dition. In several conditions containing PEG 3350 and calcium acetate long feather-like crystals
appeared (like in Figure 2.17 E). Testing them for protein content under the UV microscope,
showed the absorbance of the light by black streaks. This indicated a crystal content of DNA
only. Crystals containing glycerol as cryo-protectant were analyzed at the synchrotron and they
did not diffract. To reduce skin formation and nucleation, crystallization drops with various DNA
substrates and precipitant conditions were setup in a microbatch under oil experiment with 50%
paraffin oil and 50% silicone oil. However, under the tested conditions microcrystals for further
optimization or larger crystals could not be achieved. Taken together, different approaches have
been tried in order to get diffraction quality crystals, but under the tested conditions, no protein-
DNA substrate crystal could be achieved. Therefore, a different approach was chosen to obtain
structural information.
2.4 Structural Analysis of ceSLX4SAP and ceMUS81N by
NMR
After extensive crystallization trials of both the human and C. elegans proteins with and without
different DNA substrates, so far none of the tested conditions and crystallization methods gave
rise to crystals with diffraction quality. The used constructs for ceSLX4SAP and MUS81N were
quite stable and are highly soluble. Furthermore, with a size of 18.0 and 18.5 kDa, respectively,
the constructs are in a size range that is applicable for nuclear magnetic resonance (NMR). NMR
measurements and assignments were carried out by our collaborator Dr. Andre´ Moura˜o at the
Helmholtz Center Munich (Protein Expression and Purification Facility).
2.4.1 HSQC analysis of ceSLX4SAP and ceMUS81N
In order to analyze the proteins for their suitability for NMR spectroscopy, a two-dimensional
1H15N-HSQC (heteronuclear single quantum coherence) experiment was carried out. In this ex-
perimental setup the 1H and 15N shifts are measured as a correlation between the nitrogen atom
of a HN group and the directly bound proton. Each signal in the spectrum represents a proton
and its bound nitrogen atom. Thus, each amino acid is described as one peak in the spectrum
as every amino acid contains one HN in the peptide bound, except for proline. The side chains
of asparagine and glutamine appear as doublets. Initial HSQC spectroscopy was carried out on
the constructs ceSLX4443-606 and ceMUS811-157. The proteins were expressed in M9 minimal
medium containing 15N - ammonium sulfate as the sole nitrogen source and purified in a three
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Table 2.2: Protein constructs of ceSLX4SAP and ceMUS81N for NMR experiments. More truncated
SLX4SAP and ceMUS81N constructs were designed and tested for their expression (exp), solubility (sol), degra-
dation (deg) and DNA binding. The success is indicated by + (positive) and - (negative). DNA binding is
indicated by + (weak binding) to +++ (binding comparable to reference construct) and - (no binding). The
reference constructs are for ceSLX4 443-606 and for ceMUS81 1-157. n.d. not determined
Construct No. Protein Construct exp sol deg DNA binding
48 ceMUS81 1 - 157 +++ +++ - +++
49 1 - 140 +++ +++ ++
50 1 - 89 -
51 1 - 80 -
52 10 - 89 -
53 17 - 140 ++ ++ +++ n.d.
54 17 - 80 ++ ++ +++ n.d.
36 ceSLX4 443 - 606 +++ +++ - +++
55 443 - 588 ++ +++ + n. d.
56 443 - 515 ++ +++ + -
57 467 - 560 +++ +++ - +++
58 467 - 530 +++ +++ + -
59 470 - 606 +++ +++ +++ +++
60 470 - 515 ++ +++ - -
61 488 - 606 ++ +++ +++ n.d.
62 488 - 588 +++ +++ ++ +++
63 535 - 606 ++ ++ + -
step purification approach. The 15N labeled protein yield from 1 liter expression was 3.4 mg for
ceSLX4443-606 and 3.6 mg for ceMUS811-157. The proteins were measured at a concentration of
110 μM supplemented with 10% D2O.
The recorded 1H-15N HSQC spectra for ceSLX4443-606 (Figure 2.18 A, blue-green) and ceMUS811-157
(Figure 2.18 B, blue-green) showed good spectra with round defined peaks for both proteins. How-
ever with a size of about 18 kDa, they are still too large for simple NMR measuremenst as many
peaks overlap and thus can not be resolved for structural assignments. In addition, NMR chemi-
cal shift perturbation experiments of ceSLX4443-606 (Figure 2.18 A, red-orange) and ceMUS811-157
(Figure 2.18 B, red-orange) were carried out with the respective interaction partner. Usually in
chemical shift titration, the peaks from residues involved in the interaction with the binding part-
ner move their position in the spectrum upon change of the chemical environment. Here, bound
resonances are unobservable because of line broadening as a complex of 36 kDa has been formed
and can not be detected within the relaxation time. Upon comparison with the spectrum without
an interaction partner, it is visible that only a few resonances were not detected (Figure 2.18 black
boxes). Most of the peaks in the spectrum of 1H-15N-ceSLX4443-606 in presence of ceMUS811-157
(darkred-orange) are still detected, indicating that their environment does not change. Thus, most
amino acids in the used protein constructs are not involved in the interaction. The same obser-
vation was made for 1H-15N-ceMUS811-157. Taken together, the constructs of ceSLX4SAP as well
as the N-terminal domain of ceMUS81 had to be shortened in order to obtain a simpler spectrum
and to decrease line broadening. Based on structural predictions further truncated versions were
designed, expressed, purified and tested for DNA binding (Table 2.2).
The tested construct ceMUS811-157 was designed according to limited proteolysis results. From
the same limited proteolysis experiment, another N-terminal construct 1-105 was designed, but
did not express. Therefore, other truncations were designed according to more refined structural
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Figure 2.18: 1H-15N HSQC NMR spectra of ceSLX4SAP and ceMUS81N (A) A HSQC spectrum of 15N
labeled ceSLX4 construct 443-606 was recorded alone (blue/green) and with a 1:1 ratio of the interaction
partner ceMUS81 1-157 (red/orange). (B) A HSQC spectrum of 15N labeled ceMUS81 construct 1-157 was
recorded alone (blue/green) and with a 1:1 ratio of the interaction partner ceSLX4 443-606 (red/orange). The
spectra were recorded on a 110 μM protein sample in 10% D2O. The peaks in the black boxes are the peaks
of single proteins and where not detected in complex with the interaction partner.
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prediction and taking the chemical shift experiments into account. Many of the smaller constructs
of ceMUS81 could either not be expressed or showed strong degradation. Construct ceMUS811-140
was expressed and purified comparable to the reference ceMUS811-157. A 1H-15N HSQC spectrum
was recorded for ceMUS811-140 but this construct was still slightly too large and was not stable
during the measurement as it showed precipitation. In summary a stable and shorter ceMUS81
N-terminal construct could not be found.
The further truncated ceSLX4SAP constructs were expressed in comparable amounts to the
reference construct ceSLX4443-606 and except for few constructs they were stable towards degra-
dation during purification. Some constructs, e.g. ceSLX4488-588, showed degradation in ESI-TOF
mass spectrometry and SDS-PAGE after one freeze-thaw cycle. The stable constructs allowed
further recordings of nuclear magnetic resonance spectra.
2.4.2 NMR-Model of ceSLX4SAP
The small size of 10.4 kDa and the stability of the construct ceSLX4467-560 allowed to record a
high quality spectrum of the the ceSLX4 SAP domain. The construct ceSLX4467-560 was suitable
for further NMR experiments due to its stability and its reduction in size (94 aa compared to
164 aa ceSLX4443-606). The construct was expressed in M9 minimal medium supplemented with
15N-ammonium sulfate as sole nitrogen source and 13C-glucose as carbon source. 13C-15N double
labeled ceSLX4467-560 was purified by Ni TED column, cation exchange chromatography and SEC.
From the construct ceSLX4467-560, hereafter referred to as ceSLX4SAP, a model based on
backbone assignments could be obtained. The last 37 residues were quite flexible and could not
be resolved by the NMR structural model. Thus the model comprises residues 468-523 of ceSLX4
in an arrangement of two short α-helices and one longer α-helix (Figure 2.19 A, B). The three α-
helices encompass residues M473 - S478 (helix 1), E481 - I491 (helix 2) and K499 -L512 (helix 3).
Figure 2.19 A showed the ten best NMR models of ceSLX4SAP. Especially the last ten C-terminal
residues (514 - 523) showed a very high flexibility in the model. The first five amino acids are
flexible in a loop, followed by a short α-helix 1. This helix is connected via two amino acids to a
second short helix, which form an angle of 126◦ to each other. The second helix is connected via
a seven residue loop to the third and longest helix in the structure, both forming an angle of 62◦.
Helix 1 and 3 are parallel to each other, but in opposite directions. In general ceSLX4SAP forms
a small helical bundle reminiscent of the shape of a seven. With the two α-helices separated by a
turn the overall shape of ceSLX4SAP resembles the common fold of SAP domains [168].
In general, the SAP (SAF-A/B, Acinus, PIAS) domain is found in proteins involved in chro-
mosomal organization, like the SAF-A/B proteins [274], or in DNA repair (Ku70, STAT inhibitor
PIAS) [168]. Usually, it is located at the N-terminus of proteins and contains strongly conserved
hydrophobic, polar and bulky amino acids, which are separated by an invariant glycine [168]. The
invariant glycine of ceSLX4SAP (G492) is located in the loop region connecting α-helix 2 and α-helix
3 (marked by an orange sphere in Figure 2.19 B and E). ceSLX4SAP also contains a hydrophobic
core with the following residues: M473, F476, M479, L484, M488, I491, M493, M501, L505, Y509
and I510 (indicated in pale-orange in Figure 2.19 C and E). The extensive hydrophobic core is
formed with nearly all conserved hydrophobic residues. The conserved hydrophobic residues are
likely important for the structural integrity of the protein. Furthermore, the SAP domains of
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Figure 2.19: Structure of ceSLX4SAP (A) Ensemble of the ten final NMR structures of ceSLX4468-523. The
last ten residues show a high flexibility. (B) Cartoon representation of the the lowest energy model of (A).
Left: shape of a seven, Right: 90◦ rotation around y-axis. The orange sphere marks the invariant glycine
located in the loop region, a hallmark of SAP domains. (C) ceSLX4SAP depicted with the hydrophobic core
of the structured region (residues 468-513). (D) ceSLX4SAP with the positively charged amino acids in the
loop area. (E) Sequence alignment of the SAP domain of SLX4 from various model organisms, carried out
with MUSCLE and visualized with Jalview [215, 216]. The hydrophobic residues are colored in pale orange,
the positive residues in light green. The invariant glycine is marked by an yellow sphere. Uniprot accession
numbers [217] for these proteins are as follows: Q8IY92 (human), Q6P1D7 (mouse), A0A068EUV4 (claw frog),
F1QPU2 (zebra fish) and Q22145 (C. elegans).
64 2. Results
other proteins contain a positively charged patch [168]. This positive patch is also existent in
ceSLX4SAP (Figure 2.19 D and E). Most of the positively charged residues are located on α-helix
2 and the loop region (K495, K489, R494, K496, K498, K499). They are facing the surface of the
SAP domain.
Next, the ceSLX4SAP model was subjected to three-dimensional structural comparison, in
order to find other proteins with the same or similar fold of a SAP domain. The DALI (distance
matrix alignment) server was applied for structural comparison and structure database searching
[276]. Dali uses 3D Cartesian coordinates of Cαatoms of each protein in order to calculate residue-
residue distance matrices [277]. The Dali search found 147 entries and 58 of them were unique
structural homologs (see Appendix). Among those entries was also PIAS (protein inhibitor of
activated STAT), one of the eponyms of the SAP domain, but it was not picked for further
analysis here, because it was ranked low in comparison to other proteins. Surprisingly, the Dali
search did not gave a hit for the yeast Holliday junction resolvase Ydc2/Cce1, which requires the
SAP domain for the stabilization of the whole CCE1 protein on the HJ and thus plays a critical
role for junction resolution [127]. From the database analysis eight entries were picked for direct
structural comparison based on similar function to ceSLX4SAP or on their high similarity (Figure
2.20 A, B). Additionally, to the superimposition by Dali, the structural alignment was further
optimized by Pymol for five of the eight entries. The eight proteins can be separated into two
groups, one group is also involved in DNA repair and the proteins in the other group are involved in
various other DNA or RNA metabolic processes. For both groups the root mean square deviation
is low and the structures superimpose well (Figure 2.20 A, B). Although all eight proteins share
only a sequence identity between 10 and 20%, they all share same the invariant glycine, which is
located in the loop region between helix 2 and helix 3 (Figure 2.20 C, D). For six of them the glycine
is located in the superimposition at the same position as the ceSLX4SAP glycine, right after helix
2. In Fan1 and Eri1 is the characteristic glycine closer to helix 3 (Figure 2.20 C, right structure).
Among the reported entries the structure of the transcription factor rho had the highest Z-score of
4.5, which indicated the highest structural homology according to Dali. However, as the alignment
between ceSLX4SAP and some other structural homologs was further optimized using Pymol, the
rmsd is still a bit higher compare to, e.g. Tho1. Rho is a transcriptional terminator and functions
as a hexamer, binding either single-stranded RNA or DNA [278]. Rho contains a RNA-binding
domain, whose α-helical domain shares structural similarity with ceSLX4SAP. Furthermore, the
SAP domain could be found in Tho1, a factor involved in mRNA biogenesis [279], in the 3’-
5’exoribonuclease Eri1 (PDB Code 1zbh) as well as in the nuclear protein Hcc1 (PDB code 2do1).
Eri1 performs 3’ end processing of the 5.8S ribosomal RNA and can negatively regulate RNAi
[280]. The structure of the S. cerevisiae Tho1 SAP domain has been solved by NMR experiments
and dsDNA binding was analyzed by chemical shift perturbations [279].
Some DNA repair proteins showed a similar fold to ceSLX4SAP (Figure 2.20 A, left). The
Dali search revealed close resemblance to the SAP domain in FAN1 (FANCD2-associated nuclease
1) DNA structure-specific nuclease [281], Holliday Junction resolvase T4 endonuclease VII [147],
DNA double-strand binding protein Ku70 [282] and E. coli exonuclease I [283]. The structural
data of the four proteins was derived from crystal diffraction experiments.
Comparison of ceSLX4SAP with exonuclease I showed that the SAP-like fold of ExoI (residues
163 - 200) is located in its exonuclease domain (residues 1 - 201) [283]. Another crystal structure
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Figure 2.20: Superimposition of ceSLX4SAP with other SAP domains. Continued on the next page.
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Superimposition of ceSLX4SAP with other SAP domains. (A) Superposition of ceSLX4SAP (pink). Amino
acids 514 to 523 diverge after the helix and are omitted for clarity. Left: Structural overlay with other proteins
involved in DNA repair: Ku70 (1jeg, wheat), T4 Endonuclease VII (2qnc, lightpink), Exonuclease I (3c95, olive
green) and Fan1 (4rec, lightcyan). Right: Structural comparison with other proteins containing a SAP domain:
transcription factor Rho (1pv4, lightorange), 3’-5’ Exonuclease Eri (1zbh, paleyellow), Hcc1 (2do1, bluewhite)
and Tho1 (4uzw, yelloworange). (B) Table summarizing the structural comparison sequence alignment between
ceSLX4SAP and SAP domains from other proteins. The first four proteins are involved in DNA repair and the
lower four proteins are involved in other DNA or RNA related processes. For each protein is the Protein Data
Bank code (PDB ID) as well as the chain and residue numbers as well as number of Cα atoms annotated.
Furthermore, for sequence alignment is the percentage of sequence identity (% Sec. Id.) and the root mean
square deviation for Cα atoms (A˚) for structural comparison depicted. (C) Comparison between the SAP
domains of ceSLX4, T4 endonuclease VII, Ku70 and Fan1 for the location of the invariant glycine residue
(marked by a yellow sphere). Colors are identical to (A). (D) Sequence alignment between the SAP domains of
the different proteins from the structural alignment. The alignment was carried out with the multiple sequence
alignment tool MUSCLE and visualized using Jalview [215, 216].
of Exo I was solved in presence of ssDNA and could show how the SAP-like fold is involved in
the cleavage process of ssDNA [284]. Some residues in the SAP-fold of Exo I are involved binding
and activation of Mg2+ within the active site, whereas others, e.g. Arg 142, Arg 165, Leu 166 and
Phe 164, are involved in electrostatic interactions with the phosphates of the DNA [284].
Ku70 forms a heterodimer with Ku80 and encloses DNA ends from a DSB in a ring shape with
high affinity, thus allowing the repair by NHEJ [35, 37, 282]. The SAP domain of Ku70 is located
at the C-terminus of the protein and only present in Ku70, but not in Ku80 [168, 282]. The crystal
structure of Ku70/Ku80 heterodimer with Ku70SAP was solved in absence of a DNA substrate,
but there is also a structure bound to DNA available. The SAP domain in Ku70 is located far
away from the ring formed for DNA binding and exposed to the solvent in the crystal structure
[171, 282]. Biochemical studies indicate that Ku70SAP is responsible for the high affinity DNA
binding of the heterodimer [285]. The Ku70SAP structure has also been solved as a NMR structure
and a structural comparison has been carried out as well, showing its similarity to transcription
factor rho and T4 endonuclease VII [286]. Similar to ceSLX4SAP within Ku70SAP are conserved
Lys residues, which confer DNA binding for Ku70SAP [286].
For T4 endonuclease VII and FAN1 the crystal structures were solved in complex with a DNA
substrate [147, 281] (Figure 2.21 A). Phage T4 endonuclease VII is a Holliday Junction resolvase
and its crystal structure has been solved in complex with a HJ substrate [147]. The DNA-bound
structure shows that the HJ substrate is opened as a parallelogram and thus interrupting the
coaxial base stacking [147]. The three-helical bundle located between the arms of a HJ exhibited
a fold similar to ceSLX4SAP and has not been described as a SAP domain so far [147] (Figure 2.21
A left). These bundles form the tips of the S-shaped dimeric protein, which interact with an arm
of the HJ [147]. The depiction of molecular shape and electrostatic surface potential shows how
the SAP domain in T4 endonuclease VII is located between the arms of the HJ and forming an
interaction platform with DNA (Figure 2.21 B left). The positive charge of the SAP fold in T4
endonuclease VII and its position between the arms indicates that the SAP domain is important
for the stabilization of the protein-DNA complex (Figure 2.21 B left). Here, positively charged
residues from helix 1 and 3 are contributing to the DNA interaction. The loop connecting helix
2 and 3 is in this structure turned away from the DNA substrate. The SAP fold could through
its interactions make sure that the arms of the junctions are separated and could facilitate the
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Figure 2.21: Structural comparison of ceSLX4SAP with SAP domains from other protein in complex
with DNA substrate. (A) Left: Superposition of ceSLX4SAP (pink) with T4 Endonuclease VIISAP (T4 endo
VII, 2qnc, lightpink) in complex with HJ substrate (left) and with Fan1SAP (4rec, lightcyan) and flap DNA
substrate (right). (B) Zoomed presentation of the interaction site of T4 Endonuclease VIISAP with HJ substrate
(C) Molecular shape and electrostatic surface potential of T4 Endonuclease VIISAP in same orientation as (B
left) (2qnc, left) and Fan1SAP (4rec, right) in same orientation as (B right). (D) Surface representation
with electrostatic charge distribution of the NMR model of ceSLX4SAP (blue: positive, red: negative). The left
molecule is in same orientation as in (B). The right molecule is turned around y axis by 90◦ (E) Superimposition
of ceSLX4SAP shown colored by electrostatic surface potential with the DNA substrate from T4 Endonuclease
VII (2qnc) and FAN1 (4rec). ceSLX4SAP is in the same orientation as the respective other SAP domains from
(C).
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opening of the HJ into a parallelogram. Biochemical studies on T4 endonuclease VII showed that
the last three amino-acids of the protein are dispensable for nucleolytical cleavage [148]. However,
removal of additional four amino acids (150-153) in the SAP domain causes loss of activity [148].
This loss of activity is due to the loss of DNA binding, as the T4 endonuclease VII molecules with
shorter SAP domain showed decreased DNA binding [148].
Human FAN1 is a DNA structure-specific nuclease involved in the processing of DNA inter-
strand crosslinks [281]. The FAN1 molecule contains a SAP domain as a primary DNA-binding-
domain with a canonical SAP fold and a SAP’ region, that connects to the next domain (tetra-
tricopeptide repeat (TPR) domain) [281]. FAN1 forms a ’head to tail’ dimer, where one FAN1
molecule is carrying out the catalysis and the other auxiliary FAN1 molecule facilitates substrate
orientation and unwinding of the flap structure [281]. The SAP domain has in this dimer two
roles. In the catalytically active FAN1 molecule the canonical SAP domain interacts with the
large groove of the DNA substrate (Figure 2.21 A, right). Inspecting the shape and charge dis-
tribution of the molecule, it is apparent that most of the domain is not charged and the site
closely to the large groove is positively charged thereby stabilizing the interaction with the DNA
substrate (Figure 2.21 B, right). Lys 478 and Lys 482 are located on helix 2 of the SAP domain
and are in very close proximity to the DNA backbone of the substrate, visualized by the positively
charged patch in the surface representation (Figure 2.21 B, right). The lysines belong to the most
conserved region of FAN1, which achieves DNA binding through extensive electrostatic attraction
[281]. The SAP domain of the auxiliary FAN1 serves as an interaction module between the TPR
and the nuclease domain of the other molecule [281]. The SAP domain thus allows DNA-induced
dimerization [281]. In FAN1 the SAP domain fulfills two functions, first it confers dimerization of
the molecule by electrostatic interaction and second it is essential for nuclease activity.
Comparing the surface representation with electrostatic surface potential of ceSLX4SAP two
large charged patches are existent, one is positively charged and the other forms a small hutch
with negative charges (Figure 2.21 C). The positively charged patch is created by lysine residues
in helix 2 and the loop connecting helix 2 and 3. This strong separation is not seen in the FAN1
or T4 endonuclease VII. Superposition of ceSLX4SAP with the SAP position of FAN1 and T4
endonuclease VII and comparing ceSLX4SAP in a modeled DNA binding state suggests an indirect
interaction with the HJ (Figure 2.21 D). However, when ceSLX4SAP is modeled with the flap
substrate of FAN1, the positive charges reach into the large groove of the DNA and interact
with the phosphate backbone. The negatively charged patch is not in contact with the DNA.
There is the possibility that the two charged patches on ceSLX4SAP carry out different tasks. The
positively charged patch in ceSLX4SAP confers DNA binding and the negatively charged patch
could be involved in ceMUS81N interaction. ceMUS81N is highly positively charged and could
interact with the negatively charged patch on the SAP domain.
2.5 Biochemical Characterization of MUS81-EME1 and SLX4SAP
2.5.1 DNA Cleavage Activity of MUS81-EME1
The heterodimer MUS81-EME1 is a XPF family member interacting with SLX4 and cleaves
together with SLX1, associated with SLX4CCD, HJs in a nick and counter-nick mechanism [141].
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Figure 2.22: Cleavage activity of MUS81-EME1 complexes. (A + C) Nuclease activity of hsEME1-
MUS81 and ceEME1-MUS81 with different DNA substrates and Mg2+ or Mn2+ as cofactor. 40 nM 5’FAM
labeled substrate (marked with yellow asterisk) was mixed with 640 nM enzyme and incubated for 30 min at
37◦C. The reaction products were separated on a native PAGE and analyzed with a phosphoimager. (B + D)
Quantification of the nuclease assays carried out with different DNA substrates and either Mg2+ or Mn2+ as
cofactor. The bar chart shows the percentage of product formation quantified by using ImageJ. The leftover
uncut DA substrate was normalized against the control substrate and product formation was calculated from
the difference. The error bars depict the standard deviation from three independent experiments.
MUS81-EME1 is able to cleave nicked HJs alone as well as replication forks and 3’flaps [141, 174].
The Mg2+ ion binding site in the crystal structure of hsMUS81-EME1 is similar to the metal
on the nucleophile site in other nucleases or polymerases, which employ a two-metal-ion catalysis
[214, 223]. The crystal structure in complex with DNA substrate showed electron density only for
one Mg2+ but not for the second. So far, published studies covering the cleavage activity Mg2+
was used as a cofactor [141, 213]. In order to test the cleavage activity of the purified MUS81-
EME1 constructs, nuclease assays were carried out with Mg2+ as cofactor and additionally with
Mn2+. The reason behind testing nuclease activity with Mn2+ as cofactor is based on its similar
ligand preferences and being common surrogate for Mg2+ in the majority of enzymes [287]. In the
assay different DNA substrates were tested resembling different intermediates occurring during
DNA damage repair. For example the flap substrate resembles a replication intermediate created
by the displacement of the 5’ end of the previous Okazaki fragment during the extension of the
nascent Okazaki fragment by polymerase δ.
The full-length human and C. elegans MUS81-EME1 nuclease complexes were purified as
described previously (see section 2.1.1 and 2.3) and tested for their activity in a nuclease assay
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(Figure 2.22). For this, the DNA : enzyme ratio was 1:15 applying single-turnover conditions.
Substrate gel bands from three independent measurements were quantified and product formation
was calculated from the difference between the control substrate and the substrate after cleavage.
By choosing single-turnover conditions with high enzyme concentrations the catalytic rate at
the active site of the enzyme is being measured as all active sites are occupied. By single-turnover
measurements the usage of the divalent cation becomes an important factor and events at the
active site of the enzyme are isolated. Single-turnover condition might compensate for lacking
phosphorylation of the MUS81-EME1 complex after expression in E. coli as phosphorylation of
the EME1 ortholog Mms4 has shown to be important for nuclease activity in yeast [118].
Human MUS81-EME1 consisted of full-length EME1 and two truncated MUS81 fragments
after purification. The complex cleaved in presence of Mg2+ only weakly 3’ and 5’ flaps with
maximal 14% product formation (compare lanes 5 & 8 in Figure 2.22 A). The cleavage of 5’flaps
occurred in the same extent as compared to 3’flaps and was surprising as cleavage of this substrate
was not reported so far for hsMUS81-EME1. With the cofactor Mn2+ the cleavage of the flap
substrates increased slightly (compare lanes 6 & 9). Product formation after nHJ cleavage reached
nearly 80% with Mn2+ (lane 18).
In difference to the human MUS81-EME1 complex, C. elegans MUS81-EME1 complex with
cofactor Mn2+ 3’flap, replication fork and nHJ nearly completely (compare lanes 6, 12 & 18 in
Figure 2.22 C). Very weak product formation is seen for these substrates when Mg2+ is added,
but nHJ is cleaved to 80% (lanes 5, 11 & 17).
The unexpected cleavage behavior in presence of Mg2+ was puzzling and the question was
raised whether a co-factor needed for cleavage was needed. A co-factor, influencing cleavage
activity of ceMUS81-EME1 could be ceSLX4SAP. Therefore, the same cleavage assay was carried
out in presence of the SAP domain, but the same result was obtained (see Appendix Figure 4.9).
Information about the cleavage activity for hsMUS81-EME1 in presence of hsSLX4SAP could not
be acquired as constructs comprising hsSLX4 SAP domain posed to be degradation prone.
In the end, limited nuclease activity could be detected on the preferred substrate 3’flap and
a clear difference between human and C. elegans proteins was detected. Cleavage tests of N-
terminally truncated constructs of MUS81-EME1 from both organisms showed expected activity
towards the substrates.
2.5.2 Interaction between ceSLX4 SAP and ceMUS81N
Further biochemical characterizations were solely carried out on the C. elegans proteins as they
were more stable and gave higher yield than the human proteins. For the C. elegans SLX4 ortholog
the interaction with MUS81 has been shown by yeast-two-hybrid assay [241]. The involved domains
were examined for human proteins by yeast two-hybrid screen and immunoprecipitation. The first
106 amino acids of hsMUS81, containing the HhH domain, suffice for the interaction with hsSLX4
[201]. Interaction experiments were all carried out either by the usage of homologous expressed
protein and immunoprecipitation or yeast two hybrid screen [201, 202]. However, the interaction
between MUS81 and SLX4 has not been studied in vitro with heterologous expressed protein until
now.
First, the interaction of ceSLX4SAP with ceMUS81N was assessed by applying a direct method
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Table 2.3: Interaction assays applied for the ceSLX4SAP-ceMUS81N complex. Molecular weights of ceSLX4SAP,
ceMUS81N and ceSLX4SAP-ceMUS81N complex were determined theoretically. SEC size exclusion chromatog-
raphy, SLS static light scattering, AUC analytical ultracentrifugation
Protein Complex Exp. MWSLS (kDa) Exp. MWAUC (kDa) Theoretical MW (kDa)
ceSLX4SAP 25 / 41.7 23.3 18.05
ceMUS81N 27 / 57 21.2 18.5
ceSLX4SAP-ceMUS81N 37.8 19.3 / 28.5 36.55
like analytical gel filtration. For SEC interaction assays different pH (8.0, 7.5 and 6.5) and salt
concentrations (50, 100 and 150 mM KCl) were tested. However, a shift of the elution volume
was not detected in any of the experiments. The two proteins eluted in one peak consisting of the
single peaks of each protein alone (Figure 2.23 and Table 2.3). Additionally, static light scattering
(SLS) was performed to quantify the complex formation and determine the molecular weights of
the proteins (Figure 2.24). During an SLS experiment the protein sample is injected on a size
exclusion chromatography column and intensity of scattered light is measured to calculate the
average molecular weight. The measurements were conducted by Dr. Claire Basquin. Depending
on the concentration of ceSLX4SAP or ceMUS81N SLS indicated slightly higher molecular weights
or even formation of polymers. The obtained molecular weight for the complex indicated dimer
formation but as the single proteins showed deviating masses, it is not so solid to rely on these
values. Thus, either a different method had to be applied to get a measure for molecular weight
or the interaction partners had to be modified.
Next, it was examined whether post-translational modification like phosphorylation was re-
quired for complex assembly. One possible kinase is CDK1, which is important for interaction
of MUS81 and SLX4 in human cells [200]. Another possible kinase involved in the phosphory-
lation of SLX4 is PLK1 (Polo-like kinase 1), which has been shown to interact with SLX4 and
to phosphorylate it [114]. As for human PLK1 was a purification protocol available, it was ex-
pressed and purified as a hyperactive mutant (T210D R337A I340A) and applied to ceSLX4SAP
in a phosphorylation assay. ceMUS81N could not be phosphorylated as the assay conditions lead
to strong precipitation of the protein. The successful phosphorylation of ceSLX4SAP was assessed
by total mass analysis and phosphorylation site mapping by proteomics. hsPLK1 phosphory-
lated ceSLX4SAP at positions Ser443, Ser460, Thr467, Ser478, Thr511, Thr522, Thr578, Ser578,
Ser583, Thr598 and Ser602. Phosphorylated ceSLX4SAP and unphosphorylated ceMUS81N were
subjected to gel filtration analysis alone and in complex with each other (Figure 2.23). However,
a peak shift could not be observed. The phosphorylation of the target protein by PLK1 did not
enhance the binding between ceSLX4SAP and ceMUS81N, even though it was shown for human
SLX4 [114]. Taken together, in order to analyze the interaction between the two domains, size
exclusion chromatography is not suited. Here it seems, that the protein-protein interaction must
have either weak binding affinity or the complex has a high off rate.
Next, complex formation was studied by sedimentation velocity experiment, carried out by Dr.
Stephan Uebel and Susanne von Gronau in the biochemistry core facility (MPI of Biochemistry).
Unmodified ceSLX4 SAP and ceMUS81N were subjected alone and in 1:1 ratio to analytical ultra-
centrifugation (Figure 2.25 A). For the individual proteins the masses of the monomeric proteins
could be retrieved, each of them is a monomer. The sample with the 1:1 mixture of the two
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Figure 2.23: SEC studies for the ceSLX4SAP-ceMUS81N complex. SEC Analysis of unphosphorylated
ceSLX4SAP (lightblue), phosphorylated ceSLX4SAP (blue), ceMUS81N (lightgrey), unphosphorylated ceSLX4SAP-
ceMUS81N (black) and phosphorylated ceSLX4SAP-ceMUS81N (magenta) in 1:1 ratio at pH 8.0 and 100mM
KCl. The elution profile was visualized by UV absorbance at 280nm. Peak fractions are marked by lines and
were analyzed by SDS-PAGE with Coomassie staining (right). (M) Protein Marker in kDa, (S) Input sample
of ceSLX4SAP (N) Input sample of ceMUS81N (Co) Input sample for complex of complex. The asterisks mark
artifact bands after long exposure to heat.
proteins exhibited two peaks, corresponding to 19.3kDa and 28.5kDa. The calculated size of the
complex was with 36.5kDa 28% higher than the experimentally determined complex size. This
result indicates a low binding affinity between ceSLX4SAP and ceMUS81N and an equilibrium
between the monomeric proteins and the complex. Through the frictional ratio, the analytical ul-
tracentrifugation experiment can give information about the shape of the molecule or complex. A
frictional ratio of 1 indicates a perfect sphere, 1.2 resembles a globular protein and 2.0 a coiled-coil.
The sedimentation velocity experiments revealed a frictional ratio of 2.315 for ceSLX4 SAP and
1.598 for ceMUS81N, indicating elongated proteins. The elongation of ceSLX4SAP was partially
also seen in the NMR experiments. The last 37 residues of the molecule could not be resolved
by NMR and residues 514 to 523 were highly flexible. The flexibility indicates an unstructured
region, which is responsible for the high frictional ratio. The frictional ratio of protein complex
was determined to 1.9, which indicates again an elongated shape of the proteins. Still, sedimenta-
tion velocity experiments could not give a definite answer whether the SAP domain of SLX4 and
N-terminus of MUS81 interact with each other, which lead to further search for a method to gain
information about the interaction.
As an indirect method to determine protein-protein interactions a thermal shift assay was
applied to measure the complex formation between ceSLX4 SAP and ceMUS81N. Thermal shift
assays can be applied for quantification of protein-protein interaction and the calculation of binding
constants [288–290]. In the Thermofluor assay the melting temperature of the protein-ligand
complex is measured over different ligand concentrations. The resulting curve is then fitted to the
Boltzmann model and the KD is determined. Initially the melting temperature of was ceSLX4
SAP
(100 μM), ceMUS81N (100 μM) and ceSLX4 SAP-ceMUS81N (500 μM + 100 μM) was determined.
For ceSLX4SAP no fluorescence signal could be detected. A reason for this could be that the SAP
domain does not expose hydrophobic residues, which are in general necessary for association with
the SYPR Orange dye [291]. Thus, any signal seen for the complex stems from the fluorescence
of SYPR Orange bound to ceMUS81N. For measuring the interaction of the two proteins, the
concentration of ceMUS81N was kept constant at 100 μM and ceSLX4 SAP was titrated in a
concentration range from 5 μM to 500 μM. After incubation for 1 h on ice, the melting temperature
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Figure 2.24: SLS studies for the ceSLX4SAP-ceMUS81N complex. Static light scattering was applied
to determine the molecular weight of ceSLX4SAP, ceMUS81N and ceSLX4SAP-ceMUS81N. The curves are
UV absorbance (violet), light scattering (green) and refractive index (red) for the indicated protein complex
solution. The top panels in each spectrum show the average molecular weight values in the population of the
peaks shown in logarithmic scale.
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Figure 2.25: Interaction studies for the ceSLX4SAP-ceMUS81N complex. (A) Sedimentation velocity
experiment for ceMUS81N (left), ceSLX4SAP (right) and the complex ceSLX4SAP-ceMUS81N (bottom). The
determined molecular weights are depicted in each panel and discussed in the text. (B) Thermofluor measure-
ments of ceMUS81N and ceSLX4SAP. Left: Fluorescence of the control samples depending on the temperature.
The single proteins of ceMUS81N and ceSLX4SAP were measured at 100 μM. The complex was measured with
100 μM ceMUS81N and 500 μM ceSLX4SAP. The fluorescence of Sypro Orange ceSLX4SAP could not be de-
tected. Right: The concentration of ceMUS81N was kept constant at 100 μM and ceSLX4SAP was titrated
in a concentration range of 5 μM to 500 μM. Analysed is the dependence of the melting temperature on the
ceSLX4SAP concentration. The data points were fitted by an Boltzmann equation. The binding isotherm is
representative for the quadruplet measurement of binding isotherms. The KD of ceSLX4
SAP-ceMUS81N complex
was found to be 152 μM ± 39 under these conditions.
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for each titration point was measured (Figure 2.25 B). Applying a Boltzmann model for non-linear
regression, the KD values were calculated for each binding isotherm separately and then averaged.
For the interaction between ceSLX4 SAP and ceMUS81N the dissociation constant was determined
to 152 ± 39 μ M. The interaction between the two proteins is in moderate scale, which explains
that it could not be detected by size exclusion chromatography. For the first time the interaction
between SAP domain and N-terminus could be quantified and a dissociation constant could be
obtained.
2.5.3 DNA Binding Properties of ceSLX4SAP and ceMUS81N
SLX4 has been described to contain a SAP domain [24, 113, 115]. This domain interacts with
the MUS81-EME1 complex [201] and upon homology search it has been found that other proteins
harboring a SAP domain can have DNA binding properties [168], e.g. Ku70, FAN1 or the yeast Cc1
/ Ydc2 resolvase [127, 170, 281]. The SAP domain is typically located at the N- or C-terminus
and contains an invariant glycine between two amphipathic helices with additional positively
charged patches [168]. Hence, ceSLX4SAP was probed for DNA binding using electrophoretic
mobility shift assay (EMSA). Different 5’FAM-labeled DNA substrates mimicking several DNA
repair intermediates were added to ceSLX4SAP concentrations ranging from 0 to 2.5 μM (Fig. 2.26).
All tested substrates lead to ceSLX4SAP-DNA complex formation at the lowest protein con-
centration. However, the ratio between bound and unbound substrate varied between the tested
DNA structures. Quantification of the EMSA results showed that the interaction of ceSLX4SAP
with dsDNA is weaker compared to HJ substrates, especially at low protein concentrations. HJ
resulted in 57% ceSLX4SAP-DNA complexes at 0.25 μM whereas dsDNA has only 10% complex
formation (compare lanes 2 and 47 in Figure 2.26 A). In general, ceSLX4SAP does not show any
preference for a certain substrate, it is a promiscuous DNA binding domain. For all substrates
except for ssDNA higher order complexes are formed at protein concentrations starting between
0.75 and 1 μM, leading to a saturation of the binding. For 5’flap, dsDNA and ssDNA substrate
up to 9% of the substrate at highest protein concentration remains unbound (see lanes 45, 54 and
63 in Fig. 2.26 A and C). The binding data was fitted with non-linear regression and applying
a fit for cooperative binding mode, thermodynamic parameters were calculated from the EMSAs
(Figure 2.26 C). As statistical measurement for agreement between model and measured data R2
values are shown and except for ssDNA higher than 0.96. The high R2 values and the low residuals
show a good description of the data by the model. The dissociation constants KD of the different
DNA substrates are in the same overall range with slight differences between the substrates. It
can be observed that with increasing complexity of the substrate the KD decreases, with strongest
binding towards nHJ. Compared to the others substrates the binding towards dsDNA is weakest
with a difference in KD of 300 nM to HJ. The Hill coefficient is for most of the substrates at 2.2,
except for HJ with 3.3. The Hill coefficients of the fitted binding curves greater than 1.0 as well
as the sigmoidal shape of the binding curve point towards positive cooperativity.
At the lowest protein concentrations the EMSA for nHJ and HJ showed several shifts indicating
the formation of different complexes. For the nHJ substrate only two defined shifts and at higher
protein concentrations higher order complexes were formed (lane 2 in Figure 2.26 A). HJ substrate
presents three different shifts, which likely corresponds to four SAP molecules bound to one HJ,
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Figure 2.26: DNA binding properties of ceSLX4SAP. (A) Electrophoretic mobility shift assays (EMSAs) of
ceSLX4SAP (construct 443-606) with various 5’FAM-labeled DNA substrates. The armlength of HJ, nHJ, RF
and flaps was 16 bp, ds DNA had 32 bp and ssDNA was 32 bases long. Increasing amounts of added protein
concentration are indicated by a triangle (total concentrations 0.25, 0.50, 0.75, 1, 1.25, 1.50, 2, 2.5 μM). The
DNA concentration was kept constant at 40 nM. Different shifts of substrate-DNA complex were observed
and are marked with SAP 1-3. Higher order complexes (HOC) were detected at larger protein concentrations.
Unbound DNA is marked as free DNA. Seen is a fluorescence image of the native gel. (B) Quantitative analysis
of the bound substrate using ImageJ and non-linear regression carried out with GraphPad Prism assuming
cooperative binding. Error bars depict the standard deviation calculated from three independent experiments.
For some data points the error bar is not shown as it was smaller than the symbol depicting the mean value.
(C) Thermodynamic Parameters for ceSLX4SAP binding to different DNA substrates calculated from non-linear
regression with cooperative binding mode applying GraphPad Prism [292].
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Figure 2.27: Analysis of cooperative binding of ceSLX4SAP. (A) Electrophoretic mobility shift assays
(EMSAs) of ceSLX4SAP with 5’FAM-labeled HJ and nHJ substrate. The armlength of HJs and nHJs was 16bp.
The used protein concentrations ranged from 0, 25, 50, 75, 100, 200, 300, 400, 500 to 700 nM. Seen are
fluorescence images of the native gel. (B) Quantitative analysis of the bound substrate using ImageJ, graphical
representation with GraphPad Prism. Error bars depict the standard deviation calculated from at least three
independent experiments. HOC = higher order complexes
one SAP per arm (see Figure 2.26 lane 11). Also for flap structures maximal three shifts are
seen (lane 30 and 39), which would correspond to the binding of SAP to the two arms and the
single-stranded overhang. As the HJ and nHJ substrate showed several shifts in the native gel,
the EMSA was repeated with lower protein concentrations (Figure 2.27).
With a narrower concentration range it is visible that the critical concentration for forming
ceSLX4SAP-HJ complexes was 100 nM (Figure 2.27 A). At this concentration complex SAP 1 is
formed, which most likely refers to the binding of one SAP molecule to the Holliday junction
(SAP 1). At higher concentrations more shifts were visible, which could refer to two SAP (SAP
2), three SAP (SAP 3) and four SAP molecules (SAP 4) bound to the arms of the HJ. Thereby
it is assumed that each molecule bound to one arm of the junction. For example, at a protein
concentration of 300 nM a second shift in the native gel was visible, which indicated the binding
of two SAP molecules to the HJ. At highest protein concentration few higher order complexes are
formed, but additionally four shifts can be seen. The binding towards nHJ showed maximum three
shifts on the native gel, indicating a maximal association of three SAP molecules with the nHJ
(Figure 2.27 A right). Comparing the binding of ceSLX4SAP between HJ and nHJ, it is visible
that more SAP 1 complexes are formed at 400 nM protein concentration (Figure 2.27). Especially
for nHJ the formation of higher order complexes is much higher than for HJ.
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The formation of different shifts in electrophoretic band shift assay has been detected also for
other SAP-domain containing proteins. SAP domains show cooperative binding in general. For
spCCE1 the formation of different complexes in EMSA has also been reported [127]. Furthermore,
EMSAs of T4 endonuclease VII show several shifts from different complexes as well [148]. There,
SAP largely contributes to the DNA binding ability of T4 endonuclease VII [148].
Before the NMR backbone model was generated by Dr. Andre´ Moura˜o, several residues, which
were highly conserved in SLX4SAP from different organisms, were mutated to alanine in order to
remove charged residues. For this, residues F476, K485, R494, K498 and H513 were mutated to
alanine and hereafter named ceSLX4SAP-5A. The mutant ceSLX4SAP-5A was expressed and purified
like the wild type protein. DNA binding was tested with different DNA Substrates (Figure 2.28
A - C). The ceSLX4SAP-5A mutant displayed a weaker binding especially towards most of the
substrates compard to the wild type protein. At protein concentrations of 2 or 2.5 μM not much
higher order complexes are formed, but the protein-DNA mixture is retained in the wells of the
native PAGE (Figure 2.28 A, e.g. lanes 26 and 27). The obtained KD values assuming cooperative
binding show in general a weaker DNA binding affinity and in addition the calculated R2 values
are lower than for the wild type protein indicating a higher scatter around the regression line
(Figure 2.28 B, C). As another statistical measurement residual plots were inspected and showed
similar agreement with the model as the wild type protein. Thus, the cooperative model describes
the DNA binding for ceSLX4SAP-5A well.
Although ceSLX4SAP-5A showed a weaker DNA binding for all tested DNA substrates, the
promiscuous DNA binding is retained (Figure 2.28 A - D). In direct comparison the overall DNA
binding of ceSLX4SAP-5A was weakened compared to the ceSLX4SAP (Figure 2.28 D). The interac-
tion with nHJ was strongly reduced when KD values were compared, e.g. 201 nM for ceSLX4
SAP
and 685 nM for ceSLX4SAP-5A. This is an reduction of approximately 3.5-fold. Still the DNA in-
teraction was only reduced but not abolished as there are enough positively charged residues left,
which can interplay with the phosphate backbone. Next, the interaction of ceSLX4SAP-5A with
ceMUS81N was tested by thermal shift assay (Figure 2.28 E). A melting curve curve could not be
obtained, thus indicating that ceSLX4SAP-5A does not associate with ceMUS81N. ceSLX4SAP-5A
concentrations higher than 125 μM could not be measured as the high protein content lead to
aggregation. Through the mutation of the five charged residues the interaction was abolished.
The construct ceSLX4443-606 or ceSLX4SAP might contain two sites, one site for DNA binding and
the other site for interaction with ceMUS81N.
Next, the location of the mutated residues were compared with the NMR model and so far
published data. Residue F476 faces in our model inwards to the hydrophobic pocket. The residue
K485 is located in α-helix 1 and most likely faces to the solution. The residues R494 and K498 are
located in the loop region connecting helix 2 and helix 3. Histidine 513 is located at the end of
helix 3, where the unstructured region of the SAP domain starts. Those four residues could give
a contribution to DNA binding as well as interaction with ceMUS81N. Castor et al. published an
interaction study based on co-immuniprecipitation with several mutated residues in mouse SLX4
SAP and interaction with MUS81 was abolished when Y1340 in mmSLX4 was mutated to alanine
[202]. This residue corresponds to F476 in C. elegans and mutation to alanine lead to a blockage
in the interaction with SLX4. The other residues mutated in ceSLX4SAP-5A are possibly involved
in DNA binding and lead to the reduced DNA affinity.
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Figure 2.28: Analysis of cooperative binding of ceSLX4SAP-5A and interaction with ceMUS81N. Continued
on the following page
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Analysis of cooperative binding of ceSLX4SAP-5A and interaction with ceMUS81N. (A) Electrophoretic
mobility shift assays (EMSAs) of ceSLX4SAP-F476A, K485A, R494A, K498A, H513A with various 5’FAM-labeled DNA sub-
strates as used before. Increasing amounts of added protein concentration are indicated by a triangle (total
concentrations 0.25, 0.50, 0.75, 1, 1.25, 1.50, 2, 2.5 μM). The DNA concentration was kept constant at 40 nM.
Different shifts of substrate-DNA complex were observed and are marked with SAP 1-3. Higher order complexes
(HOC) were detected at larger protein concentrations. Seen are fluorescence images of the native gel. (B)
Quantitative analysis of the bound substrate using ImageJ and non-linear regression carried out with GraphPad
Prism assuming cooperative binding. Error bars depict the standard deviation calculated from three independent
experiments. For some data points the error bar is not shown as it was smaller than the symbol depicting the
mean value. (C) Thermodynamic Parameters for ceSLX4SAP-5A binding to different DNA substrates calculated
from non-linear regression with cooperative binding mode applying GraphPad Prism [292]. (D) Comparison of
the quantitative analysis of the bound substrate for the binding of ceSLX4SAP and ceSLX4SAP-5A. The wild type
ceSLX4SAP-DNA binding is depicted by dotted lines with triangle symbol and the mutant ceSLX4SAP-5A-DNA
interaction is depicted by the continuous line with circle symbol. (E) Thermofluor measurements of ceMUS81N
with either ceSLX4SAP (black) or ceSLX4SAP-5A (grey). The concentration of ceMUS81N was kept constant at
100 μM and either wild type or 5A mutant ceSLX4SAP was titrated in a concentration range of 5 μM to 500
μM. Analyzed is the dependence of the melting temperature on the ceSLX4SAP concentration. The data points
of ceMUS81N with ceSLX4SAP were fitted by an Boltzmann equation. The data points for ceMUS81N with
ceSLX4SAP-5A could not be fitted due to lacking complex formation.
The human MUS81 contains two domains at the N-terminus, the HhH and the WH domain
(Figure 1.6), which have been described as DNA binding domains [143, 219]. In the case of
ceMUS81 only the N-terminal HhH domain is predicted to be present in the residues 5 to 116.
For the residues spanning from 117 to 206 no secondary structure is predicted (see Appendix
4.3). From residue 207 to the end of the protein a large structured region is predicted by the
secondary structure prediction tool Jpred. This structured region corresponds to the ERCC4
domain. Comparison with the other species in the alignment shows that ceMUS81 is the shortest
ortholog of the compared species and doesn’t seem to contain a WH domain (see Appendix 4.3).
To determine whether ceMUS81N binds DNA, electrophoretic mobility shift assays were used to
study its interaction with various DNA substrates.
All tested DNA substrates formed complexes with ceMUS81N (residues 1 - 157) with the
highest binding affinity with a KD of 269 nM towards nHJ (Figure 2.29). The weakest binding
is visible towards ssDNA with only 54% DNA bound at 5 μM protein. In similar KD range of
800 to 815 nM was the binding towards dsDNA (Figure 2.29). The binding constant towards RF,
flaps an HJ were between 500 and 600 nM. The strongest binding of MUS81N was visible with
nHJ, showing a clear preference for binding towards nHJ over other, especially non-branched DNA
substrates. For all tested substrates it can be seen that a saturation of the binding is not reached.
Although the concentration of protein was in excess (125times higher), 10 - 50% of substrate is
unbound depending on the substrate. The Hill coefficients of the non-linear regression showed
values >1, but remaining free substrate at excess protein amount indicates presence of unlimited
low binding sites.
Previously, it was shown in vivo that the N-terminus of human MUS81 interacted with SLX4-
SAP domain [201]. I could demonstrate in vitro that both domains interact with each other in
absence of DNA substrate at low affinity. Thus, DNA binding was tested for the complex of
ceSLX4SAP and ceMUS81N in a band shift assay as well.
Comparing the band shift assays of the complex among the substrates HJ and nHJ, binding
is in the same range (Figure 2.30 A, B). Here, the EMSAs show much more formation of higher
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Figure 2.29: DNA binding properties of ceMUS81N(A) Electrophoretic mobility shift assays (EMSAs) of
ceMUS81N (construct 1-157) with various 5’FAM-labeled DNA substrates. The armlength of HJ, nHJ, RF
and flaps is 16 bp, ds DNA has 32 bp and ssDNA is 32 bases long. Increasing amounts of added protein
concentration are indicated by a triangle (total concentrations 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 5 μM).
The DNA concentration was kept constant at 40 nM. Different shifts depending on substrate were observed
and are marked with M-N 1-2. Higher order complexes (HOC) were detected at larger protein concentrations.
Unbound DNA is marked as free DNA. Seen is a fluorescence image of the native gel. (B) Quantitative analysis
of the bound substrate using ImageJ and GraphPad Prism applying non-linear regression with cooperative
binding mode. Error bars depict the standard deviation calculated from three independent experiments. For
some data points the error bar is not shown as it smaller than the symbol depicting the mean value. (C)
Thermodynamic parameters for ceMUS81N binding to different DNA substrates calculated from non-linear
regression with cooperative binding mode applying GraphPad Prism [292].
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Figure 2.30: DNA binding properties of ceSLX4SAP-ceMUS81N complex. (A) Electrophoretic mobility
shift assays (EMSAs) of ceSLX4SAP-ceMUS81N with 5’FAM-labeled nicked HJ and HJ. The armlength of
nHJ and HJ was 16bp. Increasing amounts of added protein concentration are indicated by a triangle (total
concentrations 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 2.00 and 2.5 μM). The DNA concentration was kept constant
at 40 nM. Different shifts depending on substrate were observed and are marked with MN-SAP 1-2. Higher
order complexes (HOC) were detected at larger protein concentrations. Unbound DNA is marked as either
nHJ or HJ. Seen is a fluorescence image of the native gel. (B) Quantitative analysis of the bound substrate
using ImageJ and non-linear regression was carried out with GraphPad Prism assuming cooperative binding.
(C) Thermodynamic parameters of complex binding to nHJ or HJ. (D +E) Comparison between the nHJ (D)
and HJ (E) binding of the different proteins. Error bars depict the standard deviation calculated from three
independent experiments. For some data points the error bar is not shown as it smaller than the symbol
depicting the mean value.
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order complexes than for the single proteins and furthermore maximal two band shifts are visible,
indicating the formation of two complexes. Furthermore, the distance between the shifts is larger
than for the single proteins, indicating that two molecules bind at the same time. Comparing
the quantifications of the single proteins ceSLX4SAP and ceMUS81N and the complex shows that
binding of nHJ substrate gives a higher binding affinity than of the single proteins (Figure 2.30 D,
E). The curve shape resembles a hyperbolic shape leading to a saturation. The binding towards
intact HJ is for ceMUS81N much weaker than for the SAP domain alone or for the complex (Figure
2.30 E). Binding of the complex to HJ is slightly stronger than of ceSLX4SAP alone. Overall, the
quantification of the band shift assays for the complex of ceSLX4SAP and ceMUS81N can not rule
out the possibility that the two domains interact individually with the substrate. Furthermore,
the protein concentration of 1 μM is 150-fold lower then the before calculated KD for complex
formation.
Additionally to the shift assays, DNA binding of ceSLX4SAP, ceMUS81N and ceSLX4SAP-
ceMUS81N was quantified by applying fluorescence anisotropy (Figure 2.31). In this method the
5’FAM-labelled DNA substrate is excited with vertically polarized light by a wavelength of 470 nm
that selectively excites a subset of fluorophores according to the relative orientation of the incoming
beam [293, 294]. The emission has a polarization as well and the extent of the polarization is
described as anisotropy. Anisotropy originates from within the fluorophore structure, in which the
transition moments for absorption and emission lie along specific directions. But the emission can
become depolarized by a number of causes. One cause is rotational diffusion, which changes the
direction of the transition moments. Fluorescence anisotropy measurements reveal the average
angular displacement of the fluorophore that occurs between absorption and emission [294]. The
displacement is dependent on the rate and extent of rotational diffusion. The rotational diffusion
in turn depends on the size and shape of the molecule. With increasing size of the complex, the
rotational diffusion is further decreased and the fluorescence anisotropy increases.
Binding isotherms showed that single ceSLX4SAP binds to 32 bp dsDNA with a KD of 149.7
±15 nM, to 16 bp armlength HJ with a KD of 135.7 ±17 nM and to 16 bp armlength nHJ with a
KD of 141.6 ±8.9 nM (Figure 2.31A & D). A clear difference in the binding towards dsDNA like
in the EMSA can not be detected in anisotropy measurements. The DNA interaction is for all
three substrates in the same range. However, the Hill coefficient is lowest for dsDNA and highest
for nHJ, giving rise to higher cooperative binding when nHJ is given as a substrate. Analysis of
the residual plots confirms that the chosen cooperative binding model for ceSLX4SAP describes
the measured data quite well, indicated by low residuals. However, the residual plot showed
heteroscedasticity. Heteroscedasticity is a statistical phenomenon, which occured at high protein
concentrations when the standard error of the anisotropy increased. This leads also to higher
residuals as the predicted values represent the measured values weaker, when they show variance.
Taken together the findings from bands shift assays and fluorescence anisotropy demonstrate the
binding of ceSLX4SAP in a cooperative manner. The structure and the branching of the DNA
substrate facilitates the binding of several SAP domains to one DNA substrate until saturation is
reached and in the case of HJ until every arm is occupied by the SAP domain.
Titration of the three different 5’FAM-labeled DNA substrates (HJ, nHJ and dsDNA) with
MUS81N showed the formation of a small plateau between 400 nM and 1 μM depending on the
substrate (Figure 2.31 B). However, a saturation of the binding could not be reached, even at
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Figure 2.31: Fluorescence anisotropy measurements. Representative binding isotherms for binding of
ceSLX4SAP (A), ceMUS81N (B) and ceSLX4SAP-ceMUS81N (C) to 16bp armlength HJ, nHJ and 32bp dsDNA
(11.2nM) with 5’-FAM-label analyzed by fluorescence anisotropy. The anisotropy is shown as a function of
protein concentration in logarithmic scale. (D) Summary of the calculated KD in nM and Hill coefficients (n).
For ceSLX4SAP and ceSLX4SAP-ceMUS81N the data were calculated by using a nonlinear fit to Hill equation
as described in Section 4.3.15. For ceMUS81N data were fitted to a binding equation describing a two-site
binding model described in Section 4.3.15. The error bars represent the standard deviation of three independent
measurements. At the bottom of each anisotropy plot is the respective residual plot for the curve fit (difference
between the calculated anisotropy of the curve fit and the measured anisotropy).
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protein concentrations of more than 100 μM (10300-fold excess of protein over DNA). To analyze
the DNA binding of ceMUS81N a two-site binding model was applied. At the first inflection point
measured data and fitted curve deviate most for dsDNA, which can be seen at the high residuals
in the plot. For nHJ the two-site binding mode is best described leading to low residuals in the
residual plot. The calculated KDs have a high deviation. Still, a clear preference of ceMUS81
N
towards nicked Holiday Junction can be detected, as the dissociation constant is significant smaller
than for the other tested residues. Band shift assays and fluorescence anisotropy showed that DNA
binding of ceMUS81N does not reach 100% DNA binding at very high protein concentration.
Especially in fluorescence anisotropy measurements it is visible that binding between ceMUS81N
and DNA substrates shows at low protein concentrations a cooperative binding mode and at
concentrations exceeding 120 nM a second binding interaction is observed. This second binding
interaction can be dependent on the positively charged ceMUS81N, as it consists of 20.4% positively
charged residues (Lys 13.4%, Arg 7%) and a pI of 9.28 resulting in a positively charged protein
in the assay buffer (pH 6.5). Thus, the binding isotherms above 120 nM protein concentrations
might result from electrostatic interactions between the already formed ceMUS81N-DNA complex
and excess ceMUS81N.
Fluorescence anisotropy was also measured for the complex ceSLX4SAP-ceMUS81N. The cal-
culated KDs are below 100 nM and up to 60% lower than for ceSLX4
SAP alone. The binding
towards HJ and nHJ is in the same range, but the binding towards dsDNA is weaker. This con-
firms the result of the band shift assays, showing a slight preference for branched DNA. Analysis of
the residual plots confirms that the chosen cooperative binding model for ceSLX4SAP-ceMUS81N
describes the measured data quite well, indicated by low residuals and no bias.
2.5.4 Mapping of the ceSLX4SAP DNA Binding Region
The standard construct applied for biochemical investigations on the ceSLX4 SAP domain ranged
from amino acid 443 to 606 and comprised 164 amino acids. This construct was also used for the
first HSQC-spectrum and was too large for chemical shift perturbation experiments (Figure 2.18).
Hereafter, several shorter SAP constructs were tested for expression, purification and DNA binding
(Table 2.2). Figure 2.32 A shows the sequence alignment of several SAP domains from different
organisms based on the ceSLX4443-606. Band shift assays of various shorter SAP constructs were
performed with nHJ as DNA substrate and a protein concentration range between 250 nM and
5 μM (Figure 2.32 B, C). Constructs ending at residue 515, after the highly conserved region in
the SAP domain, did not bind nHJ. At protein concentrations higher than 1.5 μM a smear was
detected in the native gel. The region from Ala 530 to Arg 606, which contains a conserved area,
revealed a similar binding behavior in the EMSA (Figure 2.32 B right). Both constructs alone did
not bind to DNA like the standard construct. The construct ceSLX4467-530, comprising the highly
conserved part of the SAP domain and the flexible region after helix-3, did not even show smear
in the band shift assays at high protein concentrations (Figure 2.32 C). In this study the minimal
DNA binding capability of ceSLX4SAP was defined between the residues 467 and 560.
However, the combination of ceSLX4467-530 and ceMUS81N displayed DNA binding. A quan-
titative analysis of the protein-DNA complexes was performed (Figure 2.32 D) and the complex
of ceSLX4467-530 with ceMUS81N showed similar binding affinity as the ceSLX4443-606 alone and
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Figure 2.32: Determination of the DNA binding site in ceSLX4SAP Continued on the following page.
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Determination of the DNA binding site in ceSLX4SAP (A) Sequence alignment of different SAP domains from
different species compared with the longest SAP construct of ceSLX4. The panel below depicts the constructs
tested for DNA binding. +++ indicates strong binding like seen for the standard construct ceSLX4443-606, ++
indicates DNA binding, but with lower affinity than the standard construct. (B) EMSAs of two constructs
showing very weak to no DNA binding activity. For DNA binding a 5’FAM-labelled 16bp armlength nicked HJ
substrate was used. DNA binding was tested for protein concentrations from 0 to 5 μM. (C) The construct
ceSLX4467-530 was tested for DNA binding and did not show DNA interaction. In complex with the N-terminal
domain of ceMUS81 the binding towards nHJ was tested as well. (D) Quantification of the bound substrate
using ImageJ and non-linear regression carried out with GraphPad Prism assuming cooperative binding. The
quantification is based on triplicate measurements except for ceSLX4467-530.
higher affinity than ceMUS81N alone. As the binding of the two proteins together is higher than
ceMUS81N alone, one can exclude that the DNA binding activity originates only from MUS81N.
However, the same binding affinity of ceSLX4443-606 in complex with ceMUS81N is not reached.
The bands shifts assays give information about two different characteristics of the SAP domain.
First, the highly conserved part of the SAP domain alone is not sufficient for DNA binding and
second the combination of the two DNA binding domains has higher DNA binding affinity than
the individual domains. For this process it can be possible that ceSLX4467-530 undergoes an
conformational change upon interaction with ceMUS81N and this increases binding affinity. Or it
could be possible that interaction of ceMUS81N with ceSLX4467-530 increases DNA binding affinity
of ceMUS81N.
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3. Discussion
The DNA repair factor SLX4 is considered as a scaffold protein that integrates many different
functions through divers interactions. SLX4 interacts with the structure-selective endonucleases
SLX1 and the MUS81-EME1 complex, forming the SM complex [141, 143]. So far, it is not
known how the active sites of SLX1 and MUS81-EME1 are coordinated during HJ cleavage. The
involvement of two active sites from different heterodimeric enzymes is unique to the SM complex
and represents a novel mechanisms of HJ resolution in eukaryotes [236]. My thesis addresses the
open question how SLX4 is involved in DNA interaction during DNA substrate processing. The
presented data shows a structural model for the SAP domain of SLX4 and that SLX4SAP is an
additional element in the DNA cleavage process. Based on the presented biochemical data I could
show, that the SAP domain is a promiscuous DNA binding domain and its interaction with the
N-terminus of MUS81 was analyzed in vitro. Interestingly, SLX4 expressed from HEK293 cells
was highly phosphorylated.
3.1 Reconstitution of the SM-Complex in vitro
In order to gain structural and biochemical information about the Holliday-Junction resolvase com-
plex SLX1-SLX4-MUS81-EME1, expression and purification of the four proteins was attempted
in a first step. For this human and C. elegans orthologs were first expressed in E. coli and human
SLX4-SLX1 was expressed in mammalian cells.
In general it was challenging to express the SLX1 orthologs. Expression of ceSLX1 full-length
and the N-terminally truncated construct could be accomplished in bacterial cells. However,
size-exclusion chromatography indicated soluble aggregates by early elution and in a cleavage
test in complex with ceSLX4 activity was not detected. Attempts to purify human SLX1 alone
failed, however it was possible to obtain functional protein from HEK293 co-expression with its
interaction partner SLX4. The aggregation after over-expression could arise from the reported
homodimerization of Slx1, when in inactive state [156]. Upon interaction with SLX4CCD SLX1
becomes active. Thus, the co-expression with SLX4 constructs in HEK cells was carried out and
SLX1 could be expressed soluble and showed nuclease activity after purification. Furthermore,
bacterial expressed hsSLX4 constructs showed stability issues and were therefore challenging for
crystallization as well. Moreover, C. elegans SLX4 constructs were over expressed in E. coli and
was tested for DNA binding and interaction with MUS81N. For ceSLX4SAP and ceMUS81N large
amounts of pure proteins could be purified.
90 3. Discussion
3.2 Post-Translational Modification of hsSLX4
Human SLX4 constructs were purified after expression in mammalian cell culture and samples
showed a complex phosphorylation pattern. Phosphorylation site mapping detected six phos-
phorylation sites in hsSLX41300-1834 alone and 18 in co-expression with hsSLX111-275. The here
described sites, were found in all biological triplicates. But a batch to batch variation was seen
with few sites detected from one expression but not in another one. The amount of phosphoryla-
tion and the distribution are interesting to note. The distribution of phosphorylation is different
between hsSLX41300-1834 expressed alone compared to co-expression with hsSLX111-275. When
hsSLX41300-1834 is expressed alone, the phosphorylation is reduced by approximately 3-fold. The
phosphorylation sites were mostly found at the SIM3 domain and between SAP and CCD for
SLX41300-1834 expressed alone. hsSLX41300-1834 co-expressed with SLX111-275 was much stronger
phosphorylated between the SIM3 and SAP domain. This difference in distribution between the
expression conditions is very interesting and needs further examination.
The comparison of the herein identified phosphorylation sites with the database Phosphosite
Plus showed that only a third of the SLX41300-1834 phosphorylation sites were also listed in the
database. Most entries were found for T1315 and S1329, but the biological significance is not
know. The database contains a list of phosphorylation sites found in large proteomic studies
for hundreds to thousands of proteins. The relevance of all the SLX4 phosphorylation sites and
stoichiometry is not described in the database. Further intricate experiments are needed in order
to obtain quantitative information about the detected phosphorylation sites.
Additionally, phosphorylation sites were mapped after DNA damage using different DNA dam-
aging agents in order to gain a more consistent distribution of the phosphorylation. The protocols
for the DNA damage treatment were adopted from literature and the cells were not checked for the
induction of the DNA damage or the DNA damage response. In order to confirm the induction and
extent of DNA damage additional experiments have to be carried out, e.g. metaphase spreads,
analysis of histone γ-H2AX content or 2D-electrophoresis. The phosphorylation pattern under
the influence of DNA damaging agents showed only limited differences, however some sites were
not changed under the influence of certain agents. Hydroxyurea showed the lowest difference in
phosphorylation intensity compared to control cells. Hydroxyurea causes a long chain of reactions
leading ultimately to DSB and it is possible that the incubation time or the concentration used
was not enough in order to elicit DSBs as the DNA damage state of the cells was not analyzed.
In general, the analysis and interpretation of phosphorylation sites is challenging as samples
show heterogenous phosphorylation pattern and it has been shown before that phosphorylation is
not uniform and happens at several neighboring sites [295]. This could be easily seen, when com-
paring the detected phosphorylation sites from the analysis of the co-expression of hsSLX41300-1834
with hsSLX111-275 with the untreated control cells in the experiment with DNA damaging agents.
Detected phosphorylation sites always showed subtle differences in the expression batches, which
requires enough sample replicas and a thorough analysis would involve more tests. Another dif-
ficulty for analysis is that the identification of the exact phosphorylated residue is not possible
as one peptide peptide mass fingerprinting does not yield direct sequence information [295] and
on some peptides phosphorylation can occur on several residues. Furthermore, depending on the
expression batch, different phosphorylation sites could be detected, which indicates a variation in
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kinase activity. This variation and the high phosphorylation state might also be influenced by
the expression conditions. After transfection of HEK cells they were shaken at 32◦C to increase
the protein expression [296, 297]. This sub-physiological temperature and the large amount of
protein could lead to an activation of kinases, which keep the expressed protein soluble by adding
negatively charged modifications. Although the system applied for detecting phosphorylation is
an artificial system, it was still beneficial for the here described experiments. For phosphosite
mapping large amounts of proteins for high coverage in MS are needed and SLX4 has in general
low expression levels. Therefore, your expression system is a compromise to get enough coverage
for MS analysis. Furthermore, it would also be interesting to measure the kinetics of phosphory-
lation after DNA damage in order to see if certain phosphorylation sites appear or disappear at a
certain time point.
In the depicted experimental setup, hsSLX41300-1834 was purified from unsynchronized cells.
Thus, SLX4 comes from a mixture of different stages of the cell cycle. As phosphorylation of scSlx4
is regulated in a cell cycle dependent manner [193, 194], one can assume that human SLX4 is cell
cycle regulated as well. Here, purified SLX4 consists of a mixture of molecules originated from
cells at different cell cycle stages representing different phosphorylations. At a given step in cell
cycle a single peptide can be unphosphorylated, weakly phosphorylated or highly phosphorylated.
Future analysis of the phosphorylation state of human SLX4 could elucidate the phosphorylation
status of different sites by synchronously grown cells and their arrest at different cell cycle stages.
A systematic approach would give more information about the modification state at the respective
cell cycle stage and the influence of the various DNA damaging agents.
In order to get a deeper understanding of the phosphorylation of human SLX4 it would be more
beneficial to analyze SLX4 from expression in a stable cell line. In general, stable cell lines show
less heterogeneity of the protein product and high productivity. However, to establish a stable cell
line overexpressing SLX4 is time-consuming and it would involve an inducible expression system as
SLX4 is toxic for the cells. Transient expression leads to high amount of expressed protein in short
time and is flexible towards changes in the construct and trying different crystallization conditions.
The problem is that the cell has to deal with high amount of DNA after transfection and then
large protein amounts, which have to be kept in an soluble state. Thereby phosphorylation of the
protein is also used as it keeps the highly expressed protein soluble. A stable cell line expression
SLX4 is more beneficial as it has low batch to batch variability and lower heterogeneity of the
product. Furthermore, a stable cell line produces protein amounts closer to the physiological
level, which are lower than in transient expression. As SLX4 tends to degrade, an expression level
closer to the physiological expression level could be beneficial for protein stability. With a stable
cell line, the influence of SLX4 on the cell cycle could be better understood and it would be more
straightforward to synchronize the cells with low SLX4 expression levels than with high expression
levels. Nowadays, the establishment of stable cell lines has advanced and is even possible applying
CRISPR/Cas9 technology [298]. In this method, the recombinant protein of interest is integrated
into specific genomic loci using CRISPR/Cas9 and the gene expression is driven by endogenous
promoters [298].
In SLX4 the exact physiological role of most phosphorylation sites is unclear. In this thesis I
could show that the phosphorylation pattern of hsSLX41300-1834 is very different from hsSLX41300-1834
co-expressed with hsSLX111-275. One can so far only speculate about the reason for this experi-
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mental finding. It was shown earlier that the disruption of murine Slx4 gene lead to absence of
SLX1 in Western Blot, suggesting that SLX4 regulates SLX1 protein stability [202]. Furthermore,
SLX1 is not active and stable in absence of SLX4 [156]. Through phosphorylation SLX4 activates
itself for SLX1 interaction. The phosphorylation between the domains is increased and causes
conformational change to bind the SLX1 nuclease and the MUS81-EME1 nuclease complex [200].
It might be that a specific phosphorylation pattern indicates a certain role for SLX4 as it is as a
scaffold protein involved in other DNA repair pathways.
An example for the importance of certain phosphorylation sites is the abolished SLX4-MUS81
complex formation after mutation of phosphorylated residues around the SAP domain [200]. Sim-
ilar data for the interaction between SLX1 and SLX4 is not available and so far it is unknown
how the interaction between human SLX4 and SLX1 is regulated. But comparison of the detected
sites with the Phosphosite Plus database showed that nearly half of the sites were also found in
vivo in large scale proteomic approaches. Furthermore, based on this data it would also be com-
pelling to detect the phosphorylation sites of SLX4 when co-expressed with MUS81-EME1 and
when co-expressed with both nucleases. A strong difference could already been seen between the
phosphorylation of SLX4 expressed alone and expressed with SLX1, then there might be a dif-
ference to phosphorylation in co-expression with MUS81-EME1. The co-expression with another
nuclease could change the phosphorylations around the SAP domain. The proteomic data could
give a deeper insight into the regulation of SLX4 and how certain functions could be achieved by
post-translational modification. The shown study and future studies have to be taken carefully
when discussing the biological relevance of phosphorylation sites. There is no information about
the stoichiometry of the phosphorylation site available as phosphorylated and unphosphorylated
peptide are chemically distinct and behave differently during MS. The detection methods are also
so sensitive, that phosphorylation sites might be detected, which are at very low occupancy [264].
It would be that the many detected phosphorylation sites, asynchronously grown cells and a
possible hyperactivity of kinases during protein over-expression, resulted in a heterogenous protein
sample. An applicable way to reduce the heterogeneity of the samples was not found. For future
crystallization studies of hsSLX4 1300-1834 and hsSLX111-275 the protein samples have to be either
stabilized by addition of another interaction partner or reduced in size. Another option could be
the expression in insect cells, which was not tested in the course of the presented research. Insect
cell expression offers high levels of protein expression and introduces similar post-translational
modifications as mammalian cell expression. Crystallization of the same constructs purified from
HEK cells with the background of the phosphorylation sites might be challenging even after
phosphatase treatment .
3.3 The ERCC4 Typ Nuclease MUS81-EME1
MUS81-EME1 belongs to the XPF family of endonucleases, which is diversified in different sub-
strate preferences, thereby playing different physiological roles [142, 174]. Published assays for
substrate preferences showed enzymatic activity on nicked HJs, replication forks and 3’flaps for
human MUS81-EME1 [141, 174]. Full-length ceMUS81-EME1 was expressed and purified from
bacterial cells and cleavage assays revealed that ceMUS81-EME1 had the expected activity to-
wards 3’flap, RF and nHJ when the reaction was supplemented with Mn2+ (Figure 2.22). The
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low activity of ceMUS81-EME1 in presence of Mg2+ towards its usual substrates was surprising.
It was expected that ceMUS81-EME1 would behave like the human or yeast complex, which have
been shown to cleave substrates in presence of Mg2+ in the reaction buffer [135, 141]. A possible
reason for this could be lacking post-translational modification.
Cleavage tests for human MUS81-EME1 deviated even stronger from published results as
hsMUS81-EME1 exhibited cleavage activity on nHJ only in presence of Mn2+. There are several
possible explanation for this. One could be the lack of the one Hhh domain at MUS81 as human
full-length EME1 could be purified but human MUS81 was lacking either N- or C-terminally 11
kDa. The 11kDa could correspond to the hairpin-helix-hairpin domains located at each end. A
recent publication attributed an influence of the N-terminal HhH domain to the cleavage reaction
and specificity [143]. Therefore, it is possible that the existence of the HhH domain controls the
cleavage activity and thus human MUS81-EME1 shows a divergence to before published nuclease
specificity. A lacking C-terminal HhH domain can reduce the interaction of MUS81 with EME1,
which in turn is needed for cleavage activity. Furthermore, an additional effect on the activity could
also be lacking post-translational modification of the hsMUS81-EME1 complex. From studies in
yeast it is known that the activity of the Holliday Junction resolvases is controlled in a cell cycle
dependent manner [117, 118]. The yeast ortholog of EME1, Mms4, is being phosphorylated by
Cdc5 leading to the disentanglement of joint molecules by the Mus81-Mms4 nuclease [117, 118].
The phosphorylation dependent regulation is carried out at the G2/M transition to eliminate all
chromosomal interaction for chromosome separation [118]. For human MUS81-EME1 the cleavage
of HJs is cell-cycle regulated and increases upon SLX1-SLX4-binding [117, 141, 202], but the
cleavage of RFs is not inhibited prior to mitosis nor globally stimulated by SLX1-SLX4 interaction
[200]. Due to expression of the human MUS81-EME1 complex in E. coli phosphorylation is not
introduced. In other publications the human MUS81-EME1 complex was purified from insect cell
expression and is therefore phosphorylated. Thus, lacking post-translational modification could be
another reason for the difference in cleavage activity. So far, it was proposed, that the SAP domain
of SLX4 might be important for the cleavage activity and especially on substrate relaxation of
MUS81-EME1 [143]. Under the tested conditions with C. elegans protein an influence of the SAP
domain was not detected.
Here, I showed for the first time the cleavage activity of MUS81-EME1 complexes in presence
of the two cations Mn2+ and Mn2+. Until now, cleavage assays of MUS81-EME1 complexes
have not been reported in the presence of Mn2+. The expected activity towards 3’flap, RF and
nHJ was only reached for the ceMUS81-EME1 complex with Mn2+ as cofactor. In general, the
properties of Mn2+ are quite similar to Mg2+. However, Mn2+ leads to relaxation in substrate
specificity, which has been shown for other proteins, e.g. helicase / nuclease Hef [211], translesion
DNA polymerase Dpo4 [299] and RNase H [300]. In the case of the here presented MUS81-EME1
complexes, Mn2+ is needed for proper activity. Future studies, could use human MUS81-EME1
complex purified from homologous source in order to analyze, which bivalent cation is bound
after purification. Furthermore, stability studies could be carried out in presence of either of the
divalent cation to find the one cation, which increases protein stability. So far, it has not been
studied whether Mg2+ or Mn2+ is the natural ligand for MUS81-EME1. Both published crystal
structures contained Mg2+ either in the crystallization buffer [213] or for soaking [214]. Reported
biochemical assays were carried out solely with Mg2+ as cofactor for the cleavage reaction. The
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cleavage assays published so far used only magnesium as co-factor in cleavage buffer. In the
here presented cleavage tests the MUS81-EME1 complex displayed a strong difference in activity
between the cations. Such a difference in activity between Mg2+ and Mn2+ has been observed
for RNaseH [301]. The replacement of Mg2+ with Mn2+ does not only relax the coordination
geometry but also activates the D192N mutant of RNase H and reduces substrate specificity of
retroviral RNases H in order to cleavae dsRNA [301]. Mn2+ in the D192N mutant compensates the
distance shortening between the two-metal ions in D192N RNaseH as Mn2+ shifts the first metal
binding site a bit further away from the second binding site and thus leads to a cleavage reaction
[301]. Another study about RNase H proposed the binding of one Mn2+ in the active site, which is
required for the activation of the protein [302]. Earlier it was also shown, that the binding affinity
towards Mn2+ is higher than towards Mg2+ [303]. Thus, a similar mechanism could also play a
role for the MUS81-EME1 complex. Instead of Mg2+ the actual cation is Mn2+ and the cleavage
activity is enhanced. However, more investigations have to be carried out in order to determine
the divalent cation involved in the active site. It would also be interesting, whether the activity
of active site mutant changes upon interaction with Mn2+, which was seen for RNase HI [301].
3.4 Interaction between ceMUS81N and ceSLX4SAP
Earlier studies on SLX4 and MUS81 showed by yeast-two-hybrid assay and co-immunoprecipi-
tation that SLX4SAP and MUS81N interact with each other [201, 202]. So far, the complex between
the two domains has not been reconstituted in vitro and furthermore it has not been quantified
until now. Here, the interaction between the two domains from C. elegans was tested in vitro by
direct measurements, size-exclusion chromatography, SLS and AUC, and by an indirect method,
thermofluor. ceMUS81N and ceSLX4SAP interaction could not detected by direct measurements
including size exclusion chromatography (analytical SEC and SLS). In order to simulate the protein
modification of homologous expressed protein, phosphorylation of the proteins was attempted
but in a gel filtration assay the interaction of the two domains was not detected. It could be
possible that the phosphorylation by PLK1 did not give the correct phosphorylation pattern for
the interaction to happen. Sedimentation velocity experiments did not give clear data about the
complex formation, either. Finally, a thermal shift assay could show and quantify the interaction
to 152 μM (Figure 2.25). Other quantitative methods, e.g. isothermal titration calorimetry and
microscale thermophoresis, were applied as well. However, due to various technical problems
during the experimental procedure, they did not give a quantitative reproducible measure in the
case of these two protein constructs. The direct measurements could not show interaction between
the two domains, as either no shift was seen in gel filtration or the single domains showed much
higher masses than expected. This findings indicated that the affinity between the domains is
weak and the complex falls apart during gel filtration.
The low affinity of the two proteins measured in vitro could also be an effect of missing post-
translational modification. It remains to be tested whether phosphorylation with a kinase other
than PLK1, e.g. CDK1, influences interaction in vitro. A recent study showed by coimmunoprecip-
itation, that CDK1 phosphorylation at the SAP domain is important for interaction with MUS81
[200]. The dissociation constant of ceSLX4SAP and ceMUS81N gives a weak binding between the
two domains. It also means that at a concentration of 152 μM half of the proteins are present as a
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Figure 3.1: Thermodynamic cycle of DNA binding for ceSLX4SAP, ceMUS81N and ceSLX4SAP-
ceMUS81N complex. Interaction Scheme of ceMUS81and ceSLX4SAP with each other, alone with nHJ and
HJ as well as both together with HJ and nHJ. The binding affinities with DNA were calculated from fluo-
rescence anisotropy measurement (Figure 2.31, the binding affinity between was calculated from Thermofluor
measurements (Figure 2.25) )
complex. This kind of high protein concentration might be biologically only reached in the nucleus
in a very confined region. MUS81 and SLX4 are both located in the nucleus and form foci after
induction of DNA damage [114, 209, 304]. Deep proteome mapping of HeLa cells identified the
copy number per cell for MUS81, EME1 and SLX4 at 2700, 1700 and 220, respectively [305]. Given
that HeLa cells have an average nucleus size of 690 fl (690 μm3) [306], the average concentrations
of MUS81, EME1 and SLX4 are 6.49 nM, 4.1 nM and 528.95 pM, respectively. The concentration
of MUS81 in the cell is thus more than 20,000-fold lower than the measured KD of the interaction
between ceMUS81N and ceSLX4SAP measured in vitro. Thus, there must be the possibility in the
cell to lower the high binding constant by additional measures, e.g. post-translational modification
or phase separation. The weak binding between the complexes in absence of DNA can be explained
by the fact that the two proteins might not strongly interact without the presence of DNA damage,
without DNA or additional binding factors in general. Upon DNA damage SLX4 will be recruited
to the DNA lesion and then recruit the nucleases [14, 158]. EME1 in the MUS81 complex will be
phosphorylated and by this activates MUS81. Depending on a certain phosphorylation MUS81
could undergo a conformational change and interact with SLX4. The before mentioned studies
showing the interaction between the two proteins used protein from one step purification coming
from expression of stable transfected cell lines.
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3.5 Biological Implications for the DNA binding of ceSLX4
and ceMUS81
SLX4 contains a DNA binding domain, the SAP domain, which has been found in other proteins
being involved in DNA metabolism. Typical examples are chromatin-associated proteins, such as
the scaffold attachment factors SAF-A and SAF-B, PIAS family members, DNA repair proteins,
like the non-homologous end joining protein Ku70 [168]. The typical characterization of the SAP,
two amphipatic helices stabilized by hydrophobic residues in their interface and polar residues
facing to the solvent. The two helices are usually separated by a conserved glycine in the loop
region and could also be found in ceSLX4SAP. Direct evidence that the SAP motif binds DNA has
come from studies of SAF-A and Ku70 [169, 170]. The SAP domain can either be used as the main
DNA binding component of a protein (e.g. SAF-A) [169] or as an additional stabilizing element
(e.g. Ku70 and SpCCE1) [127, 171]. A single SAP domain forms a relatively weak interaction
with DNA, which can be undetectable in solution in the case of SAF-Box [274]. When many SAP
domains are brought into close proximity, cooperative effects lead to high affinity DNA binding as
in the case of SAF-A [274].
Characteristically, the SAP domain contains many positively charged residues, which undergo
ionic and hydrogen bonding with the phosphate backbone of the DNA backbone. DNA binding
of ceSLX4SAP was determined by band shift assays and fluorescence anisotropy, both measure-
ments revealed KDs in the range from 140 to 200 nM. Band shift assays of ceSLX4
SAP showed
a cooperative behavior with higher level shifts depending on the branching of the substrate. As
SAP domains show cooperative binding [274], it is possible that each arm of the HJ is occupied
by one SAP molecule (Figure 3.3). At low protein concentrations one SAP binds to one arm of
the junction (Figure 3.3). With increasing protein concentration more HJs are occupied by one
SAP, but at the same time the ratio of HJs attracting a second or even third SAP is increasing.
If non-cooperative binding was assumed then all HJs would be occupied first by one SAP and at
increasing protein concentrations a second SAP would bind to the arms. In an EMSA, before the
second shift would appear all free DNA would be bound by one SAP and with increasing protein
concentrations a second shift would be visible.
In the case of the binding to nHJ, the band shift assay shows hardly any nHJ-complexes with
four SAP. A possible reason for this could be the that the SAP does not interact strongly with
the arm containing the nick owing to the higher flexibility of the arm. In the band shift assays
with lower protein concentrations of ceSLX4SAP several shifts owing to the formation of different
complexes were visible (Figure 2.27). This pattern of shift positions is also seen for T4 endonuclease
VII [148]. Band shifts assays with HJ substrate showed up to four shifts with increasing amounts
of protein. Golz et al. asummed that each shift represents a different complex between T4
endonuclease VII and HJ with all binding sites being saturated in the highest shift position.
Stepwise loading reflects one physical unit (monomer, dimer and multimer) of the protein binding
first and attract three further units to the same DNA molecule. For ceSLX4SAP the molecular
mechanism and the stoichiometry of the recognition reaction between SAP and HJ could be similar.
A possible way to further examine the stoichiometry is the introduction of mutations for amino
acids, which are involved in the SAP-SAP interface. Mutation of these sites could lead reduction
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Figure 3.2: Model for cooperative binding of ceSLX4SAP. After the binding of the first SAP domain to the
Holliday Junction, there are two possibles scenarios for the binding of a second SAP domain. First, assuming
cooperative binding, the second SAP domain will interact cooperatively with the already bound SAP domain
and bind to a neighboring arm of the same HJ. Second, assuming non-cooperative binding, the second SAP
domain will interact with any arm of another HJ.
or abolishment of the several shifts.
Another hint towards cooperative binding comes from the comparison with the SAP domain
of SAF-A. SAF-ASAP shows only strong DNA binding with protein immobilized either on a mem-
brane or on Sepharose beads [169]. Testing the DNA binding in solution leads to only weak
DNA binding. The same is true for ceSLX4SAP, DNA interaction in solution during gel filtration
could not be detected. A possible explanation for this effect could be that protein-protein inter-
actions are necessary for a specific binding. During gel filtration experiments the proteins are too
much diluted and lose contact with each other. However, as there is no structural information
of ceSLX4SAP in complex with HJ available, it is very speculative if, how and where SAP would
interact with each other.
The cooperative binding towards DNA seen with ceSLX4SAP alone and in complex with
ceMUS81N could result either from alterations in DNA structure or can be mediated by direct
protein-protein interactions. For the first case, DNA structure can change after protein binding to
one site, which in turn facilitates binding to the others sites. From biophysical and crystallization
studies of the HJ two main conformations of the HJ are known, open square-planar or stacked-X
conformation[307, 308]. The square planar shape is adopted in the absence of cations, when the
repulsion of the unshielded negatively charged phosphates directs the four arms of the junction
into a corner of a square [307]. The stacked X shape of the HJ exists in presence of divalent metal
ions and the arms undergo pairwise coaxial stacking [307, 308]. Yeast SpCCe and S. pombe YDC2
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bind the HJ in a open square shape. Wheras, the X-shape of the HJ has been seen in complex
with E. coli RuvC or Sulfolobus sulfataricus Hjc [307]. Interestingly, in the crystal structure of T4
endonuclease VII the HJ is a hybrid of the square-planar and stacked X-conformation of the HJ
[147]. T4 endonuclease VII protrudes into the junction point and opens it to a parallelogram [147].
Taking the different HJ conformations into account, it can be possible that either ceSLX4SAP and
ceMUS81N alone or in complex stabilize a certain conformation of the HJ in order to facilitate the
cleavage mechanism.
Secondly, the cooperative binding could arise from direct protein-protein interactions. Then
the protein bound to one arm of the junction could interact with a protein bound to the other
arm which requires the DNA to undergo conformational changes. To distinguish between these
possibilities, further experimental evidence is needed. To check for alterations in DNA structure
after protein binding, further bands shift assays employing Holliday Junctions with more diverse
arm lengths, different symmetries (2-fold or no symmetry instead of 4-fold symmetry) and more
nicks could lead to greater understanding in protein-DNA complex formation on the Holliday
Junction. A change in DNA conformation induced by protein binding could also be detected by
DNase I footprinting as DNase I cuts preferentially sequences in widened minor grooves [309].
Thus, from the available experimental data it can be assumed here that for HJ substrate up to
four ceSLX4SAP can bind it, one per arm. At very high protein concentrations, the formation of
higher order complexes is more prevalent, due to possible non-specific interactions.
Cooperative binding of ceSLX4SAP started at concentrations of 100 nM in the refined band
shift assay with HJ (Figure 2.27 A). But the SLX4 concentration in the nucleus could be 0.5 nM
estimated from the proteomic analysis of HeLa cells [305]. Upon DNA damage induction SLX4 was
seen to form foci [114, 304]. In these foci, SLX4 concentration could locally exceed the theoretical
concentration of 0.5 nM. DNA lesions could lead through the DNA damage signaling to an increase
of SLX4, which in turn attracts more SLX4 proteins due to the cooperative behavior of the SAP
domain. Furthermore, SLX4 contains a dimerization domain [157], which could further enhance
the cooperative binding of two SAP domains. The dimerization and the cooperative binding
mode could help to immobilize the HJ for the activity of the nucleases, which interact with SLX4.
It remains speculative, whether the SAP domain has also a control function towards the start
of the nuclease recruitment. Only after reaching a certain protein concentration threshold the
SAP domain binds DNA and in complex with associated nuclease complex formation with DNA
happens already at lower concentrations. In general, SLX4 is involved in many different cellular
pathways, thus cooperative binding to HJ could be of considerable importance to different ways
of controlling and bringing it into activity at certain cell stages.
The SAP domain seems to work as an auxiliary DNA binding domain in general. In T4
endonuclease VII the SAP domain is located between the arms of the HJ and positive charged
residues undergo hydrogen bonding with the HJ arm [147]. In yeast SpCCe1, another HJ resolvase,
the SAP domain is required for the stabilization of the interaction with the HJ [127]. As SpCCE1
undergoes branch migration the stable junction binding is necessary to move the resolvase to the
cleavable sites [127]. The promiscuity of the SAP domain could be seen as a versatile tool by SLX4
to be able to scan the genome for damage while piggybacking the nucleases. Upon the encounter
of a cleavable substrate the affinity of SLX4SAP, maybe also directed by MUS81N, increases and
the two nicks in the HJ are introduced.
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Fluorescence anisotropy data of ceMUS81N (residues 1 - 157) showed a two-site binding mode.
However, the N-terminus of ceMUS81 shows in the alignment with MUS81 orthologs from other
species only one structured domain, instead of two domains. Thus, it is unlikely that the used
ceMUS81 constructs contains two DNA binding sites. The band shift assays especially with
dsDNA and ssDNA show that saturation is not perceived at the tested conditions. First, this
could suggest negative cooperativity or multiple classes of binding sites (also discussed in [310]).
Negative cooperativity can be excluded as the curve shape of the anisotropy measurement and
the band shift assays point clearly towards positive cooperativity. The presence of two binding
sites can neither be excluded nor included. Additional experiments would be needed in order to
find out about a second binding site on this construct, e.g. cross-linking experiments. However,
it is more likely that the cooperative binding of ceMUS81N is overlaid by non-specific binding at
high protein concentrations, which can be described by a linear function. As suggested by Mendel
& Mendel [310], in such a case of non-specific binding, the total binding should be measured
and the binding data is separated into two components, one of which represents the non-specific
binding. Thus, at low ceMUS81N concentrations the prevalent binding mode is mostly represented
by cooperative binding to the DNA. However, it is already influenced by non-specific binding. At
protein concentrations higher than 120 nM, the binding isotherm is mainly related to non-specific
binding. Biologically, this case will not occur as the MUS81 concentration is unlikely to jump
to a concentration of up to 10 μM in the nucleus. Anisotropy was measured at pH 6.5 resulting
in a positively charged protein (pI 9.28). The excess protein undergoes electrostatic interactions
at protein concentration higher than 120 nM. Taken together, the non-specific interaction is an
artifact of the measurement with no biological relevance. As the non-specific binding is influencing
the DNA binding, the calculated Kd values are an estimate for ceMUS81
N.
In previous studies on human MUS81, fluorescence anisotropy measurements of the N-terminal
HhH domain (residues 10 - 90) [143] and the WH domain (residues 128 - 230) [219] were carried
out as well. The WH domain binds dsDNA with a KD of 6.6 μM showing a plateau in the
binding reaction at 60 μM [219]. The DNA binding of the HhH domain was tested in presence
of flap structures, single and double-stranded DNA [143]. Wyatt et al. could not reach a plateau
anisotropy value for dsDNA, but could detect a preference for ssDNA in comparison to dsDNA and
additionally, binding towards flap structures, all in low nM range. As the ceMUS81 N-terminus
does likely not contain the WH domain, the DNA binding property can be attributed to the HhH
domain. The ceMUS81N construct shows a similar behavior towards dsDNA in anisotropy as the
human HhH domain.
ceMUS81N favors the binding towards nHJ over dsDNA shown by the lower dissociation
constants in band shift assays and fluorescence anisotropy. In contrast to hsMUS81HhH [143],
ceMUS81N band shift assays show no strong difference between binding to ssDNA and dsDNA.
The band shift assays show like the fluorescence anisotropy measurements non-specific binding to-
wards the tested DNA substrates, which can be seen from unbound substrate even at high protein
concentrations. The weakest binding is visible towards ssDNA with only 54% DNA bound at 5 μM
protein. In similar KD range of 800 to 815 nM was the binding towards dsDNA (Figure 2.29). The
binding constant towards RF, flaps and HJ was between 500 and 600 nM. The strongest binding of
the MUS81N was visible with nHJ, showing a clear preference for binding towards nHJ over other,
especially non-branched DNA substrates. For all tested substrates it can be seen that at excess
100 3. Discussion
MU
S81
ER
CC
4
MUS81N
SLX4CCD
SLX1RING
SLX1GIY
SLX4SAP
Assembly	of	the	Nucleases
EM
E1
MU
S81
ER
CC
4
MUS81N
SLX4CCD
SLX1RING
SLX1GIY
SLX4SAP
Introduc�on	of	the	1st	cut
MU
S81
ER
CC
4
MUS81N
SLX4CCD
SLX1 RING
SLX1 GIY
SLX4SAP
EM
E1
Introduc�on	of	the	2nd	cut
Figure 3.3: Model for HJ cleavage. Through the interaction of SLX4SAP (displayed with electrostatic surface
potential) with the HJ substrate, the interacting nucleases might be placed and coordinated by SLX4 at the
substrate. SLX1 will then introduce the first cut at the HJ substate. This leads to an conformational change
in MUS81 and MUS81 will introduce the second cut at the HJ.
of protein there is still unbound substrate available. Although the concentration of protein was
125times higher than the substrate concentration (5000 nM - 40 nM), substrate is not fully bound
at the highest concentration of ceMUS81N. Taken together, the shape of the anisotropy curve for
ceMUS81N shows positive cooperativity, which is overlayed by non-specific binding. therefore, the
binding isotherm gives rise to a more linear shape after the first inflection point.
3.6 A Modified HJ Resolution Model
The following section will give an updated model about the resolution of Holliday Junctionsby an
SM-complex in the context of the full length proteins based on the NMR model of ceSLX4SAP,
the here presented biochemical analysis of the single domains as well as published results.
SLX4SAP and MUS81N are alone and in complex promiscuous DNA binding domains. Based
on this promiscuity is can be possible that the proteins scan alone or in form of the SM-complex
the genome until they encounter a suitable substrate, e.g. a Holliday Junction.
In a first step the SAP domain of SLX4 would then bind to the HJ substrate in a cooperative
manner (Figure 3.3). This binding could occur similar to T4 endonuclease VII, where the SAP
domains is located between the arms of the open-planar HJ and stabilizes the interaction [147].
SLX4 brings the MUS81-EME1 nuclease through interaction with the N-terminal domain MUS81
into position. Upon DNA-binding of SAP at the same time an conformational change in the CCD
domain of SLX4 could bring the associated SLX1 nuclease into position. It has been proposed that
SLX1 forms an inactive homodimer and upon formation of the SLX1-SLX4 complex the SLX1
nuclease becomes active [156]. Another possibility is SLX1 only exists in a complex with SLX4
and gets activated by post-translational modifications similar to the interaction between SLX4 and
MUS81 [200]. After the activation, SLX1 nuclease recognizes the HJ substrate and introduces a
nick in the HJ. The performance of the cleavage reaction puts SLX1 in a post-nick state and might
lead to an conformational change in SLX1. SLX1 in post-nick state could subsequently trigger
a movement within SLX4, resulting in the activation of MUS81. In this relay the N-terminus of
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MUS81 could be the link between MUS81 activity after the first incision. MUS81 recognizes the
substrate and introduces the second cut on the HJ. The motions across the C-terminal part of
SLX4 and N-terminus of MUS81 could relay the catalytic residues in MUS81 and then promote
the positioning of the catalytic residues. Furthermore, the catalysis could be assisted by changes
in the HJ structure itself after the initial incision. The introduction of the first nick transforms the
relatively stiff HJ into a more bendable DNA substrate. This substrate is better being recognized
by the MUS81-EME1 complex through its 5’ end binding pocket [214]. In human MUS81 are two
N-terminal domains involved in DNA binding, the HhH and the WH domain. The latter domain
is not present in C. elegans MUS81. In the end, SLX4 has to coordinate the active site of two
nucleases in order to introduce the two nicks within the lifetime of the complex. Additionally
to the nucleases there are three more domains in the human complex, which interact with the
DNA substrate, SLX4SAP, MUS81HhH and MUS81WH. In total the remarkable number five DNA-
interacting sites have to be coordinated within the SM-complex. This also includes the proper
positioning of the active sites on the substrate. Each DNA-binding domain has to recognize the
DNA and through several conformational changes in the whole complex the nuclease domains have
to recognize their specific substrate and cleave in a spatial and timely coordinated manner.
This presented model can also be extended as SLX4 can dimerize via its BTB domain [157, 164].
Together with the dimerization multiple MUS81 molecules are bridged by SLX4, but it is not
known whether dimerization is cell-cycle regulated or required for the bridging of MUS81 molecules
[164, 200]. There is the possibility that the complex is activated through the proposed SUMO-
E3 ligase activity of SLX4 [164]. SLX4 has been shown to SUMOylate XPF and itself, which is
proposed to be important for activation of the endonuclease partners [164]. The nuclease XPF-
ERCC1 works together with the complex of SLX1-SLX4-MUS81-EME1 by enhancing the cleavage
activity of SLX1 and MUS81 [143]. In the context of a double HJ, which occurs at the end of
homologous recombination, the dimerization of SLX4 and its associated endonucleases could be
important for the coordinated introduction of four nicks on two HJs.
The outlined model explains a possible cleavage mode for HJs, but there are more DNA
intermediate structures. During recombination other DNA substrates arise as intermediates and
SLX4 has been shown to be involved in other repair functions, e.g. in ICL repair. ICL repair is
initiated by signaling by the FA core complex and monoubiquitylation of FANCD2, which lead to
recruitment of the nuclease XPF-ERCC1 by SLX4 via a so far not determined mechanism [108]. It
is proposed the SLX4 does not only bring XPF but also other nucleases to the lesion [108], which
suggests that the nucleases also recognize other substrates in the context of the SMX-complex.
After the cleavage reaction of XPF-ERCC1 translesion synthesis and homologous recombination
are promoted. In the course of homologous recombination SLX4 might be involved again with its
nuclease set.
3.7 Open Questions and Outlook
In conclusion, the presented study describes for the first time a model for the structure of SLX4SAP
and shows that this domain is a promiscuous DNA binding domain. Interaction of SLX4 with
DNA is central for its function to position the nucleases at the junction. Hydrophobic residues
between the helices of the SAP fold are important for structural integrity. The positive patch on
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ceSLX4SAP is essential for DNA binding. The negatively charged patch could be an interaction
site for the N-terminus of MUS81. The here presented studies on SLX4-SLX1 and MUS81-EME1
raise further structural and biochemical questions which are being addressed in future work. In
the four-protein complex there are three DNA-binding sites and two active sites. Human SLX4
has been shown in literature to alter the substrate specificity of MUS81-EME1 [143], giving rise
to the question on the conformational changes and repositioning of nucleases involved in complex
formation. So far, it is not yet clear, how the four proteins will be positioned concretely at the
HJ. There is also the question why the cells have evolved this multi-nuclease complex. Its activity
has to be tightly regulated by post-translational modification and is constrained to a late phase
of the cell cycle [141, 143, 200]. The temporal regulation prevents unrestrained cleavage leading
to chromosome aberrations. NMR experiments showed how flexible the truncated versions of
ceSLX4SAP and ceMUS81N still were. Based on this experiments much shorter SAP constructs
were designed and tested for DNA binding. Now, optimized constructs for SLX4SAP and MUS81N
are a good starting point for further structural studies. NMR experiments are a helpful tool for
designing protein constructs which can not be identified by limited proteolysis anymore. Future
structural studies on SLX4 with its nucleases and in complex with Holliday Junctions could give an
deeper insight on the organization of these proteins at the Holliday Junction. As SLX4 contains
a dimerization domain, it would be further interesting, how a dimer of SLX4 with associated
nucleases is being coordinated and regulated especially in the context of double Holliday Junctions
and how these enzymes facilitate different DNA repair functions.
Furthermore, the influence of SAP on the cleavage reaction is not yet fully investigated. Kinetic
measurements could shed light to the extent of how SAP is making an impact on the cleavage of
SLX1 and MUS81. So far, it has been investigated that mutations in the SAP domain lead to
decreased survival in presence of DNA damaging agents and reduce interaction with MUS81 [202].
4. Materials and Methods
4.1 Materials
4.1.1 Consumables and Chemicals
Unless otherwise stated all chemicals were purchased from Roche Diagnostics (Mannheim, Ger-
many), Merck (Darmstadt, Germany), Qiagen (Hilden, Germany), Roth (Karlsruhe, Germany),
Sigma-Aldrich (Mu¨nchen, Germany) and Serva (Heidelberg, Germany). Enzymes were ordered
from New England Biolabs (NEB) (Frankfurt/Main, Germany), ThermoFisher Scientific (Waltham,
MA, USA) or prepared by Biochemistry Core Facility of Max-Planck Institute of Biochemistry
(Martinsried, Germany). The enzymes used for tag cleavage (Senp2, 3C, Senp2 mod) were pre-
pared by Maren Klu¨gel and Marcus Hammerl. Nucleotids were ordered from Eurofins/MWG
(Ebersberg, Germany). For expression in HEK cells, the FreeStyleTMexpression medium was or-
dered from ThermoFisher Scientific (Waltham, MA, USA) and the transfectant polyethyleneimid
(PEI) was ordered from Polyscienes (Warrington, PA, USA). Gel and plasmid extraction kits were
purchased from Macherey-Nagel (Du¨ren, Germany). DNA oligonucleotids were synthesized by Eu-
rofins Genomics (Ebersberg, Germany). Chromatography material and columns were ordered from
GE Healthcare (Mu¨nchen, Germany), Macherey-Nagel (Du¨ren, Germany), Qiagen (Hilden, Ger-
many), IBA (Go¨ttingen, Germany) and Roche (Basel, Switzerland). Crystallization Screens and
cryo-loops were obtained from Hampton Research (Aliso Viejo, CA, USA), and Qiagen (Hilden,
Germany).
4.1.2 Media
Table 4.1: Media for bacterial and mammalian cell expression.
Medium Composition Cell Type
LB 1% (w/v) Bacto Trypton, 0.5% (w/v) Yeast extract, 1% (w/v) NaCl, pH 7.2 E. coli
SOC 2% (w/v) Bacto Trypton, 0.5% (w/v) Yeast extract, 100 mM NaCl, 1 mM
MgCl2, 2.5 mM KCl, 10 mM MgSO4, 0.4% glucose, pH 7.2
E. coli
TB 1.2% (w/v) Bacto Trypton, 2.4% (w/v) Yeast extract, 0.004% (v/v) glyc-
erol, supplemented with phosphate buffer (10%(v/v), 0.17 M KH2PO4, 0.72M
K2HPO4
E. coli
M9 33.7 mM Na2HPO4, 22 mM KH2PO4, 8.55 mM NaCl, 9.35 mM 15NH4Cl,
supplemented with 0.4% glucose or 13C-glucose, 1 mM MgSO4, 0.3 mM
CaCl2, 1 μg biotin, 1 μg thiamin, 1x trace element solution
E. coli
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Medium Composition Cell Type
FreeStyle animal origin-free, chemically-defined, protein-free, supplemented with 1%
FCS
Mammalian Cells
4.1.3 Bacterial Strains and Cell Line
Table 4.2: Bacterial strains
Bacterial Strain Species Genotype
XL1 blue E. coli recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ proAB
lacIqZΔM15 Tn10 (Tetr)]
DH5α E. coli F- θ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK-
mK
+) phoA supE44 λ- thi-1 gyrA96 relA1
BL21 DE3 gold E. coli B F- opmT hsdS(rB
- mB
-) dcm+ Tetr gal λ(DE3) endA Hte
BL21 DE3 gold pRIL E. coli B F- opmT hsdS(rB
- mB
-) dcm+ Tetr gal λ(DE3) endA Hte [pRIL
Camr]
BL21 DE3 gold pRARE E. coli B F- opmT hsdS(rB
- mB
-) dcm+ Tetr gal λ(DE3) endA Hte [pRARE
Camr]
B834 (DE3) pLysS E. coli F- opmT hsdS(rB
- mB
-) gal dcm met - λ(DE3) pLysS (CamR)
Table 4.3: Cell line
Cell line Description
HEK293S Human embryonic kidney cells (GntI -) cells containing Adenovirus 5 DNA,
used for transient expression of recombinant protein with PEI, cultivated in
suspension
4.1.4 Antibiotic Solutions
Table 4.4: Antibiotic stock solutions
Antibiotic Stock Solution End Concentration
Ampicillin 100 mg/ml 0.1 mg/ml
Kanamycin 50 mg/ml 50 μg/ml
Chloramphenicol 34 mg/ml 34 μg/ml
Tetracycline 10 mg/ml 0.01 mg/ml
4.1.5 Vectors and Plasmids
Table 4.5: Plasmids used for expression. bax vectors were used for expression in E. coli and hex vectors for
expression in HEK293S cell culture. GFP (green fluorescent protein) and mVenus both contained the A206K
mutation to ensure monomeric state of the fluorescent dyes.
Name Application Tag Tag cleavage
pCB-bax04 Bacterial expression of proteins N-terminal 8x His-SUMO-Tag Senp2
pCB-bax10 Bacterial expression of proteins C-terminal CPD-8xHis-Tag CPD
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Name Application Tag Tag cleavage
pCB-bax25 Bacterial expression of proteins N-terminal 8x His-SUMO-Tag, C-terminal
CPD-Twinstrep-tag
Senp2, CPD
pCB-hex12 Mammalian expression of proteins N-terminal-Kozak sequence-8xHis-
eGFP(A206K)-SUMO (R63T, R70E)
Senp2
pCB-hex28 Mammalian expression of proteins N-terminal hTee-658, C-terminal 3C-
mVenus(A206K)-SSGS-linker-rho1d4
3C protease
pCB-hex28L21 Mammalian expression of proteins N-terminal L21 leader-Kozak-sequence,
C-terminal-3C-mVenus(A206K)-SSGS-
linker-rho1d4
3C protease
pCB-hex29L21 Mammalian expression of proteins N-terminal-hTee-658-L21leader-Kozak
sequence-eGFP(A206K)-3C
3C protease
Table 4.6: Cloned constructs. The insertion site LIC-SUMO contains the SUMO tag always at the N-
terminus. The insertion site LIC-CPD contains the CPD tag at the C-terminus. LIC ligation independent
cloning, SUMO small ubiquitin like modifier, CDP cysteine protease domain.
No. Construct Vector Primer Insertion site
1a hsEME1syn 1-570-RBS-
MUS81syn 1-551
pCB-bax04 CBp1243, CBp1204 LIC SUMO
1b hsEME1syn 1-570-RBS-
MUS81syn 1-551
pCB-bax25 CBp1243, CBp1331 LIC SUMO CPD
2a hsEME1syn 178-570-RBS-
MUS81syn 241-551
pCB-bax04 CBp1213, CBp1204 LIC SUMO
2b hsEME1syn 178-570-RBS-
MUS81syn 241-551
pCB-bax25 CBp1213, CBp1331 LIC SUMO CPD
3 hsEME1syn 246-570-RBS-
MUS81syn 241-551
pCB-bax04 CBp1206, CBp1204 LIC SUMO
4a hsEME1syn 210-570-RBS-
MUS81syn 133-551
pCB-bax04 CBp1205, CBp1204 LIC SUMO
4b hsEME1syn 210-570-RBS-
MUS81syn 133-551
pCB-bax25 CBp1205, CBp1331 LIC SUMO CPD
5a hsEME1syn 233-570-RBS-
MUS81syn 256-551
pCB-bax04 CBp1214, CBp1204 LIC SUMO
5b hsEME1syn 233-570-RBS-
MUS81syn 256-551
pCB-bax25 CBp1214, CBp1331 LIC SUMO CPD
6a hsMUS81syn 2-225 pCB-bax04 CBp1333, CBp1335 LIC SUMO
6b hsMUS81syn 1-225 pCB-bax10 CBp1334, CBp1336 LIC CPD
7a hsSLX4 1-1834 pCB-bax04 CBp083, CBp084 LIC SUMO
7b hsSLX4 1-1834 pCB-bax10 Cbp495, CBp498 LIC SUMO
8 hsSLX4 1309-1824 pCB-bax10 CBp670, CBp676 LIC CPD
9 hsSLX4 1492-1824 pCB-bax10 CBp671, CBp676 LIC CPD
10 hsSLX4 1516-1824 pCB-bax10 CBp672, CBp676 LIC CPD
11 hsSLX4 1647-1824 pCB-bax10 CBp673, CBp676 LIC CPD
12 hsSLX4 1706-1824 pCB-bax10 CBp674, CBp676 LIC CPD
13 hsSLX4 1748-1824 pCB-bax10 CBp1171, CBp676 LIC CPD
14a hsSLX4 1492-1648 pCB-bax04 CBp1373, CBp1375 LIC SUMO
14b hsSLX4 1492-1648 pCB-bax10 CBp671, CBp675 LIC CPD
15a hsSLX4 1516-1648 pCB-bax04 CBp1374, CBp1375 LIC SUMO
15b hsSLX4 1516-1648 pCB-bax10 CBp672, CBp675 LIC CPD
16 hsSLX4 1565-1648 pCB-bax04 CBp150, CBp675 LIC SUMO
17a hsSLX1 1-275 pCB-bax04 CBp085, CBp086 LIC SUMO
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17b hsSLX1 1-275 pCB-bax10 CBp501, CBp796 LIC CPD
18 hsSLX1 11-258 + hsSLX4
1300-1824
pCB-bax10,
pCB-bax10
CBp490, CBP491,
CBp497, CBp676
LIC CPD
19 hsSLX1 11-258 + hsSLX4
1706-1824
pCB-bax10,
pCB-bax10
CBp490, CBP491,
CB674, CBp676
LIC CPD
20 hsSLX4 1-1834 pCB-hex12 CBp083, CBp084 LIC SUMO
21 hsSLX4 667-1834 pCB-hex12 CBp354, CBp084 LIC SUMO
22 hsSLX4 1300-1934 pCB-hex12 CBp149, CBp084 LIC SUMO
23a hsSLX1 1-275 pCB-hex12 CBp085, CBp086 LIC SUMO
23b hsSLX1 1-275 pCB-hex29 CBp085, CBp086 LIC SUMO
24 hsSLX1 11-275, hsSLX4 1300-
1834
pCB-hex12,
hex28L21
CBp200, CBp086,
CBp729, CBp738
LIC SUMO, LIC 3C
25 hsSLX1 11-258, hsSLX4 1300-
1834
pCB-hex12,
hex28L21
CBp200, CBp203,
CBp729, CBp738
LIC SUMO, LIC 3C
26 hsSLX1 11-275, hsSLX4 1489-
1818
pCB-hex12,
hex28L21
CBp200, CBp086,
CBp823, CBp827
LIC SUMO
27 hsSLX1 11-275, hsSLX4 1647-
1818
pCB-hex12,
hex28L21
CBp200, CBp086,
CBp816, CBp827
LIC SUMO
28 hsSLX1 11-258, hsSLX4 1647-
1818
pCB-hex12,
hex28L21
CBp200, CBp203,
CBp816, CBp827
LIC SUMO
29 hsSLX1 11-275, hsSLX4 1706-
1818
pCB-hex12,
hex28L21
CBp200, CBp086,
CBp817, CBp827
LIC SUMO
30 hsSLX4 1706-1834-P2A-
hsSLX1 11-258
hex28L21 CBp817, CBp216,
CBp595, CBp933
LIC 3C
31 ceSLX4 1-718 pCB-bax04 CBp472, CBp473 LIC SUMO
32 ceSLX4 225-718 pCB-bax04 CBp685, CBp473 LIC SUMO
33 ceSLX4 277-718 pCB-bax04 CBp686, CBp473 LIC SUMO
34 ceSLX4 467-718 pCB-bax04 CBp687, CBp473 LIC SUMO
35 ceSLX4 535-718 pCB-bax04 CBp682, CBp473 LIC SUMO
36 ceSLX4 443-606 pCB-bax04 CBp1350, CBp683 LIC SUMO
37 ceSLX4 467-606 pCB-bax04 CBp687, CBp683 LIC SUMO
38 ceSLX1 1-443 pCB-bax04 CBp474, CBp475 LIC SUMO
39 ceSLX1 168-443 pCB-bax04 CBp550, CBp475 LIC SUMO
40 ceSLX4 1-718-RBS-ceSLX1 1-
443
pCB-bax04 CBp472, CBp636,
CBp637, CBp475
LIC SUMO
41 ceSLX4 1-718-RBS-ceSLX1
168-443
pCB-bax04 CBp472, CBp636,
CBp638, CBp475
LIC SUMO
42 ceMUS81 1-445-RBS-ceEME1
1-454
pCB-bax04 CBp476, CBp633,
CBp634, CBp527
LIC SUMO
43 ceMUS81 191-445-RBS-
ceEME1 1-454
pCB-bax04 CBp574, CBp633,
CBp634, CBp527
LIC SUMO
44 ceMUS81 1-445-RBS-ceEME1
161-454
pCB-bax04 CBp476, CBp633,
CBp709, CBp527
LIC SUMO
45 ceEME1 1-454 -RBS-ceMUS81
1-445
pCB-bax04 CBp526, CBp635,
CBp632, CBp477
LIC SUMO
46 ceEME1 161-454 -RBS-
ceMUS81 1-445
pCB-bax04 CBp575, CBp635,
CBp632, CBp477
LIC SUMO
47 ceEME1 231-454 -RBS-
ceMUS81 198-445
pCB-bax04 CBp1183, CBp635,
CBp1186, CBp477
LIC SUMO
48a ceMUS81 1-157 pCB-bax04 CBp476, CBp1185 LIC SUMO
48b ceMUS81 1-157 pCB-bax10 CBp611, CBp1285 LIC CPD
49 ceMUS81 1-140 pCB-bax04 CBp476, CBp1566 LIC SUMO
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50 ceMUS81 1-89 pCB-bax04 CBp476, CBp1818 LIC SUMO
51 ceMUS81 1-80 pCB-bax04 CBp476, CBp1565 LIC SUMO
52 ceMUS81 10-89 pCB-bax04 CBp1817, CBp1818 LIC SUMO
53 ceMUS81 17-140 pCB-bax04 CBp1564, CBp1566 LIC SUMO
54 ceMUS81 17-80 pCB-bax04 CBp1564, CBp1565 LIC SUMO
55 ceSLX4 443-588 pCB-bax04 CBp1350, CBp1563 LIC SUMO
56 ceSLX4 443-515 pCB-bax04 CBp1350, CBp1562 LIC SUMO
57 ceSLX4 467-560 pCB-bax04 CBp687, CBp1693 LIC SUMO
58 ceSLX4 467-530 pCB-bax04 CBp687, CBp1691 LIC SUMO
59 ceSLX4 470-606 pCB-bax04 CBp1561, CBp683 LIC SUMO
60 ceSLX4 470-515 pCB-bax04 CBp1561, CBp1562 LIC SUMO
61 ceSLX4 488-606 pCB-bax04 CBp681, CBp683 LIC SUMO
62 ceSLX4 488-588 pCB-bax04 CBp681, CBp1563 LIC SUMO
63 ceSLX4 535-606 pCB-bax04 CBp682, CBp683 LIC SUMO
64 pCB-hex15-hsPLK1 T210D
R337A I340A (DAA)
pCB-hex15 CBp468, CbBp469 LIC SUMO
4.1.6 Oligonucleotides
Table 4.7: Oligonucleotides for cloning. The small letters correspond to the LIC overhangs. Capital letters
correspond to the sequence of the gene of interest.
Name Sequence (5’ → 3’)
CBp083 accaggaacaaaccggcggccgctcgatgAAACTGAGTGTGAATGAGGCTCAGCTAGGCTTCTAC
CBp084 gcaaagcaccggcctcgttaGTTCCGCTCCACCTTCTTCTTGCCCC
CBp085 accaggaacaaaccggcggccgctcgatgGGTCCCGCGGGGGTCGCG
CBp086 gcaaagcaccggcctcgttaGGTCTCCAGCAGGTCTGTCCAGTGTG
CBp126 gcaaagcaccggcctcgttaGTTCCGCTCCACCTTCTTCTTGCCCCGAGGC
CBp149 accaggaacaaaccggcggccgctcgGAAGGGAACGAAGTCGCACAGAAGTTTTCTGTCATC
CBp185 ccaggggccctcgGAAGGGAACGAAGTCGCACAGAAGTTTTCTG
CBp200 accaggaacaaaccggcggccgctcgGGGCGCTTTTTCGGCGTCTACC
CBp203 gcaaagcaccggcctcgttaTTCTTTCTCAGTGTCCATCTGGCACAG
CBp216 ggaacagcacctcctcGTTCCGCTCCACCTTCTTCTTGCCCCG
CBp217 gaggagaaccccggccctatgGGTCCCGCGGGGGTCGCG
CBp354 ccaggggccctcgatgGGCGGCCGCACCTTGCTCTCCC
CBp468 accaggaacaaaccggcggcATGAGTGCTGCAGTGACTGCAGG
CBp469 gcaaagcaccggccTTAGGAGGCCTTGAGACGGTTGCTGG
CBp472 accaggaacaaaccggcggcATGAATGATTCATCACTAAAAAAGGCAC
CBp473 gcaaagcaccggccTTATAGTCTTCTTTTGTAGCCGCCACG
CBp474 accaggaacaaaccggcggcATGGAGACATTCATATTGTCGTCTGATTC
CBp475 gcaaagcaccggccTTATTTTTTCGACGAAATTGGACTGATTTCTCG
CBp476 accaggaacaaaccggcggcATGTCGAATCAATCAAAACGGGTCACAG
CBp477 gcaaagcaccggccTTATTGAACAAAAAATTTGAAAAGGTTACGAGTA
CBp490 aagaaggagatatacatATGGGGCGCTTTTTCGGCGTCTACC
CBp491 accgcccgcgagTTCTTTCTCAGTGTCCATCTGGCACAG
CBp495 aagaaggagatatacatATGAAACTGAGTGTGAATGAGGCTCAGC
CBp497 aagaaggagatatacatATGGAAGGGAACGAAGTCGCACAGAAGTT
CBp498 accgcccgcgagGTTCCGCTCCACCTTCTTCTTGCC
CBp501 cgcggccgccaccATGGGTCCCGCGGGGGTCGCG
CBp526 accaggaacaaaccggcggcATGGACGAGGCGATTGTAGTCCTCTC
CBp527 gcaaagcaccggccTTATTCGACAACAGAATTTCCAGTTTCATCAGTG
CBp550 accaggaacaaaccggcggcGTTCAAAATGAGTTTTACGGAGTTTATTG
CBp574 accaggaacaaaccggcggcTCAGATCCATTATCTTTCAGACTTCTCAC
CBp575 accaggaacaaaccggcggcACCAATTCGAAATGCGAGCTCTACAC
CBp595 gaggagaaccccggccctGGGCGCTTTTTCGGCGTCTACC
CBp611 aagaaggagatatacatATGTCGAATCAATCAAAACGGGTCACAG
CBp632 ataattttgtttaactttaagaaggagatatacatATGTCGAATCAATCAAAACGGGTCACAG
CBp633 gttaaacaaaattattactagtttaTTGAACAAAAAATTTGAAAAGGTTACGAGTA
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CBp634 ataattttgtttaactttaagaaggagatatacatATGGACGAGGCGATTGTAGTCCTCTC
CBp635 gttaaacaaaattattactagtttaTTCGACAACAGAATTTCCAGTTTC
CBp636 gttaaacaaaattattactagtTTATAGTCTTCTTTTGTAGCCGCCACG
CBp637 ataattttgtttaactttaagaaggagatatacatATGGAGACATTCATATTGTCGTCTGATTC
CBp638 ataattttgtttaactttaagaaggagatatacatATGGTTCAAAATGAGTTTTACGGAGTTTA
CBp670 aagaaggagatatacatATGTCTGTCATCAGGCCCCAGACACCAC
CBp671 aagaaggagatatacatATGTCCTCGGGCGCGGGCTCC
CBp672 aagaaggagatatacatATGGGGGAAGAGCAGAGGCCTCCAG
CBp673 aagaaggagatatacatATGGCCACCACAGGACCTGGGGCCC
CBp674 aagaaggagatatacatATGTCTGTGGATGGCAGTGACAGCTCC
CBp675 accgcccgcgagGGTGGCCTCCTGCTGGGCATG
CBp676 accgcccgcgagCTGCCGCCTCCTGCCCTGG
CBp681 accaggaacaaaccggcggcATGAAAGAGATCGGGATGCGGCC
CBp682 accaggaacaaaccggcggcGTTTCGGAACAAGGAGGAAAGGGTG
CBp683 gcaaagcaccggccTTATCGCTCGTCATTTGATATATTCAATG
CBp685 accaggaacaaaccggcggcTACGAACAACTCTCATCTGACATGC
CBp686 accaggaacaaaccggcggcTCTGAAAATATTCAAGTCGAGCACAC
CBp687 accaggaacaaaccggcggcACCAATGATATAACTCCAATGCCTGC
CBp709 ataattttgtttaactttaagaaggagatatacatATGACCAATTCGAAATGCGAGCTC
CBp729 aaaaaaccgccaccATGGAAGGGAACGAAGTCGCACAGAAGTT
CBp738 ggaacagaaccaccagGTTCCGCTCCACCTTCTTCTTGCC
CBp796 accgcccgcgagGGTCTCCAGCAGGTCTGTCCAGTG
CBp816 aaaaaaccgccaccATGGCCACCACAGGACCTGGGGCCC
CBp817 aaaaaaccgccaccATGTCTGTGGATGGCAGTGACAGCTCC
CBp823 aaaaaaccgccaccATGCAAGAGAAGTCCTCGGGCGCG
CBp827 ggaacagaaccaccagGAGCTTCTCCCTGCGGGTGGC
CBp933 ggaacagcacctccagTTCTTTCTCAGTGTCCATCTGGCACAG
CBp1171 aagaaggagatatacatATGCAGGCGGCGGACACAGACGA
CBp1183 accaggaacaaaccggcggcATGTTTGAATATTCTTCAACACAAAACTTGTTC
CBp1185 gcaaagcaccggccTTATTTCGTTTTAGTGAGTGGAACACTTGGTTG
CBp1186 ataattttgtttaactttaagaaggagatatacatATGCTTCTCACTTGTCGACCTTTTGAG
CBp1204 gcaaagcaccggccTTAGGTCAGCGGACCATAGCTAC
CBp1205 accaggaacaaaccggcggcAGCCATGGTTGTCGTCAGCAGC
CBp1206 accaggaacaaaccggcggcGAAGAATGTCTGAAACATATTATTGTTGT
CBp1213 accaggaacaaaccggcggcGGTCAGAGCAGCAGCCTGGC
CBp1214 accaggaacaaaccggcggcAATGCAGCACTGGTTACCCGTATGAAAG
CBp1243 aagaaggagatatacatATGcaccatcaccatcaccatcaccat
CBp1285 accgcccgcgagTTTCGTTTTAGTGAGTGGAACACTTGGTTG
CBp1331 accgcccgcgagGGTCAGCGGACCATAGCTACAATACAG
CBp1333 accaggaacaaaccggcggcGCAGCACCGGTTCGCCTGG
CBp1334 aagaaggagatatacatATGGCAGCACCGGTTCGCCTG
CBp1335 gcaaagcaccggccttaCAGCAGGCTCAGACCTTCGC
CBp1336 accgcccgcgagCAGGCTCAGACCTTCGCTTTC
CBp1350 accaggaacaaaccggcggcTCCAATGTCATTACTCCAATCCGCAACAT
CBp1373 accaggaacaaaccggcggcTCCTCGGGCGCGGGCTCC
CBp1374 accaggaacaaaccggcggcGGGGAAGAGCAGAGGCCTCCAG
CBp1375 gcaaagcaccggccTTAGGTGGCCTCCTGCTGGGCATG
CBp1561 accaggaacaaaccggcggcATAACTCCAATGCCTGCATTCGATTC
CBp1562 gcaaagcaccggccTTATTCTGGATGTAATGTGATATATGCTTTCT
CBp1563 gcaaagcaccggccTTAATCATCGGAAACATTGGATACATTTTTGG
CBp1564 accaggaacaaaccggcggcAACACTTTTTTCGAAAAAGTTTTAAAATTCCAAC
CBp1565 gcaaagcaccggccTTAGACGTTCCACGTTTCTTCCAATTTTAG
CBp1566 gcaaagcaccggccTTATTCGAATTCATTTTCTATATCAACAATGGTT
CBp1691 gcaaagcaccggccTTATGCAGATCTGACAAGCGGACG
CBp1693 gcaaagcaccggccTTACGGCGATGCAATCATTCTTTCAC
CBp1817 accaggaacaaaccggcggcGTGAGAATTGAGCATTCGAAGAACACT
CBp1818 gcaaagcaccggccTTAATCCTGGCCATTGTTCTCTCGGC
Table 4.8: Oligonucleotides used for mutagenesis.
Name Sequence (5’ → 3’) Description
CBp1366 GACTCAGCACGAGCCCAGGGCCTCAG TAG-
GAAAC
forward mutagenesis primer for
hsSLX4 (T1290E)
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CBp1367 CGTTCCCTTCCCTGTTTCCTACTG reverse mutagenesis primer for hsSLX4
(T1290)
CBp1368 AGTGCCCATAGAGCCGATGCCACAGT ATTC-
CATTATG
forward mutagenesis primer for
hsSLX4 (T1561E)
CBp1369 CACCGGCGTCTCCATAATGGAATAC reverse mutagenesis primer for hsSLX4
(T1561)
CBp1370 CCATTATGGAGGAGCCGGTGCTGAA GAAG-
GAACTG
forward mutagenesis primer for hsSLX
4(T1571E)
CBp1371 CTCCAAACCTATCCAGTTCCTTCTTCAG reverse mutagenesis primer for
hsSLX4(T1571)
CBp1372 GTGCCCATAGAGCCGATGCCACAGTATT
CCATTATGGAGGAGCCGGTGCTGAA GAAGG
forward mutagenesis primer for
hsSLX4 (T1561E, T1571E)
Table 4.9: Oligonucleotides used for sequencing.
Name Sequence (5’ → 3’) Description
T7fw TAATACGACTCACTATAGG forward sequencing primer for pCB-bax vectors
T7rev GCTAGTTATTGCTCAGCGG reverse sequencing primer for pCB-bax vectors
CBp099 CGCGCCACCAGACATAATAG forward sequencing primer for pCB-hex vectors
CBp079 CGCGCCACCAGACATAATAG reverse sequencing primer for pCB-hex vectors
CBp107 AGCCTCCTCCTTCCTGTTTG forward sequencing primer for human slx4 - 1
CBp108 AGAGGTCTGAAACGGAGAGG forward sequencing primer for human slx4 - 2
CBp109 TCAGAGCTGAGCGAGCGAAG forward sequencing primer for human slx4 - 3
CBp110 GACTCAGAGGGCAAACCATG forward sequencing primer for human slx4 - 4
CBp111 TCAGAGCCGTCCCAAATAAC forward sequencing primer for human slx4 - 5
CBp112 TCCCAGAGCCCACCAAGAAG forward sequencing primer for human slx4 - 6
CBp113 AGTCGGAGACAGTGACGATG forward sequencing primer for human slx4 - 7
CBp114 ACCAGACCCTGGACTCAGAC forward sequencing primer for human slx4 - 8
CBp214 GGTGCTGTTCCAGGGACCAGGCG forward primer for amplifying 3C-P2A LIC cassette
CBp215 GGGCCGGGGTTCTCCTCAACGTC reverse primer for amplifying 3C-P2A LIC cassette
CBp257 TGTCAAAGACAGGGTGTTCC forward sequencing primer for hex-sumo
CBp510 GCGGGTTTCACCACCATCTG reverse sequencing primer for Ccpd vectors
CBp579 GTCCAGCTCGACCAGGATG reverse sequencing primer hex-gfp-rev (pEGFPN1rev)
CBp657 TCCCGATACGAACAACTCTC forward sequencing primer for ceSLX4 (central part)
CBp1196 ATTGCTCTAAAATTGGAAGAAACG forward sequencing primer for ceMUS81 (start @ 69)
CBp1277 CTGCAGTTCACGCAGCAGTT reverse sequencing primer of hsMUS81syn (ending @ 292)
4.1.7 Buffer for Large Scale Plasmid DNA Preparation
Table 4.10: Buffers for large scale preparation of vector DNA. H3PO4: buffer pH was adjusted using
phosphoric acid; EDTA ethylenediaminetetraacetic acid; SDS sodium dodecyl sulfate.
Buffer Composition
Res+ (Resuspension) 50 mM Tris-H3PO4 pH 8.0 (4◦C), 10 mM EDTA, 100 μg/ml RNase A
Lys + (Lysis) 200 mM Sodium hydroxide, 1% (w/v) SDS
Neu+ (Neutralization) 2.8 M Potassium acetate pH 5.1, set pH with acetic acid
Equ+ (equilibration) 100 mM Tris-H3PO4 pH 6.5, 0.9 M KCl, 10% v/v ethanol, 0.6% (v/v) Triton
X-114
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Endo+ (Endotoxin Wash) 100 mM Tris-H3PO4 pH 6.5, 1.15 M KCl, 10% (v/v) ethanol, 0.6% (v/v) Triton
X-114
Fil+ (Filter Wash) 100 mM Tris-H3PO4 pH 6.5, 1.15 M KCl
Wash+ (Column Wash) 100 mM Tris-H3PO4 pH 7.0 , 1.15 M KCl, 15% (v/v) ethanol
Elu+ (Elution) 100 mM Tris-H3PO4 pH 8.9, 1 M KCl, 10% (v/v) isopropanol
4.1.8 Buffers for Protein Purification
Table 4.11: Buffers used for Protein Purification. *Lys 2 - 7 were supplemented with 1mM AEBSF, 1μM Le-
upeptin, 1μM Pepstatin A, 1μM Aprotinin. FL full length; IMAC immobilized metal affinity chromatography;
β-ME β-Mercaptoethanol; DTT dithiothreitol; EDTA ethylendiaminetetraacetic acid; CW Chaperone wash;
ATP adenosine triphosphate; IP6 Inositol-6-phosphate; HABA 2-[4 -hydroxy-benzeneazo]benzoic acid; GFP-B
GFP affinity chromatography; Strep affinity purification with recombinant Strep-tag R©; IEX ion exchange chro-
matography; SEC size exclusion chromatography; TCEP Tris(2-carboxyethyl)phosphine; Phosphatase inhibitor
cocktail see Table 4.12
Buffer Composition Protein Application
Lys 1 50 mM NaH2PO4 pH 7.5, 500 mM NaCl, 25 mM Im-
idazole, 10 mM MgCl2
Bacterial expression test Cell lysis
Lys 2* 20 mM Hepes pH 8.0, 500 mM NaCl, 5 mM β-ME, 30
mM Imidazole
hsEME1-MUS81 FL & trun-
cations, ceEME1-MUS81,
ceMUS81N
Cell lysis
Lys 3* 50 mM Tris pH 7.5, 450 mM NaCl, 5 mM DTT,
0.5% NP40, 3750 U Serratia marcenses DNase, 1 mM
EDTA
hsSLX4 and hsSLX1 con-
structs
Cell lysis
Lys 4* 20 mM Tris pH 7.5, 1 M NaCl, 5 mM DTT, 1 mM
EDTA, 5 mM Imidazole
hsSLX4 SAP constructs,
ceSLX4 constructs
Cell lysis
Lys 5* 1x PBS, 750 mM NaCl, 5 mM DTT, 0.5% NP4, 3 mM
EDTA
hsPLK1 DAA Cell Lysis
Lys 6* 20 mM Hepes pH 8.0, 500 mM NaCl, 3 mM DTT, 5
mM Imidazole, 5 mM EDTA
ceMUS81 N-terminal con-
structs
Cell lysis
Lys 7* 20 mM Tris pH 7.5, 1 M KCl, 5 mM β-ME, 10 mM
Imidazole
hsSLX4 CPD constructs Cell lysis
Lys 8* 50 mM Tris pH 7.5, 150 mM NaCl, 5 mM DTT, 0.5%
NP40, 1 mM EDTA, 75 mM urea, phosphatase in-
hibitor cocktail
hsSLX4 and hsSLX1 con-
structs
Cell lysis
His 1 20 mM Hepes pH 8.0, 500 mM NaCl, 5% (w/v) glyc-
erol, 5 mM β-ME, 30 mM Imidazole
hsEME1-MUS81, ceEME1-
MUS81, ceMUS81N
IMAC
His 2 20 mM Hepes pH 8.0, 1 M NaCl, 5% (w/v) glycerol,
5 mM β-ME, 30 mM Imidazole
hsEME1-MUS81 truncations IMAC
His 3 20 mM Tris pH 7.5, 1 M NaCl, 10% (w/v) glycerol, 5
mM DTT, 5 mM Imidazole
hsSLX4 SAP constructs,
ceSLX4
IMAC
His 4 20 mM Hepes pH 8.0, 500 mM NaCl, 5 mM DTT, 5
mM EDTA, 5 mM Imidazole
ceMUS81 N-terminal con-
structs
IMAC
His 5 20 mM Tris pH 7.5, 1 M KCl, 5mM β-ME, 5% (w/v)
glycerol, 30 mM Imidazole
hsSLX4 CPD constructs IMAC
CW 1 20 mM Hepes pH 8.0, 500 mM NaCl, 5% (w/v) glyc-
erol, 5 mM β-ME, 2 mM ATP, 5 mM MgSO4
hsEME1-MUS81 FL & trunca-
tions, ceEME1-MUS81
IMAC
CW 2 20 mM Hepes pH 8.0, 1 M NaCl, 5% (w/v) glycerol,
5 mM β-ME, 2 mM ATP, 5 mM MgSO4
hsMUS812-225 IMAC
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CW 3 20 mM Tris pH 7.5, 1 M NaCl, 5 mM DTT, 2 mM
ATP, 5 mM MgCl2
hsSLX4 SAP constructs,
ceSLX4
IMAC
CW 4 50 mM Tris pH 7.5, 500 mM NaCl, 3 mM DTT, 2 mM
ATP, 5 mM MgSO4
hsSLX4 construct, hsPLK1
DAA
IMAC
CW 5 20 mM Hepes pH 8.0, 500 mM NaCl, 3 mM DTT, 2
mM ATP, 5 mM MgSO4
ceMUS81 N-terminal con-
structs
IMAC
CW 6 20 mM Tris pH 7.5, 1 M KCl, 5mM β-ME, 2 mM ATP,
5 mM MgSO4
hsSLX4 CPD constructs IMAC
His Elu 1 50 mM NaH2PO4 pH 7.5, 250 mM NaCl, 700 mM
Imidazole
Bacterial expression test IMAC
His Elu 2 20 mM Hepes pH 8.0, 100 mM NaCl, 5% (w/v) glyc-
erol, 600 mM Imidazole, 5 mM β-Mercaptoethanol
hsEME1-MUS81FL & trunca-
tions, ceEME1-MUS81
IMAC
His Elu 3 20 mM Tris pH 7.5, 100 mM NaCl, 10% (w/v) glycerol,
300 mM Imidazole, 5 mM DTT
ceSLX4, ceMUS81N IMAC
His Elu 4 20 mM Hepes pH 8.0, 100 mM NaCl, 5% (w/v) glyc-
erol, 1 mM IP6, 5 mM β-ME
ceMUS81N IMAC
His Elu 5 20 mM Tris pH 7.5, 150 mM KCl, 5 mM β-ME, 300
mM Imidazole, 5% (w/v) glycerol
hsSLX4 CPD constructs IMAC
His Elu 6 50 mM Tris pH 8.0, 100 mM NaCl, 5% (w/v) glycerol,
350 mM Imidazole, 5 mM β-Mercaptoethanol
hsEME1-MUS81 truncations
Strep 1 50 mM Tris pH 8.0, 500 mM NaCl, 1 mM EDTA hsEME1-MUS81 truncations Strep
Strep 2 50 mM Tris pH 8.0, 150 mM NaCl, 10 mM IP6 hsEME1-MUS81 truncations Strep
Strep 3 50 mM Tris pH 8.0, 150 mM NaCl, 0.1 mM EDTA,
2.5 mM desthiobiotin
hsEME1-MUS81 truncations Strep
Strep 4 50 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 1
mM HABA
hsEME1-MUS81 truncations Strep
Strep 5 50 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA hsEME1-MUS81 truncations Strep
GFP 1 50 mM Tris pH 7.5, 1 M NaCl, 5 mM DTT hsSLX4 and hsSLX1 con-
structs, hsPLK1 DAA
GFP-B
GFP 2 50 mM Tris pH 7.5, 150 mM NaCl, 5 mM DTT hsSLX4 and hsSLX1 con-
structs, hsPLK1 DAA
GFP-B
IEX 1 A 20 mM Hepes pH 8.0, 3 mM DTT, 5% (w/v) glycerol hsEME1-MUS81 FL & trunca-
tions, hsSLX4 SAP constructs,
ceSLX4SAP, ceMUS81N
IEX
IEX 1 B 20 mM Hepes pH 8.0, 2 M NaCl, 3 mM DTT, 5%
(w/v) glycerol
hsEME1-MUS81 FL & trunca-
tions, hsSLX4 SAP constructs,
ceSLX4SAP, ceMUS81N
IEX
IEX 2 A 20 mM MES pH 6.0, 3 mM DTT, 10% (w/v) glycerol ceSLX4 IEX
IEX 2 B 20 mM MES pH 6.0, 2 M NaCl, 3 mM DTT, 10%
(w/v) glycerol
ceSLX4 IEX
IEX 3 A 20 mM Bis-Tris pH 6.5, 5% (w/v) glycerol, 3 mM
DTT, 1 mM EDTA
hsSLX4 CPD constructs CEX
IEX 3 B 20 mM Bis-Tris pH 6.5, 2 M NaCl, 5% (w/v) glycerol,
3 mM DTT, 1 mM EDTA
hsSLX4 CPD constructs CEX
SEC 1 20 mM Hepes pH 8.0, 150 mM NaCl, 3 mM DTT hsEME1-MUS81 FL SEC
SEC 2 20 mM Hepes pH 8.0, 200 mM NaCl, 3 mM DTT hsEME1-MUS81 truncations,
ceSLX4 SAP constructs
SEC
SEC 3 20 mM Hepes pH 8.0, 300 mM NaCl, 1 mM TCEP hsMUS812-225 SEC
SEC 4 20 mM Bis-Tris-Propane pH 7.5, 200 mM KCl, 5%
w/v glycerol, 3 mM DTT
hsSLX4 and hsSLX1 con-
structs
SEC
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SEC 5 20 mM Hepes pH 7.5, 150 mM NaCl, 3 mM DTT ceSLX4 SEC
SEC 6 20 mM Bis-Tris-Propane pH 7.5, 200 mM KCl, 1 mM
TCEP
hsSLX4 SAP constructs,
ceSLX4 SAP constructs,
hsPLK1 DAA, ceMUS81N
SEC
SEC 7 20 mM Hepes pH 8.0, 100 mM NaCl, 5% (w/v) glyc-
erole, 3 mM DTT
ceEME1-MUS81 SEC
SEC 8 20 mM Potassium phosphate pH 8.0, 100 mM KCl,
1mM TCEP
Interaction assay on SEC SEC
SEC 9 20 mM Potassium phosphate pH 6.5, 100 mM KCl, 1
mM TCEP
ceMUS81N, Interaction assay
on SEC
SEC
SEC 10 20 mM Bis-Tris-Propane, 200 mM KCl, 5% (w/v)
glycerol, 3 mM DTT
hsSLX4 CPD constructs SEC
Table 4.12: Phosphatase inhibitors.Phosphatase Inhibitor Cocktail A is derived from Merck Phosphatase
Inhibitor Cocktail II, Phosphatase Inhibitor Cocktail B is derived from Merck Phosphatase Inhibitor Cocktail
III.
Phosphatase Cocktail Concentration Components Target Phosphatases
Cocktail A 100x
200 mM Imidazole Alkaline Phosphatase
100 mM Sodium Fluoride Acid Phosphatase
115 mM Sodium Molybdate Acid Phosphatase
100 mM Sodium Orthovanadate Protein Tyrosine phosphatases, Alka-
line Phosphatase
400 mM Sodium Tartrate Acid Phosphatase
Cocktail B 10x
50 mM Sodium Fluoride Acid Phosphatase
20 mM β-Glycerophosphate Ser/Thr Phosphatase
20 mM Sodium Pyrophosphate Ser/Thr Phosphatase
2 mM Sodium Orthovanadate Protein Tyrosine phosphatases, Alka-
line Phosphatase
4.1.9 Equipment
Table 4.13: Equipment
Instrument Supplier
Ultrasonic homogenizer Bandelin electronics, Berlin, Germany
Dounce homogenizer B. Braun, Melsungen, Germany
A¨KTA purification systems GE Healthcare, Mu¨nchen, Germany
NanoDrop (ND-1000) spectrophotometer PeqLab, Erlangen, Germany
TyphoonTM FL 7000 PhosphoImager GE Healthcare, Mu¨nchen, Germany
Genius Pro Fluorescence reader Tecan, Ma¨nnedorf, Switzerland
Cellometer Auto T4 Bright Field Cell Counter Nexcelom Bioscience, Lawrence, MA, USA
JANSi UVEX-m JANSi, Seattle, WA, USA
Prometheus NT.48 nanoDSF Nanotemper Technologies GmbH, Munich, Germany
4.1.10 Bioinformatic tools and software
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Table 4.14: Software
Software Developer / Supplier
APBS [311]
ApE v2.0.44 M. Wayne Davis
BLASTp [312]
coot [313]
Dali server [276, 277]
GlobPlot [270]
GPS 3.0 [265]
GraphPad Prism 7.0c GraphPad Software, La Jolla, CA, USA
HHpred So¨ding et al. [314]
i-Control Tecan, Ma¨nnedorf, Switzerland
Inkscape Version 0.48.2 [315]
Jalview Waterhouse et al. [216]
MaxQuant Cox and Mann, 2008 [316]
MUSCLE Edgar [215]
Origin 8.1 Origin Lab, Northampton, MA, USA
PDB2PQR [317]
Phaser Version [318]
Phenix [319]
Phyre2 [320]
Protparam [321]
Pymol [322]
SEDFIT package, version 12.1b Schuck [323]
UNICORN GE Healthcare
XDS [324]
Alignments
The homologous sequences were collected using the program Jalview and the alignment of the
sequences was carried out with the algorithm MUSCLE (Multiple Sequence comparison by Log-
Expectation) [215, 216]. Jalview was used for the visualization of the alignment.
Secondary Structure Prediction
Secondary structure prediction and homology detection was carried out with HHpred, JPred and
Phyre2 [314, 320, 325]. The tool GlopPlot was used for globular domain prediction [270].
Calculation of Protein Properties
Molecular weight, absorption coefficient and the isoelectric point (pI) of the protein were calculated
with the ProtParam tool from the Expasy homepage (www.expasy.org/tool/protaram.html). The
calculation of the pI was important for the design of purification strategy. In order quantify the
purified protein amounts absorption coefficients and molecular weights were obtained from the
Protparam tool.
Figures
The molecular figures of ceSLX4SAP were created using the program pymol. Graphical represen-
tations were made with the vector graphics editor Inkscape [315].
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4.2 Methods
4.2.1 Cloning Procedures
DNA Templates
Human SLX4 was provided by Wade Harper (HMS, Boston, USA). SLX1 was obtained from Mam-
malian Gene Collection (MGC, IMAGE clone 2823474). hs-MUS81 and EME1 were synthesized
in two pieces as codon optimized GeneArt String DNA fragments by InvitrogenTM and cloned as a
bicistronic construct into bax04 by T4 processing. C. elegans cDNA was provided by Dr. Karsten
Klage (MPIB) and genes were directly amplified by polymerase chain reaction.
Polymerase Chain Reaction
Polymerase Chain Reaction (PCR) was applied for the amplification of the DNA sequences. The
used constructs were amplified from template plasmids, cDNA or synthesized DNA. The reactions
were carried out according to standard protocol and standard program (see tables 4.15 and 4.16)
using PhusionTM High-Fidelity DNA Polymerase Master Mix (NEB). The 2x Phusion Master Mix
contained already the Phusion polymerase, Phusion DNA polymerase buffer and dNTPs. The
annealing temperature was adjusted to the respective primers and ranged between 58 and 63◦C.
The extension time was adjusted to the size of the gene of interest with 30s / kb.
Table 4.15: PCR reaction mixture.
Component Stock Concentration Final Concentration Amount
Template ∼ 50-200 ng/ μl 5-20 ng 1 μl
Forward Primer 10 μM 0.5 μM 1 μl
Reverse Primer 10 μM 0.5 μM 1 μl
Phusion Master Mix 2x 1x 10 μl
DMSO 100% 3% 0.6 μl
ddH2O add to 20 μl 6.4 μl
Table 4.16: PCR program for amplification
Step Temperature (◦C) Duration Cycles
Initial Denaturation 98 30 s
Denaturation 98 20 s
Annealing 58 - 63 30 s 30
Extension 72 30 s / kb
Final Extension 72 5 min
Cooling 10 ∞
Constructs containing two or more proteins were generated in a two-step PCR. First, the
individual proteins were amplified by PCR in a way that the reverse primer and the forward
primer of the open reading frame in first position and second position, respectively, contained
overhangs with a ribosome binding site. After gel extraction the fragments were mixed in 1:1
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molar ratio for the second PCR step. In this PCR the primer of the first open reading frame and
the reverse primer of the second open reading frame were used.
The PCR product was afterwards analyzed by agarose gel electrophoresis (0.8 % w/v) in 1x
TAE buffer (40mM Tris, 20mM Acetic acid, 1mM EDTA pH 8.0). The correctly sized PCR
product was cut out of the gel and isolated using the NuceloSpinTM Gel and PCR Clean-up Kit
(MN).
Cloning into bax and hex Vectors
The amplified PCR product was cloned into various pCB vectors, being generated by the lab of
Christian Biertu¨mpfel, by Ligase independent cloning (LIC). This method relies on the generation
of complementary single-stranded overhangs by T4 DNA polymerase, which contains a 3’ - 5’
exonuclease activity [326]. Vector and PCR product can circularize based on their cohesive ends
without ligase activity. Remaining nicks on the plasmid are repaired by E. coli RecA [326].
First, the vector was linearized with restriction enzyme BspQI (NEB) for 1h at 50◦C as
described in Table 4.17. To separate between cut and uncut vector the digested vector was analyzed
on a 0.8% agarose gel loading the equivalent volume of 250ng vector per lane. The corresponding
bands of linearized vector were cut and the DNA was isolated with NucleoSpinTM Gel and PCR
Clean-up Kit (MN).
Table 4.17: Mixture for vector linearization in order to prepare it for T4 processing
Component Stock Concentration Amount
Vector 2 μg
Cutsmart buffer 10x 4 μl
BspQI 10,000 U/ml 8 U
ddH2O to 40 μl
In order to generate the overhangs for annealing with the construct the linearized vector was
processed with T4 DNA Polymerase (NEB) (see Table 4.18).
Table 4.18: Mixture for T4 processing of the vector in order to prepare it for LIC cloning
Component Stock Concentration Amount
linearized vector 450 ng
NEB buffer 2.1 10x 3 μl
T4 DNA Polymerase 3,000 U/ml 0.6 μl
dTTP 25 mM 3 μl
DTT 100 mM 1.5 μl
ddH2O to 30 μl
Likewise, the gel-purified PCR product (see section 4.2.1) was processed with T4 DNA poly-
merase by mixing according to table 4.19. Insert and vector processing mixtures were incubated
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at room temperature for 30 min. The enzyme was heat inactivated by incubation for 20 min at
75◦C .
Table 4.19: Mixture for T4 processing of the insert in order to prepare it for T4 processing.
Component Stock Concentration Amount
linearized vector 600 ng
NEB buffer 2.1 10x 2 μl
T4 DNA Polymerase 3,000 U/ml 0.4 μl
dATP 25 mM 2 μl
DTT 100 mM 1 μl
ddH2O to 20 μl
The annealing reaction was performed by mixing 4 μl T4 processed insert with 1 μl T4 processed
vector (Table 4.19) and incubating 20 min at room temperature. After addition of 1μl EDTA (4.16
mM final concentration), the reaction mix was incubated for 10 min at room temperature. For
transformation, chemical competent E. coli cells were mixed with 4 μl of annealing reaction and
proceeded as in section 4.2.1. Maximal five colonies were picked and tested for false-positives
by colony-PCR (see section 4.2.1) or restriction digest. Two positive clones were amplified and
plasmids were prepared using NuceloSpinTM Plasmid Kit (Macherey-Nagel, Du¨ren, Germany). To
verify the correct sequence the clones were sent for sequencing (Eurofins Genomics, Ebersberg,
Germany or Biochemistry Core Facility (MPIB)).
Screening of Constructs
In order to identify positive clones, maximal five colonies were picked and either subjected to
colony PCR (cPCR) or grown over night, isolated and subjected to restriction digest. cPCR was
carried out in a 10 μl reaction volume according to Table 4.20 and 4.21. The extension time
depended on the length of the inserted gene of interest and was usually calculated to 1 min per
kb. The cPCR products were analyzed by 0.8% w/v agarose gel electrophoresis in 1x TAE.
Table 4.20: Reaction mixture for colony PCR
Component Stock Concentration Final Concentration Amount
Forward T7 Primer 10 μM 0.3 μM 0.3 μl
Reverse T7 Primer 10 μM 0.3 μM 0.3 μl
dNTPs 2mM 0.2 mM 1 μl
ThermoPol buffer 10x 1x 1 μl
Taq polymerase 5000 U/ml 1 U 0.2 μl
ddH2O 7.2 μl
Table 4.21: PCR program for colony screening
Step Temperature
(◦C)
Duration Cycles
Initial Denaturation 95 5 min
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Step Temperature
(◦C)
Duration Cycles
Denaturation 95 30 s
Annealing 52 30 s 25
Extension 72 1 min / kb
Final Extension 72 5 min
Cooling 10 ∞
Alternatively to colony PCR, restriction digest was carried to check for positive clones. The
prepared plasmid was subjected to restriction in 10 μl reaction volume containing 500 ng plasmid,
1 μl 10x CutSmart buffer and 4 U of the respective restriction enzymes. The reactions were
incubated at 37◦C for 1 h and analyzed on a 0.8% w/v agarose gel. The sequence of one to two
positive clones was further verified by sequencing (Eurofins, Ebersberg, Germany or Biochemistry
Core Facility, MPIB, Martinsried, Germany).
Cloning of Mutants by Site-Directed Mutagenesis
Mutations were inserted into the gene of interest via PCR with partially overlapping primers. The
forwards primer contained the mutation and is complementary with the reverse primer for 10 - 15
nucleotides at the 3’ end. The mutation in the forward primer was flanked by 15 - 20 nucleotides.
Both primers had a length between 30 - 40 nucleotides. For insertion of the mutation the standard
PCR reaction mixture was used (see Table 4.15). The PCR program for site-directed mutagenesis
was applied (see Table 4.22). Afterwards, the PCR product was digested with 5 U DpnI for
1 h at 37◦C. For transformation, 4 μl of the digested PCR product was mixed with XL1 blue
competent E. coli cells. A maximum of five colonies was subjected to amplification and plasmids
were prepared with NucleospinTM Plasmid Kit (Macherey-Nagel, Du¨ren, Germany). To asses the
successful insertion of the mutation the plasmids were sent to sequencing (Eurofins, Ebersberg,
Germany or Biochemistry Core Facility, MPIB, Martinsried, Germany).
Table 4.22: PCR program for site-directed mutagenesis
Step Temperature (◦C) Duration Cycles
Initial Denaturation 98 30 s
Denaturation 98 20 s
Annealing 58 - 63 60 s 30
Extension 72 30 s / kb
Final Extension 72 5min
Cooling 10 ∞
The construct ceSLX4443-606 F476A K485A R494A K498A H513A was synthesized by Eurofins
(Ebersberg, Germany) and resuspended in water to a concetration of 30 ngμl. The DNA fragment
was subjected to T4 processing (see Table 4.19), annealing with N-terminal His8-SUMO vector
(pCB-bax04) and cloning into XL1 blue bacteria.
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Large Scale Preparation of DNA Plasmids
For transient transfection of HEK cells, large amounts of vector were needed. Thus, the desired
vector was transformed into XL1 blue cells (for procedure see following subsections) and plated
on agar plates containing the respective antibiotics. Next day, one colony was picked and a 25 ml
LB pre-culture with the antibiotics was shaken in the incubator at 250 rpm and 37◦C over night.
Then a 600 ml LB culture with the respective antibiotics was inoculated with 600 μl pre-culture
and incubated for 16 - 18 h at 37◦C and 220 rpm in 2 l Erlenmeyer flasks with baﬄes reaching
final OD600 values higher than 4.5. The bacterial cells were harvested at 8000 g for 10 min. Pellets
were either flash frozen in liquid nitrogen and stored at -80◦C or used directly. For large scale
plasmid preparation the buffers from table 4.10 were applied according to the steps written in the
manual MN NucleoBondTMXtra Maxi for low-copy plasmid preparation. DNA binding columns
were used from the Kit and regenerated after usage extensively washing with 1 M HCl, incubation
over night and neutralizing with water. Folded paper filters (diameter 185mm) for loading the
lysate on the columns were supplied by WhatmanTM/ GE Healthcare. After precipitation of
the eluted plasmid DNA by isopropanol, the pellet was centrifuged at 3220 g for 90 min. The
supernatant was removed and after washing with 70% ethanol the pellet was spun down at 3220
g for another 60 min. After this the plasmid pellet was transferred under the sterile hood and
dried under sterile conditions. The pellet was dissolved completely in 1 ml sterile ddH2O shaking
at 37◦C and 165 rpm. The purity of the plasmid solution was assessed by measuring 260/280 and
260/230 ratios. The concentration of the plasmid was measured by Nanodrop.
Preparation of Competent Cells
Chemical competent cells were prepared according to the following protocol. The bacterial strain
for cloning or expression was plated on agar plates containing the respective antibiotics. One
single colony was picked for over night pre-culture. 100 ml LB media were inoculated with 2ml
pre-culture in a 500 ml flask and the culture was grown at 37◦C to OD600 0.5. Cells were cooled
down to 4◦C and centrifuged at 3000 rpm for 15 min in an Eppendorf Centrifuge 5810 R (Hamburg,
Germany). Bacterial pellet was resuspended in 10 ml TSS buffer (1% (w/v) trypone, 0.5% (w/v)
Yeast extract, 100 mM NaCl, 10 %(w/v) PEG3000, 5%(v/v) DMSO, 50 mM MgCl2, pH 6.5) and
2.5 ml 86% glycerol was added. Cells were aliquoted to 50 μl and flash frozen in liquid nitrogen.
Competence was preserved by long-term storage at -80◦C.
Transformation of Competent Cells
Chemical-competent cells were thawed from -80◦C for 5min on ice. For re-transformation of
plasmid ∼10 ng and for cloning 4 μl annealing reaction were mixed with 50 μl cells and incubated
for 25 min on ice. The heat shock was applied at 42◦C for 45 s and the cells were cooled down
on ice for 5 min. After adding 200 μl SOC-medium, the cells were shaken at 37◦C 1000 rpm for
maximal one hour. The bacteria were plated on agar-plates containing the respective antibiotic
(Table 4.4) and incubated over night at 37◦C.
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4.2.2 Protein Expression
Pull-Down Experiments for Expression and Solubility Testing for Expression in E.
coli
In order to assess the expression and solubility of cloned constructs pull-down experiments were
performed by testing different bacterial strains, media and Isopropyl-β- D-thiogalacto-pyranoside
(IPTG) concentrations. The different bacterial strains were transformed with the respective plas-
mid and grown over night on agar plates with respective antibiotics, Afterwards a 3 ml overnight
LB-culture was inoculated with one colony. Small Scale expression tests were carried out in 4 ml
media inoculated with 40 μl over night culture in 24 deep-well plates with round bottom (What-
man, Maidstone, UK). Bacteria were grown for 6 h at 37◦C shaking at 800 rpm. Cultures were
induced with respective IPTG concentration or auto-induction and shaken at 16◦C or room tem-
perature over night. Next day, cultures were harvested at 3130 g for 10 min and the pellet was
resuspendend in Lysis buffer 1 supplemented with 1 μl benzonase / 100 ml lysis buffer. Sonication
and pull down steps were carried out on a Tecan Workstation, Tecan Freedom Evo 150. Bacterial
cells were lysed by sonication with a Vibra-CellTM VC750 Processor (Sonics, Newton, CT, USA)
complemented with 24 Tip Horn from Qsonica, LLC (Newton, CT, USA). Cells were sonicated
for 4 min at 50% with pulse on/off 1 s/1 s and again for 2 min with the same settings. Lysates
were spun down at 13200 rpm for 30 min at 4◦C and applied to 50 μl MediaScout RoboColumns
(Atoll GmbH, Ravensburg; now: OPUS RoboColumns by Repligen, Waltham, MA) with Chelat-
ing Sepharose FF (GE Healthcare). Proteins were eluted with elution buffer His Elu 1. Samples
of cells before induction, induced cells, lysate, insoluble fraction and eluate were analyzed by
SDS-PAGE. The steps from pellet resuspension to elution were carried out by Ariane Fischer
(Crystallization Facility, MPIB).
Expression in E. coli
Large scale protein expression was typically carried out in 2l Erlenmeyer flasks with baﬄes (2l
flasks were manufactured from Klimax; Glasgertebau Ochs introduced 3 baﬄes up to 30% of
total flask height) containing 500 ml medium supplemented with appropriate antibiotics (Table
4.4). The medium was inoculated with 500 μl small-scale pre-culture (1:100 dilution). For the
pre-culture, 20 ml LB medium with the appropriate antibiotics were inoculated with colonies of
freshly-transformed E. coli cells and grown for 1 h at 37◦C shaking at 220 rpm. After inoculation
the large scale bacterial cultures were raised at 37◦C and 120 rpm to an optical density of OD600
1.5 - 1.7. The temperature of the shaker was then reduced to 16◦C and cells were cooled down
at 4◦C. Protein expression was induced with respective amount of IPTG for 16 - 18 h at 16◦C.
The cells were harvested by centrifugation (8000 g, 10 min) and either freshly used for protein
purification or stored at -80◦C.
Table 4.23: Expression conditions for large scale protein production in E. coli cells. All expressions were
carried out at 16◦C for 16 - 18 h. FL full length
No. Expressed construct E. coli strain Condition
1 hsEME1-MUS81 FL BL21 DE3 gold TB 0.5 mM IPTG
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No. Expressed construct E. coli strain Media
2 - 5 hsEME1-MUS81 trun-
cations
BL21 (DE3) gold TB 0.5 mM IPTG
6 hsMUS81 2-225 BL21 DE3 gold TB 0.5 mM IPTG
7 hsSLX4 1-1834 (FL) BL21 DE3 gold
pRARE
TB 0.5 mM IPTG
8 hsSLX4 1309- 1824 B834 pLysS ZY
9 hsSLX4 1492 - 1824 BL21 DE gold pRARE TB 0.5 mM IPTG
10 hsSLX4 1516 - 1824 BL21 DE gold pRARE TB 0.5 mM IPTG
11 hsSLX4 1647 - 1824 B834 pLysS TB 0.5 mM IPTG
12 hsSLX4 1706-1824 B834 pLysS TB 0.5 mM IPTG
13 hsSLX4 1748-1824 B834 pLysS TB 0.5 mM IPTG
14 - 16 hsSLX4SAP trunca-
tions
BL21 DE3 gold
pRARE
TB 0.5mM IPTG
17 hsSLX1 1-275 BL21 DE gold pRIL ZY
18 hsSLX4 1300-1824 +
hsSLX1 11-258
BL21 DE gold, B834
pLysS
TB 0.5 mM IPTG, ZY
19 hsSLX4 1706-1824 +
hsSLX1 11-258
BL21 DE3 gold
pRARE, B834 pLysS
TB 0.5 mM IPTG, ZY
31 ceSLX4 1-1834 (FL) BL21 DE gold pRIL TB 1 mM IPTG
32 - 35 ceSLX4 N-terminal
truncations
BL21 DE gold pRARE TB 0.5 mM IPTG
36 - 37 ceSLX4SAP constructs BL21 DE gold pRARE TB 0.5 mM IPTG
38 + 39 ceSLX1 FL & 168-443 B834 pLysS TB 0.5 mM IPTG
40 + 41 ceSLX4-ceSLX1 FL &
168-443
BL21 DE gold pRARE TB 0.5 mM IPTG
42 - 44 ceMUS81-EME1 con-
structs
BL21 DE gold pRARE TB 0.5 mM IPTG
45 - 47 ceEME1-MUS81 con-
structs
BL21 DE gold pRARE TB 0.5 mM IPTG
48 - 54 ceMUS81 N-terminal
constructs
BL21 DE gold pRARE TB 0.5 mM IPTG
55 - 63 ceSLX4SAP constructs BL21 DE gold pRARE TB 0.5 mM IPTG
Expression in E. coli in Minimal Medium
Expression of 15N- and 15N-13C-labeled proteins was carried out in M9 minimal medium supple-
mented with 15N ammonium chloride, 0.4% glucose or 2 g 13C-glucose, 1 mM MgSO4, 0.3 mM
CaCl2, 1 μ g biotin, 1 μ g thiamin and 1x trace elements solution (0.134 mM EDTA, 31 μ mM
FeCL3-6h2, 0.62 μ M ZnCl2, 0.76 μM CuCl2-2H2O) according to the protocol by Dr. Arie Geerlof,
Helmholtz Center Munich. Bacterial cells transfected with the respective plasmid were plated
on agar plates containing appropriate antibiotics. A 20 ml overnight pre-culture in LB medium
was grown and cells were pelleted for 10 min at 3220 g. The supernatant was discarded and the
cell pellet was washed with 5 ml sterile water and resuspended in M9 media. The bacterial cells
were grown until OD600 0.8 at 37
◦ C. Afterwards, the temperature was reduced to 20◦ C and
the bacterial cells were induced with the respective amount of IPTG. Cells were harvested like
described before.
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Expression Tests for HEK Culture
For initial vector and construct testing different ratios between transfectant (Polyethyleneimide,
PEI) and DNA as well as expression times were tested in HEK293 cells. Proteins were tagged
with GFP in order to facilitate protein detection. For example, in a 1:1 setup 1 μg vector and
1 μg PEI per 1 ml of cell culture were mixed with 500 μl Freestyle media and incubated for 8 min
at 37◦C. The transfection mix was added to 1.5 x 106 cells/ml in 10 ml FreestyleTM expression
media (ThermoFisher Scientific) supplememted with 1% FCS. Small scale expression tests were
carried out in TubeSpin R© Bioreactors 50 (TPP, Trasadingen, Switzerland) and grown for up to
three days with every day sampling. Whole cell samples were spun down at 1200 g for 3 min. The
cell pellet was dissolved with 6x GFP loading dye (150 mM Tris / HCl pH 7.5, 15 mM EDTA,
15% (w/v) glycerol, 0.02% bromphenol blue, 150 mM DTT, 5% SDS according to [257]) and an
equivalent of 0.2 x 106 cells/ml was loaded on a SDS-PAGE. In gel Fluorescence was detected with
TyphoonTM FLA 7000 PhosphoImager (GE Healthcare) with excitation at 473 nm and filter at
520 nm.
Expression in HEK Cells
HEK293 cells were adapted to suspension culture and grown in FreeStyleTM expression media
(ThermoFisher Scientific) supplemented with 1% fetal calf serum (FCS). The cells were cultivated
in wide neck DURANTM GLS 80TM laboratory glass bottles with permeable membrane cap (DWK
Life Sciences, Mainz, Germany) and raised at 37◦C, 7.5% CO2, 63% humidity, and 165rpm to high
cell density. One day before expression set-up the cells were split to 0.8 x 106 cells/ml. On the
day of the expression the HEK293 cells were grown to a cells density of 1.5 x 106 cells / ml.
The cells were transiently transfected with a 4:2 mixture of polyethylenimid (PEI) and DNA in
FreeStyleTM expression media. For each ml of cell culture 2 μg DNA was mixed in a 50 ml conical
centrifuge tube with 4 μg PEI in a volume of 5% of the total expression volume. The mixture
was incubated at room temperature for 8 min and added directly to the target cell culture. To
slow down cell growth valproic acid (VPA) was added to an end concentration of 3.75 mM and
cells were cultivated at 32◦C. 24 h after setting up the expression the cells were harvested by
centrifugation at 2000 g for 20 min. The cell pellet was then washed with 1x phosphate buffered
saline (PBS) and directly used for protein purification.
Table 4.24: Expression conditions for large scale protein production in suspension culture of HEK cells.
No. Expressed construct Condition (PEI:DNA)
20 hsSLX4 1-1834 3:1
21 hsSLX4 667-1834 3:1
22 hsSLX4 1300-1834 3:1
23 hsSLX1 1-275 2:1
24 hsSLX1 11-275 + hsSLX4 1300-1834 4:2
25 hsSLX1 11-258 + hsSLX4 1300-1834 4:2
26 hsSLX1 11-275 + hsSLX4 1489-1834 4:2
27 - 29 hsSLX1 constructs with hsSLX4 CCD constructs 4:2
30 hsSLX4 1706-1834 - P2A-hsSLX1 11-258 4:2
122 4. Materials and Methods
4.2.3 Protein Purification
In general, all purification steps were carried out at 4◦C. The detailed buffer composition for the
purification is listed in Table 4.11. Loading of the cleared lysate on the Ni and ion exchange (IEX)
columns and washing steps were performed using a peristaltic pump (Reglo ICC, Ismatec, Cole-
Parmer GmbH, Wertheim, Germany). Linear gradients for elution were administered by A¨KTA
Prime systems (GE Healthcare) by using mixtures of IEX A and B buffers. Gel filtration was
carried out on A¨KTA Purifier system.
Purification of hsEME1-MUS81
Recombinantly and bicistronically expressed HIS-SUMO-hsEME1-MUS81 was purified from freshly
harvested BL21 gold cells. The cell pellet was resuspended at 4◦C with lysisbuffer 2 (Lys2 ) and
lysed by sonication (Bandelin Sonoplus, tip VS70, pulse ON/OFF 0.5/1 s, 40% amplitude, 10
min). The lysate was clarified by centrifugation at 75600 g for 30 min. The soluble fraction was
loaded on a Ni-NTA column (5 ml, ProtinoTM Ni-NTA, Macherey-Nagel) and washed with His-1
buffer (His 1) followed by a chaperone-wash (CW 1) and another wash with His-1 buffer. The
immobilized protein complex was eluted with high imidazole buffer (His Elu 2). The eluted protein
complex was directly loaded onto a Heparin column (5 ml, HiTrap Heparin HP, GE Healthcare),
which was directly connected to the lower end of the Ni column. For washing and elution the
Heparin column was connected to a A¨KTA prime system and washed with 5% IEX B buffer (100
mM NaCl). For elution a gradient from 5% to 60% IEX B (1.2 M NaCl) in 60 ml was applied. The
His-SUMO tag on hsEME1 was cleaved with SUMO-protease (final concentration 0.01mg/ml) for
30 min at 4◦C. The cleavage mix was concentrated by ultra-filtration and subjected to gel filtration
(Superdex 200 16/600 column, GE Healthcare) pre-equilibrated with SEC buffer 1 (SEC 1). In
the end, the purified proteins were concentrated by ultra-filtration and used for further analysis
or crystallization. To store the protein, 86% glycerol was added to a final concentration of 10%
(v/v), aliquoted, flash frozen in liquid nitrogen and frozen at -80◦C.
Purification of hsEME1-MUS81 Truncations from bax25
hsEME1-MUS81 constructs in vector bax25 with N-terminal SUMO tag on EME1 and C-terminal
CPD-TwinStrep tag on MUS81 were bacterially expressed in BL21 gold cells. After harvest of
bacteria the bacterial pellet was resuspended in lysis buffer (Lys 2) and lysed by sonication like
the full length proteins of hsEME1-MUS81. After clarification of the lysate, the soluble protein
fraction was loaded on Ni column (5 ml, ProtinoTM Ni-NTA, Macherey-Nagel). Afterwards the
column was washed with His washbuffer (His 2) and chaperon wash buffer (CW 1). Proteins
were eluted with HIs elutionbuffer (His Elu 6). In order to reduce the imidazole concentration to
100mM, the Ni pool was diluted with 3.5x volume of His Elu 6 buffer without imidazole. The
diluted Ni pool was loaded on Strep-Tactin R© Superflow R© column (1 ml, IBA GmbH, Go¨ttingen,
Germany), equilibrated with Strep 1 buffer. The bound protein was eluted by activation of CPD by
washing with Strep 2 buffer. The remaining CPD-Twinstrep-tag was displaced from the column
by washing with Strep 3 buffer. The Strep-Tactin R© Superflow R© column was regenerated by
subsequently washing with Strep 4 and Strep 5 buffer. The remaining SUMO-tag on hsEME1
construct was cleaved by the addition of Senp2 (0.01 mg/ml).
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Purification of hsEME1-MUS81 truncations - N-terminal SUMO tag
hsEME1-MUS81 constructs were expressed in a bicistronic vector and purified from either fresh
pellet after harvest or stored bacterial pellets at -80◦C. Lysis was carried out in the same way
as for full-length hsEME1-MUS81 applying Lys 2 buffer. After application of cleared lysate on
Ni-NTA column (5 ml, ProtinoTM Ni-NTA, Macherey-Nagel) and washed with His-2 buffer (His
2) followed by a chaperone-wash (CW 1). The immobilized protein complex was eluted with His
Elu 2 directly into Heparin column (5 ml, HiTrap Heparin HP, GE Healthcare). Wash and elution
of Heparin column was done in the same order as for hsEME1-MUS81 FL with IEX A and IEX B
buffers, except for the washing step with 10% IEX B. Cleavage and concentration of the proteins
were performed according to the protocol for FL proteins. The cleaved mix was subjected to gel
filtration (Superdex 75 16/600 column, GE Healthcare) pre-equilibrated with SEC buffer 2 (SEC
2). The purified proteins were used for further analysis and crystallization. Proteins were stored
in 10% (v/v) glycerol at -80◦C.
Purification of hsMUS812-225
Recombinantly expressed hsMUS81 2-225 with N-terminal His8-SUMO solubility tag was purified
from BL21 gold cells. Lysis was carried out in the same way as for full-length hsEME1-MUS81
applying Lys 2 buffer. After application of cleared lysate on Ni-NTA column (5 ml, ProtinoTM Ni-
NTA, Macherey-Nagel) the column was washed with His-2 buffer (His 2) followed by a chaperone-
wash (CW 2). The immobilized protein complex was eluted with His Elu 2 directly into Heparin
column (5 ml, HiTrap Heparin HP, GE Healthcare). Wash and elution of Heparin column was
done in the same order as for hsEME1-MUS81 FL with IEX A and IEX B buffers. The Heparin
pool was cleaved for 1 h at 4◦C on the rocker and after dilution to 100 mM NaCl re-applied to
Heparin column in order to separate protein from tag. The pool of the second Heparin column
run was concentrated and injected into gel filtration column (Superdex 75 16/600 column, GE
Healthcare) equilibrated with SEC buffer 3 (SEC 3). The purified proteins were either used for
further analysis and crystallization or were stored in 10% (v/v) glycerol at -80◦C.
Purification of hsSLX41300-1834 + hsSLX111-275from HEK Cell Expression
Transiently co-expressed hsSLX41300-1834 with C-terminal 3C-mVENUS-1d4 tag and hsSLX111-275
with N-terminal His8-eGFP-SUMO tag was purified from HEK293 cells directly after harvest. The
cell pellet was homogenized in 50 ml lysisbuffer 3 (Lys 3) by a Dounce homogenizer (B. Braun,
Melsungen), moving the pestle 30 times up and down, and subjected to sonication (Bandelin
Sonoplus, tip VS70, pulse ON/OFF 0.5/1.5 s, 20% amplitude, 5 min). The lysate was clarified by
centrifugation at 75600 g for 1 h. The soluble fraction was filtered by 0.22 μm CorningTM bottle
top filters (Corning Incorporated Life Sciences, Tewksbury, MA, USA) and then applied to GFP
binder column (1 ml, HiTrap NHS-Activated HP affinity column (GE Healthcare) coupled with
anti-GFP VHH purified protein). The column was washed extensively with High salt wash buffer
(GFP 1) and then with Low Salt buffer (GFP 2). For elution 100 μl 1 mg/ml Senp2 mod (modified
for application in mammalian cell culture) was mixed with 10 μl 1 mg/ml 3C protease in a volume
of 1 ml GFP 2 buffer, injected into the GFP binder column and incubated at 4◦C over night.
The proteins were eluted with 2.5 ml High salt buffer (GFP 1) and the GFP binder column was
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regenerated with 0.1 M Citrate. The proteins were applied to gel filtration column S200 16/600
(GE Healthcare) equilibrated with SEC buffer (SEC 4). The purified proteins were used for further
analysis or stored in 10% (v/v) glycerol at -80◦C.
Purification of CPD-Tagged hsSLX4 Constructs
Bacterially expressed hsSLX4 constructs with C-terminal CPD-His8 tag were purified by resuspen-
sion in Lys 7 buffer and the cells were sonicated (Bandelin Sonoplus, tip VS70T, pulse ON/OFF
0.5/1 s, 40% amplitude, 15 min). After separating soluble and insoluble fraction by centrifugation
for 45 min at 75600 g, the soluble fraction was loaded on two IMAC columns (1CV = 10ml, His-
Trap HP, GE Healthcare) and washed with His 5 buffer. The ATP buffer wash was carried out
with CW 6 buffer. The protein was eluted with His Elu 5 buffer, fractions containing the tagged
protein were pooled and tag cleavage was induced by addition of 0.1 M IP6 (end concentration
40 μM) for 30 min at 4◦C. Salt concentration and pH were adjusted by dilution with buffer IEX
3 A to 50 mM salt and pH 6.5 and the sample was loaded on cation exchange column (5 ml,
HiTrapTM SP HP, GE Healthcare). After washing with 3% IEX 3 B (60 mM NaCl) the protein
was eluted by applying a gradient from 3% to 60% B. The peak fractions were pooled and con-
centrated via ultrafiltration.At last the protein was purified by SEC (Superdex 75 10/300, GE
Healthcare) pre-equilibrated with SEC buffer (SEC 10), concentrated, flash-frozen and stored at
-80◦C.
Purification of hsSLX4 SAP Constructs
Constructs of human SLX4 SAP domain were expressed with N-terminal His8-SUMO tag in E. coli
and cell pellet was directly used after harvest. The cell paste was resuspendend in lysisbuffer Lys 4
supplemented with 10mM EDTA and 2 μM Pepstatin and lysed by sonication (Bandelin Sonoplus,
tip VS70T, pulse ON/OFF 0.5/1 s, 40% amplitude, 12 min). The cleared lysate (centrifugation at
75600 g for 3 0min) was loaded on a Ni-column (5ml, cOmpleteTM His-Tag purification column,
Roche) and subsequently washed with buffer His 3, CW 3 and eluted with His Elu 3 supplemented
with 3 mM DTT. The Ni pool was diluted with IEX 1 buffer A to 44 mM NaCl and loaded on
anion exchange column (Q Sepharose Fast Flow, GE Healthcare). The protein was eluted by a
linear gradient from 4% to 60% IEX 1 B buffer. The peak fractions were pooled and the SUMO
tag was cleaved over night at 4◦C by addition of Senp2 (end concentration 0.014 mg/ml). After
concentrating by ultrafiltration the cleavage mix was injected on gel filtration column (Superdex
75 16/600, GE Healtcare) pre-equilibrated with SEC buffer (SEC 6). The peak fractions were
pooled, concentrated, flash-frozen and stored at -80◦C.
Purification of ceSLX4
Full-length ceSLX4 was expressed with N-terminal His8-SUMO tag in BL21 gold pRIL cells.
The cell pellet was resuspended in Lys 4 buffer and lysed by sonication (Bandelin Sonoplus, tip
VS70T, pulse ON/OFF 0.5/1 s, 40% amplitude, 8 min). The lysate was clarified by centrifugation
at 75600 g for 45 min. The soluble fraction was loaded on a Ni-column (5 ml, cOmpleteTM His-Tag
purification column, Roche) and washed with His-3 buffer (His 3) followed by a chaperone-wash
(CW 3) and elution with Elu 3 buffer (His Elu 3). The His8-SUMO-tag was cleaved over night by
4.2 Methods 125
addition of Senp2 to the pooled fractions. The cleavage mixture was loaded on to a SP-sepharose
column (5 ml, HiTrapTM SP HP, GE Healthcare), washed with 5% IEX 2 B (100 mM NaCl), and
eluted from cation exchange column using a gradient to 60% IEX 2 B. The protein was purified in
a last step by SEC (Superose 6 16/600 column, GE Healthcare) pre-equilibrated with SEC buffer
(SEC 5), concentrated by ultra-filtration, flash-frozen and stored at -80◦C.
Purification ceSLX4SAP Constructs
This purification protocol applies to all ceSLX4 SAP constructs. His8-SUMo tagged SAP con-
structs of ceSLX4 were expressed in E. coli. The cell pellets were resuspended in Lys 4 buffer
supplemented with 10 mM EDTA and 2 μM Pepstatin and lysed by sonication (Bandelin Sono-
plus, tip VS70T, pulse ON/OFF 0.5/1 s, 40% amplitude, 10 min). After centrifugation (75600 g
30 min) the clarified fraction was loaded on His-cOmplete Ni column (5 ml, cOmpleteTM His-Tag
purification column, Roche) and the resin was first washed with His buffer 3 (His 3), then with
chaperon-wash buffer 3 (CW 3). The His-tagged protein was directly eluted with His Elu 3 into
a subsequent connected Heparin column (5 ml, HiTrapTM Heparin HP, GE Healthcare). After
washing with 5% IEX 1 buffer B (IEX 1 B), the protein was eluted with an linear gradient to
60% IEX 1 buffer B (IEX 1 B). The His8-SUMO-tag was cleaved off by incubation with Senp2
protease (final concentration 0.02 mg/ml) over night at 4◦C. The cleavage mix was desalted to
5% IEX 1 buffer B (IEX 1 B, 100 mM NaCl) and applied to SP-Sepharose column (5 ml, HiTrap
TM SP HP, GE Healthcare), washed with 5% IEX 2 B (100 mM NaCl), and eluted from cation
exchange column using a linear gradient to 60% IEX 2 B. Finally, the protein was purified by SEC
(Superdex 75 16/600, GE Healthcare) using SEC buffer 6 (SEC 6), concentrated, supplemented
with 10% glycerol for storage, flash frozen and stored at -80◦C.
Purification of ceEME1-MUS81
The bicistronically expressed protein complex consisting of ceEME1 and ceMUS81 was purified
after expression in E. coli. Cells were resuspended in lysisbuffer 2 (Lys 2) and lysed by sonication
(Bandelin Sonoplus, tip VS70T, pulse ON/OFF 0.5/1s, 40% amplitude, 10min). The clarified
lysate was loaded onto Ni-NTA Superflow cartridges (2x 5 ml, Qiagen GmbH, Hilden, Germany).
After washing with washbuffer His 1 and CW 1, the proteins were directly eluted with His Elu 2
into one connected Heparin column (5 ml, HiTrapTM Heparin HP, GE Healthcare). Subsequently,
the proteins were washed with 5% IEX 1 B (100 mM NaCl) and eluted by a linear gradient from
5% to 60& IEX 1 B. The His8-SUMO tag was cleaved off from ceEME1 by incubation with Senp2
(final concentration 0.01 mg/ml) during concentrating of the proteins. The cleavage mixture was
subjected to gel filtration (Superdex 200 16/600, GE Healthcare) with buffer SEC 7, concentrated,
flash frozen and stored at -80◦C.
Purification of Truncated ceEME1-MUS81 Constructs
Truncated versions of the bicistronically expressed ceEME1-MUS81 complex were purified in the
same way as outlined for ceEME1-MUS81 full length proteins (Section ?? with the exception that
instead of Qiagen Ni-NTA Superflow cartridges ProtinoTM Ni-NTA columns were applied because
they had higher binding capacity for the better expressed truncated ceEME1-MUS81 constructs.
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Purification of ceMUS81N
ceMUS81N construct 1-157 was purified either with C-terminal CPD tag or with N-terminal His8-
SUMO tag. This paragraph describes the purification with the CPD-tag and the subsequent para-
graph explains the purification of the SUMO-tagged ceMUS81N and more truncated N-terminal
ceMUS81 constructs. ceMUS81N was expressed in E. coli and resuspended in Lys 2 buffer. Cells
were lysed by sonication (Bandelin Sonoplus, tip VS70T, pulse ON/OFF 0.5/1 s, 40% amplitude,
10 min) and after clarification was the lysate loaded on two Ni-NTA columns (10ml, Ni-NTA
superflow cartridges, Qiagen). The resin was washed with His 1 buffer, followed by a chaperon
wash with buffer CW 1. Tag cleavage was induced by washing with His Elu 4. The remaining
His8-CDP-tag was removed from Ni column by washing with His Elu 1 buffer. The eluted protein
after His Elu 3 was loaded on two Heparin columns (10 ml, HiTrap Heparin HP, GE Healthcare),
and after removing unbound contaminants with 5% buffer IEX 1 B (100 mM NaCl) eluted by a
gradient from 100 mM NaCl to 1.2 M NaCl. The pooled fractions were subjected to gel filtration
(S75 16/600, GE Healthcare) with SEC 6 buffer. The fractions containing the clean protein were
pooled, flash frozen and stored at -80◦C.
Purification of ceMUS81 N-terminal Truncations
Further truncations of ceMUS81N expressed with N-terminal-His8-SUMO tag were expressed in
BL21 (DE3) pRARE E. coli cells and lysed by sonication, as outlined before, in Lys 6 buffer.
The lysate was clarified by centrifugation at 75600g for 30min at 10◦C. The clarified fraction was
loaded on His-cOmplete Ni column (5ml, cOmpleteTM His-Tag purification column, Roche) and
washed with His 4 buffer followed by chaperon wash (CW 5) and elution with His Elu 2 buffer,
supplemented with 3mM DTT. Tag cleavage was induced by addition of Senp2 (final concentration
0.0025mg/ml) and incubation for 2h on ice. The cleavage mix was loaded at low pump speed on an
IEX column (HiTrapTM SP HP, GE Healthcare). After washing with 5% IEX 1 B buffer (100mM
NaCl), the protein was eluted in a gradient to 60% IEX 1 B buffer (1.2M NaCl). The SP pool
was pooled, concentrated by ultra-filtration and subjected to SEC (S75 16/600, GE Healthcare)
pre-equilibrated with SEC 9 buffer. In the end, the purified protein was concentrated by ultra-
filtration, flash frozen after supplementing with 10% (v/v) glycerol and stored at -80◦C.
Purification of hsPLK1 DAA
The hyperactive mutant of hsPLK1 (T210D R337A I340A) was lysed by douncing with 30 strokes
and sonication for 2 min in Lys buffer 5 after three day expression in HEK293 suspension culture.
Lysate was loaded on GFP-binder column (1ml, HiTrap NHS-Activated HP affinity column (GE
Healthcare) coupled with anti-GFP VHH purified protein) and washed subsequently with GFP 1
buffer, CW 4 and GFP 2 buffer. Cleavage of the tag was carried out by incubation over night at
4◦C with 1 ml 0.1 mg/ml Senp2 (modified for application with proteins expressed in human cell
culture) supplemented with GFP 2 buffer. Next day, PLK1 was eluted by applying 4 ml GFP 1
buffer and further purified by gel filtration (S200 16/600, GE Healthcare) in buffer SEC 6. The
SEC pool was supplemented with 10% glycerol (w/v) and stored at -80◦C.
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4.3 Biochemical Assays
4.3.1 Determination of Protein Concentration and Purity
Protein purity was assessed by SDS-Gel electrophoresis, by monitoring the absorption ratio A260/A280
during size exclusion chromatography and at Nanodrop measurements. Protein concentrations
were measured by NanoDrop spectrophotometer (Thermo Scientific, UK) at absorbance 280nm
and 260nm. The extinction coefficients were calculated using the ProtParam tool (ExPASy, SIB
bioinformatics resource portal) [321]. Protein concentrations for the ceSLX4SAP constructs were
not measured with NanoDrop as the extinction coefficient contained already an error of 10% due
to the presence of only one tyrosine in the protein. The protein concentration was assessed using
the Bicinchoninic acid (BCA) Protein Assay Kit (NovagenTM, EMD Millipore Comp, Billerica,
MA USA) according to manufacturer proceedings for micro-scale assay.
Protein concentrations for MUS81, EME1 and SLX4 in one HeLa cell [305] were estimated by
applying the following formulas: The estimated volume of one HeLa nucleus 690 μ3 [306], which
corresponds to 690 fl (690 · 10-15l).
n =
N
NA
(4.1)
with n being the substance amount, N the particle number and NA the Avogadro constant
(6.02214086 · 1023 mol-1). The molar concentration c is then calculated by the following for-
mula:
c =
n
V
(4.2)
with V being the volume of the cell nucleus.
4.3.2 Polyacrylamide Gel Electrophoresis
Purity of protein was assessed by sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) according to Laemmli [327] using 12.5 to 18% gels. SDS-Gels were stained with
Coomassie brilliant blue R-250.
4.3.3 Native Gel Electrophoresis
To analyze the DNA-binding properties of the used constructs, EMSA was carried out with self-
made Tris-Borate gels (0.5x Tris-Borate, 6% 19:1 Acrylamide:Bisacrylamide, 0.2% TEMED, 0.08%
APS). The gels were pre-equilibrated for 120 - 180 min in 0.5x TB buffer at 100 V and 4◦C. After
loading the samples, the gels were incubated for 5 min at 4◦C to let the sample diffuse slowly into
the gel. Gels were then ran for 10 min at 200 V and for another 30 to 60 min at 100 V. The gels
were analyzed by fluorescence imaging (see section ??).
4.3.4 Limited Proteolysis
For limited proteolysis, 10 μl protein was used at 0.6 mg/ml in respective gel filtration buffer,
mixed with 3 μl protease solution and incubated for 30 min on ice. Trypsin, Subtilisin, Elastase,
GluC and Chymotrypsin were diluted from 1 mg/ml stock using protease dilution buffer (20 mM
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Hepes pH 7.5, 50 mM NaCl, 10 mM MgSO4) and were applied at three different concentrations
(0.1 mg/ml, 0.01 mg/ml, 0.001 mg/ml). The reaction was stopped by adding 3 μl 6x LAEMMLI
buffer and incubation for 5 min at 95◦C. The degradation products were separated by SDS-PAGE
and stained with Coomassie for visualization. Peptide finger printing was carried out by Nagarjuna
Nagaraj, PhD (MPIB Biochemistry Core Facility).
4.3.5 Mass Spectrometry Analysis
For peptide fingerprinting after limited proteolysis, protein samples were cut out from SDS-PAGE.
Sample processing and peptide analysis was carried out by Dr. Nagarjuna Nagaraj and his team
(Biochemistry Core Facility, MPIB). Prior to protein digest, the protein sequence was subjected
to in silico enzymatic digest with MS-Digest of ProteinProspector [328]. Samples were digested
with Trypsin or a combination of Trypsin and GluC for human SLX4 constructs [329] in order
to increase sequence coverage. The peptides were analyzed by Orbitrap mass spectrometry [330]
and identified using Max Quant software [316]. To determine the total mass of proteins or protein
fragments, 40 μl of a 1 mg/ml protein solution was analyzed by electrospray ionization time-
of-flight mass spectrometry(ESI-TOF MS). The measurement was carried out with a BRUKER
microTOF mass spectrometer by Elisabeth Weyher-Stingl, Antonio Piras or Victoria Sanchez
(MPIB Biochemistry Core Facility, MPIB).
4.3.6 Treatment with DNA Damaging Agents
HEK293 cells were raised to 1.5 x 106 cells per ml and transiently transfected with C-terminally
mVenus tagged hsSLX41300-1834 and N-terminally eGFP-tagged hsSLX111-275 according to the
HEK expression protocol (see section 4.2.2). Next day the cells were separated into 50 ml aliquots,
DNA damaging agents were added and the mixture was incubated according to table 4.25.
Table 4.25: DNA damaging agents. Application scheme of DNA damaging agents to HEK suspension
culture. The reference gives credit to the publication of the experimental conditions used.
DNA damaging Agent Stock concentration End concentration Incubation time Reference
Hydroxyurea 150 mM 2 mM 3h [267]
Mitomycin C 500 μg/ml 0.1 μg/ml 1h [112]
Methylmethanesulfonate 1 M 2 mM 1h [113]
Etoposide 50 mM 5 μM 1h [268]
The cells were harvested by centrifugation at 2000 g for 10 min and resuspended in lysis buffer
(Lys 8). This lysis buffer was supplemented with Phosphatase inhibitor cocktail A & B. Cells were
homogenized in a 5 ml dounce homogenizer, incubated for 30 min on ice and sonicated for 2 min
(VS70T tip, 20%, 0.5/1.5 s on/off). The lysate was transferred into 2 ml reaction tubes and the
lysate was clarified by centrifugation at 21130 g for 15 min at 4◦C. The soluble fraction was then
incubated for 1 h at t 4◦C with GFP-binder beads (200 μl 50% slurry, HiTrap NHS-Activated HP
affinity beads (GE Healthcare) coupled with anti-GFP VHH purified protein), equilibrated with
GFP 2 buffer. For separation of bound and unbound protein, the beads were centrifuged at 2500
g for 2 min. Beads were washed three times with GFP 1 buffer, two times with CW 4 buffer
followed by washing in GFP 2 buffer. The tag was cleaved off by incubation for 1 h on rotating
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wheel with 3C protease (end concentration 0.06 mg/ml) in GFP 2 buffer. Proteins were separated
from the beads by centrifugation at 2500 g for 2 min and subsequently subjected to phosphosite
analysis by Dr. Nagarjuna Nagaraj (MPIB).
4.3.7 Phosphosite Identification by MS
Sample Preparation and Processing
hsSLX41300-1834 and hsSLX41300-1834-hsSLX111-275 purified by anti-GFP-affinity were dephospho-
rylated by different phosphatases. For this, 40 μg protein was incubated with 7 U of the respective
phosphatase and reaction buffer in a 70 μl reaction volume for 1 h at 37◦C (see Table 4.26). The
reactions were stopped by cooling down on ice.
Table 4.26: Dephosphorylation of hsSLX41300-1834. Different phosphatases and their respective buffer were
applied for dephosphorylation of hsSLX41300-1834.
Phosphatase Reaction buffer Supplier
λ-Phosphatase 10 mM MnCl2 NEB
Shrimp phosphatase Cutsmart NEB
Fast Alkaline Phosphatase FastAP buffer ThermoFisher
Antarctic Phosphatase Antarctic PPT buffer NEB
The samples were further handled by Dr. Nagarjuna Nagaraj (Biochemistry Core Facility,
MPIB) and co-workers. According to their protocol 40 μl sample were added to 40 μl guanidium
denaturation buffer (6 M guanidium hydrochloride, 10 mM TCEP and 40 mM Chloroacetamide
in 25 mM Tris pH 8.5) and the mixture was heated at 70◦C for 2 minutes. The samples were
then diluted by adding 400 μl of 50 mM ammonium bicarbonate solution and vortexed well. Each
sample was divided into two aliqouts. One aliqout was digested with 2 μg of sequencing grade
modified trypsin (Promega, Madison, WI, USA) and the other half with 2 μg trypsin followed
by 2 μg of sequencing grade Glu-C (Roche) The digestion was carried out overnight at 25◦C and
37◦C for Glu-C and trypsin respectively. After digestion the peptides were purified using C18
StageTips and loaded for LC-MSMS analysis. The purified peptides were loaded on 15 cm long
pulled emitters packed with 1.9 μm reprosil C18 beads (Dr Maisch GmbH, Ammerbuch-Entringen,
Germany) and eluted over a 140 minute gradient directly into a Q Exactive HF mass spectrometer
via a nano-electrospray source. The mass spectrometer was operated in a data-dependent manner
and up to top 15 peptides like features were selected for HCD fragmentation. Dynamic exclusion
was enabled to minimize repeat sequencing of same peptides. All raw data were processed using
MaxQuant computational platform. The peak lists were searched against a custom database
containing only the relevant proteins present in the sample using Andromeda search engine that
is built into Maxquant platform.
Analysis of Phosphorylation Sites
The analysis of the data was carried but myself. For this two parameters were taken into account,
the localization probability and the peak intensity. The probability for one phosphorylation at a
specific site had to be higher than 75%. This is important, when one peptide contained more than
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one detected phosphorylation site. Phosphorylation sites were only taken into account when the
peak intensity in the spectrum was significantly above the background, usually ranging from 1 x
E7 to 3 x E11. For the Phosphosite detection of hsSLX41300-1834 alone three different independent
phosphorylation site detections from three different expression batches were analyzed. For the
detection of the phosphosites in hsSLX41300-1834 in co-expression with hsSLX1 and in presence
of DNA-damaging agents, three independent measurements were performed. The intensities were
grouped by treatment and the average intensity given in the three measurements for one site was
taken. For graphical presentation in a heat map, logarithmized (log2) intensities were clustered.
4.3.8 In vitro Kinase assay
The hyperactive mutant hsPLK1 T210D R337A I340A was applied for phosphorylation of ceSLX4SAP.
The reaction was carried out in 50 mM Tris pH 7.5, 100 mM KCl, 10 mM MgCl2, 5 mM DTT,
200 μM ATP according to [331]. 500 μM ceSLX4SAP was incubated with 109 nM hsPLK1 T210D
R337A I340A for 30 min at 30◦C. The resulting phosphorylation mix was either subjected to gel
filtration interaction assays or sent for phosphosite detection by mass spectrometry and ESI-TOF
mass spectrometry.
4.3.9 Cleavage Assay
DNA substrates were synthesized by Eurofins (Ebersberg, Germany) and resuspended in annealing
buffer (20 mM Hepes/KOH pH 7.9, 50 mM KCl, 0.1 mM EDTA). The substrates resemble different
DNA intermediates during DNA damage repair and were designed based on 30 bp arm length HJ
(see Table 4.27). Oligonucleotide CB209 was 5’ 6FAM labeled. Cleavage assays were carried out
in cleavage buffer (50 mM Tris pH 8.0, 1 mM DTT, 100 μg/ml BSA, 5 mM MgCl2 and 150 mM
NaCl) using 40 nM DNA substrate and 640 nM protein. The reaction mixture was incubated for
30 min at 37◦C and the reaction was stopped by adding 1 μl Proteinase K, 0.5 μl 0.5 M EDTA and
0.3 μl 10%SDS. The cleavage products were separated by native gel electrophoresis with 10% TB
gels at room temperature for 30 min running constant at 2 W. Gels were analyzed by fluorescence
imaging (excitation 473 nm, filter 520 nm, TyphoonTM FL 7000 PhosphoImager, GE Healthcare).
The DNA substrate bands were quantified using ImageJ. The uncut DNA substrate bands were
normalized against the control substrate bands and product formation was calculated from the
difference.
Table 4.27: DNA substrates used for nuclease activity tests
DNA Substrate Oligo Name Sequence
ds CB209 5’FAM-ACGCTGCCGAATTCTACCAGTGCCTTGCTAGGA
CATCTTTGCCCACCTGCAGGTTCACCC
CB215 GGGTGAACCTGCAGGTGGGCAAAGATGTCCTAG CAAG-
GCACTGGTAGAATTCGGCAGCGT
3’flap CB209 5’FAM-ACGCTGCCGAATTCTACCAGTGCCTTGCTAGGA
CATCTTTGCCCACCTGCAGGTTCACCC
CB212 CGATAGTCGGATCCTCTAGACAGCTCCATGTAGCAAG
GCACTGGTAGAATTCGGCAGCGT
CB217 CATGGAGCTGTCTAGAGGATCCGACTATCG
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DNA Substrate Oligo Name Sequence
5’flap CB209 5’FAM-ACGCTGCCGAATTCTACCAGTGCCTTGCTAGGA
CATCTTTGCCCACCTGCAGGTTCACCC
CB212 CGATAGTCGGATCCTCTAGACAGCTCCATGTAGCAAG
GCACTGGTAGAATTCGGCAGCGT
CB218 GGGTGAACCTGCAGGTGGGCAAAGATGTCC
RF CB209 5’FAM-ACGCTGCCGAATTCTACCAGTGCCTTGCTAGGA
CATCTTTGCCCACCTGCAGGTTCACCC
CB212 CGATAGTCGGATCCTCTAGACAGCTCCATGTAGCAAG
GCACTGGTAGAATTCGGCAGCGT
CB217 CATGGAGCTGTCTAGAGGATCCGACTATCG
CB218 GGGTGAACCTGCAGGTGGGCAAAGATGTCC
HJ CB209 5’FAM-ACGCTGCCGAATTCTACCAGTGCCTTGCTAGGA
CATCTTTGCCCACCTGCAGGTTCACCC
CB210 GGGTGAACCTGCAGGTGGGCAAAGATGTCCATCT GTTG-
TAATCGTCAAGCTTTATGCCGT
CB211 ACGGCATAAAGCTTGACGATTACAACAGATCATG GAGCT-
GTCTAGAGGATCCGACTATCG
CB212 CGATAGTCGGATCCTCTAGACAGCTCCATGTAGCAAG
GCACTGGTAGAATTCGGCAGCGT
nHJ CB209 5’FAM-ACGCTGCCGAATTCTACCAGTGCCTTGCTAGGA
CATCTTTGCCCACCTGCAGGTTCACCC
CB210 GGGTGAACCTGCAGGTGGGCAAAGATGTCCATC TGTTG-
TAATCGTCAAGCTTTATGCCGT
CB213 ACGGCATAAAGCTTGACGATTACAACAGATC
CB214 P-ATGGAGCTGTCTAGAGGATCCGACTATCG
CB212 CGATAGTCGGATCCTCTAGACAGCTCCATGTAGCAAG
GCACTGGTAGAATTCGGCAGCGT
4.3.10 Electrophoretic Shift Assays
For EMSA analysis, proteins were incubated with DNA substrates and the formed complexes were
analyzed by native PAGE. EMSAs were run like described in section 4.3.3. For first analysis DNA
binding was analyzed in a protein concentration range from 0.25 to 2.5 or 5 μM. Gels were analyzed
by fluorescence imaging (excitation 473 nm, filter 520 nm, TyphoonTM FL 7000 PhosphoImager,
GE Healthcare).
Table 4.28: DNA substrates used for Fluorescence Anisotropy measurements and bands shift assays
DNA Substrate Oligo Name Sequence
ss 4w1616-1 5’FAM-CTCGAAGAATTCCGGA TTAGGGATGCCGTCTG
ds 4w1616-1 5’FAM-CTCGAAGAATTCCGGA TTAGGGATGCCGTCTG
ds1616-2 CAGACGGCATCCCTAA TCCGGAATTCTTCGAG
3’flap 4w1616-1 5’FAM-CTCGAAGAATTCCGGA TTAGGGATGCCGTCTG
4w1616-4 CGTTCTGAGCCTAGCG TCCGGAATTCTTCGAG
4w1616-3n6 pCGCTAGGCTCAGAACG
5’flap 4w1616-1 5’FAM-CTCGAAGAATTCCGGA TTAGGGATGCCGTCTG
4w1616-4 CGTTCTGAGCCTAGCG TCCGGAATTCTTCGAG
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DNA Substrate Oligo Name Sequence
4w1616-2n5 CAGACGGCATCCCTAA
RF 4w1616-1 5’FAM-CTCGAAGAATTCCGGA TTAGGGATGCCGTCTG
4w1616-2n5 CAGACGGCATCCCTAA
4w1616-3n6 pCGCTAGGCTCAGAACG
4w1616-4 CGTTCTGAGCCTAGCG TCCGGAATTCTTCGAG
HJ 4w1616-1 5’FAM-CTCGAAGAATTCCGGA TTAGGGATGCCGTCTG
4w1616-2 CAGACGGCATCCCTAA GCTCCATCGTGGCGGA
4w1616-3 TCCGCCACGATGGAGC CGCTAGGCTCAGAACG
4w1616-4 CGTTCTGAGCCTAGCG TCCGGAATTCTTCGAG
nHJ 4w1616-1 5’FAM-CTCGAAGAATTCCGGA TTAGGGATGCCGTCTG
4w1616-2n3 CAGACGGCATCCCTAA GC
4w1616-2n4 pTCCATCGTGGCGGA
4w1616-3 TCCGCCACGATGGAGC CGCTAGGCTCAGAACG
4w1616-4 CGTTCTGAGCCTAGCG TCCGGAATTCTTCGAG
The KD was calculated using Graphpad Prism 7 by applying non-linear regression and specific
binding with Hill Slope (Equation 4.3).
y = Bmax · x
h
KdD +X
h
(4.3)
y is the Protein-DNA complex in percent, x is the protein DNA concentration. Bmax is the
maximum specific in percent. KD is the protein concentration needed to achieve half-maximum
binding at equilibrium. h is the Hill slope. If h is 1.0, then a monomer binds with no cooperativity
to one site. When h is greater than 1.0, then the binding graph shows sigmoidal shape, meaning
the protein has multiple binding sites with positive cooperativity. The quality of the non-linear
regression was assessed with R squared and residual plot analysis and the agreement between
observed and calculated binding isotherm was evaluated applying a confidence interval of 95%.
4.3.11 SEC-based Protein-Protein Interaction
For the analysis of interaction between ceSLX4SAP and ceMUS81N, both proteins were mixed in a
1:1 molar ratio. Both proteins were mixed together at a concentration of 600μM of each protein.
The mixture was incubated for 30 min on ice. Finally, a 40 μul sample at a final concentration
of 150 μM, supplemented with SEC 8 buffer, was injected on a Superdex 75 3.2/30 column (GE
Healthcare) on A¨KTAmicro, equilibrated with SEC 8 buffer. The single proteins were subjected
to analytical gel filtration at 1.11 μM (ceMUS81N) and 1.29 μM (ceSLX4SAP).
4.3.12 Static Light Scattering
In order to determine molecular weight and monodispersity of a protein sample static light scat-
tering experiments were carried out. Static light scattering experiments were performed by Dr.
Claire Basquin at the MPI for Biochemistry. In principle, the sample passes through a size ex-
clusion chromatography column, which is directly connected to a detector for light scattering
(LS), ultraviolet absorbance (UV) and refractive index (RI). Here, A¨KTA micro (GE Healtcare)
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was used as a chromatography system coupled to a TDA 302 detector (Viscothek, now Malvern
Pananalytical, Kassel, Germany) monitoring refractive index and right angle scattering. The pro-
tein samples (xx) were either injected onto Superdex S200 5/150 or Superdex S75 5/150 GL (3 ml
column volume, GE Healtcare) column. As a standard bovine serum albumine was used and the
refractive index increment (dn/dc) was set to 0.185 ml/g for the calculations.
4.3.13 Analytical Ultracentrifugation
Sedimentation velocity experiments were performed in the Biochemistry Core Facility at Max-
Planck-Institute of Biochemistry by Susanne von Gronau and Dr. Stephan Uebel on an Optima
XL-I analytical ultracentrifuge (Beckman Inc., Palo Alto, CA, U.S.A.) using an An-60 Ti rotor
and double-sector epon centerpieces. The single protein constructs ceSLX4SAP and ceMUS81N
were submitted in 20 mM Bis-tris-Propane pH 7.5, 200 mM KCl, 1 mM TCEP (SEC 6) at
concentrations of 25 mg/ml (OD280 0.77) and 1.75 mg/ml (OD280 0.8), respectively. The complex
of both proteins was submitted at 3.2 mg/ml (OD280 0.87). Buffer density and viscosity was
measured with a DMA 5000 densitometer and an AMVn viscosimeter, respectively (both Anton
Paar, Graz, Austria). Protein concentration distribution was monitored at 280 nm at 50,000 rpm
and 10◦C. Time-derivative analysis was computed with the SEDFIT package, version 12.1b [323],
resulting in a c(s) distribution and an estimate for the molecular weight Mf from the sedimentation
coefficient and the diffusion coefficient, as inferred from the broadening of the sedimentation
boundary, assuming that all observed species share the same frictional coefficient f/f0.
4.3.14 Thermal Shift Assay
For Thermofluor 100 μM ceMUS81N was mixed with 5 - 500 μM ceSLX4SAP in a total volume
of 50 μl of SEC 9 buffer supplemented with 3 mM TCEP. The reaction mixtures were incubated
for 1h on ice. Afterwards the protein complexes were mixed with 1μ l 1:10 Sypro Orange dye
(5000x, Invitrogen) in a 96-well PCR plate (Eppendorf). The plate was sealed and heated in a
real-time PCR system (Eppendorf) from 20◦C to 80◦C applying increments of 0.5◦C. Changes in
fluorescence were observed simultaneously with excitation and emission wavelengths of 470 nm
and 550 nm, respectively. To obtain the binding constant, a Boltzmann model was used to fit the
fluorescence data (Equation 4.4).
y = Top+
Bottom− Top
1 + e
x−KD
dx
(4.4)
The thermal shift measurements were carried out in quatruplets by Dr. Claire Basquin. The
dissociation constant was calculated from the average of the KDs from each of the four binding
isotherms.
4.3.15 Fluorescence Anisotropy
Fluorescence Anisotropy is a method to monitor the binding interaction of two species applying
equilibrium titration experiments and relies on the change in anisotropy when two species are
interacting. The anisotropy is measured as the difference in polarization along different axes of
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the fluorophore, applying 5’-6-carboxy-fluorescein (5’-FAM)-labeled Holliday Junction, (HJ with
16bp armlengths), nicked Holliday Junction (HJ with 16 bp armlength and nick at 2 bp from the
junction point on the exchanging strand) and 32 bp dsDNA (Table 4.28). Fluorescence anisotropy
measurements were carried out at room temperature with Infinite M1000 Pro (Tecan, Ma¨nnedorf,
Switzerland) using Tecan i-Control software. The DNA substrates were used at a final concentra-
tion of 11.2 nM and were incubated at room temperature for 10 min with varying concentrations
of ceSLX4SAP and ceMUS81N alone as well as in complex using assay buffer (20 mM Potassium
chloride pH 6.5, 100 mM KCl and 1 mM TCEP). The excitation and emission wavelengths were
470 nm and 535 nm, respectively. Each titration point was measured three times with 10 reads at
an integration time of 40 μs. Measurements were made in triplicate. The data for ceSLX4SAP and
ceSLX4SAP-ceMUS81Nwere analyzed by non-linear regression using the Hill function (Equation
4.5) included in the program Origin (Origin Lab; http://www.originlab.com).
Atotal = A0 + (Amax −A0) x
n
kn + xn
(4.5)
Atotal is the measured anisotropy, A0 is the intrinsic anisotropy of the DNA substrate, Amax
is the anisotropy of the saturated protein-DNA complex, n is the Hill coefficient and x is the
concentration of the protein. For ceMUS81N a two-site binding mode was assumed and curves
were fit with equation 4.6.
Atotal =
Amax1 · x
k1 + x
+
Amax2 · x
k2 + x
(4.6)
Atotal is the measured anisotropy, Amax1 is the maximal anisotropy for the first binding site, Amax2
is the maximal anisotropy for the second binding class and x is the concentration of the protein.
To assess the quality of the non-linear regression, residual plot analysis was performed and the
agreement between the observed and calculated binding isotherms was evaluated.
4.3.16 Nano Differential Scanning Fluorimetry
Nano differential scanning fluorimetry (nanoDSF) is a method to determine protein stability by
testing different buffers using the intrinsic fluorescence of tryptophan and tyrosine residues in a
protein. The fluorescence of Trp and Tyr residues is used as a measure for protein stability. For
the experiment, the protein with an end concentration of 0.5 mg/ml was mixed with the buffer
in a volume of 10 μl. Different buffer substances, pH values and salt concentrations were tested.
Samples were taken up into Prometheus NT.48 glass Capillaries (Nanotemper Technologies GmbH,
Munich, Germany). Measurements were carried out on a Prometheus NT.48 by Nanotemper
TEchnologies GmbH (Munich, Germany) with a laser intensity of 30 % scanning a temperature
range from 20 - 90◦C with a ramp of 1◦C / min. The ratio of fluorescence at 350 and 330 nm was
plotted against the temperature using the program PR.ThermControl (Nanotemper Technologies
GmbH). The melting temperature of the proteins was determined for each tested condition by
the minimum or maximum of the peak of the first derivative. For the crystallization trials of
the ceSLX4SAP constructs buffer conditions with low melting temperature and thus low protein
stability were applied.
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4.3.17 Crystallization Procedures
Initial Screening
Protein samples were purified and subjected alone or in complex with various DNA substrates for
crystallization. The design of the DNA substrates was based on the 16bp arm length Holliday
Junction as used for EMSAs (see Table 4.28). For the screening of the HJ arm length the length
of the single oligos was varied keeping either four-fold symmetry or two-fold symmetry. Initial
crystallization experiments were performed in 96 well sitting drop plates using commercially avail-
able or self-made screens. For initial screening, 100 nl protein solution was mixed with 100 nl
reservoir solution using a Phenix nanodispenser robot (Art Robbins Instrument, Sunnyvale, CA,
USA). Initial hits were optimized in 96-well sitting drop plates or in 72-well Terasaki microbatch
plates (Molecular Dimension, Newmarket, Suffolk, UK). The crystallization plates except for the
microbatch plates were automatically imaged by the imaging system of the crystallization facility
(Max-Planck Institute for Biochemistry, Martinsried). The initial screening plates as well as deep
well plates with screening buffer conditions were set up by Dr. Karina Valer-Saldan˜a or Sabine
Pleyer from the Crystallization Facility (MPIB). Crystal hits were checked for protein content
with the UV fluorescence microscope JANSi UVEX-m scanning in near UV (300 - 400 nm) zone.
Microbatch under oil crystallization experiments were carried out for example for the complex
of ceEME1161-454-ceMUS81K270M-ceSLX4467-606 with various DNA substrates tested. Drops of
1 μl protein sample with 1 μl reservoir were setup under a layer of 50% paraffin oil and 50%
silicone oil in 72-well Terasaki microbatch plates (Molecular Dimensions, Newmarket, UK).
To reduce vapor diffusion, oil was layered on the reservoir of 96-well sitting drop crystallization
trials. For each reservoir, 70 μl of a mixture of 80% paraffin oil and 20% silicone oil was put on
the reservoir.
Matrix-Microseeding
Matrix-Microseeding was carried out according to protocol from Hampton Research Seed Bead
Kit and drops were setup with 50 nl seed stock, 150 nl protein and 200 nl reservoir. The primary
screening temperature was 20◦C, infrequently plates were set up at 4◦C.
Formulation Buffer Screening
The C. elegans SLX4 constructs of the C-terminus expressed very well and the proteins were highly
soluble after purification. Thus, high protein concentrations could be achieved for crystallization
which lead to difficulties with pipetting when setting up crystallization trials. Therefore different
formulation buffers were tested in a nanoDSF experiment (see Section 4.3.16).
Cryo-Protection
For cryo-protection, 0.5 μl cryo-protectant (list of cryo-protectant used, see Table 4.29) was added
to the drop with the corresponding crystals and in subsequent steps another 1 and 2 μl cryoprotec-
tant was added. In the end, the crystals were in the respective cryo-protectant and were picked up
from the cryo-protectant solution using nylon cryo-loops with suitable size (Hampton Research,
Aliso Viejo, CA, USA) and plunged into liquid nitrogen.
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Table 4.29: List of the respective cryoprotectants used for the protecting the crystals at the synchrotron.
Protein-DNA Complex Cryo-Protectant Solution
hsEME1178-570-MUS81241-551 + 17-5’flap 30% ethylene glycol, 0.1 M Mes pH 6.5, 5.5%
ethanol
ceEME1161-454-MUS81K270M + ceSLX4467-606 + 4w4xn16n1 20 % PEG 3350, 0.2 M Calcium acetate, 34%
glycerol
ceEME1161-454-MUS81D268A + ceSLX4467-606 + 4w4xn17n3 1.4 M Sodium/Potassium Phosphate, 0.1 M
Sodium Malonate, 25% glycerol
ceEME1161-454-MUS81D268A + ceSLX4467-606 + 4w4x17n3 27% PEG MME500 0.1 M Bis-Tris pH 5.5, 0.05
M Magnesium chloride, 17.5% glycerol
ceMUS811-140 50mM Tris pH 8, 0.2M Magnesium chloride,
35% PEG3350, 15% glycerol
Data Collection
Data of the plunged crystals were collected at 100◦K at the Swiss Light Source (Villingen, Switzer-
land) by Dr. Jerome Basquin using the PXIII beamline and a MarCCD detector.
Molecular Replacement
The data obtained from PXIII beamline was processed using XDS [324]. Molecular replacement
was carried out using Phaser [318] and the published structure of hsMUS81-EME1 bound to DNA
substrate (protein data base entry 4P0P) as a search model. Refinement was carried out using
Phenix [319]. The model was visualized and compared to the published structure applying coot
[313].
4.3.18 NMR Spectroscopy
Sample Preparation
Proteins were expressed in M9 minimal medium supplemented with 15N ammonium chloride, 0.4%
glucose, 1 mM MgSO4, 0.3 mM CaCl2, 1 μ g biotin, 1 μ g thiamin and 1x trace elements solution
(0.134 mM EDTA, 31 μ mM FeCL3-6h2, 0.62 μ M ZnCl2, 0.76 μM CuCl2-2H2O) according to
the protocol by Dr. Arie Geerlof, Helmholtz Center Munich. Bacterial cells transfected with the
respective plasmid were plated on agar plates containing appropriate antibiotics. A 20 ml overnight
pre-culture in LB medium was grown and cells were pelleted for 10 min at 3220 g. The supernatant
was discarded and the cell pellet was washed with 5 ml sterile water and resuspended in M9 media.
The bacterial cells were grown until OD600 0.8 at 37
◦ C. Afterwards, the temperature was reduced
to 20◦ C and the bacterial cells were induced with the respective amount of IPTG. Cells were
harvested like in section 4.2.2 and purification was carried out like described for ceSLX4SAP and
ceMUS81N, except after Ni TED column the elution fraction was cleaved over night and then
subjected to cation exchange on a SP-Sepharose column and gel filtration with buffer SEC 9. The
labelled proteins were concentrated to amounts of higher than 300 μM and supplemented with
10% heavy water D2O. Proteins with
15N-13C label were expressed in M9 medium as well, but in
addition glucose was replaced by 13C-glucose.
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NMR Experiments
NMR experiments were carried by Dr. Andre´ Moura˜o at the Helmholtz Center Munich. NMR
spectra were acquired at 298 K on a Bruker Avance III 600 and 800-MHz equipped with a cry-
oprobe. The protein samples were measured in 3 mm NMR tubes. Data analysis was performed
using NMRPipe. 1H, 15N and 13C backbone resonance assignments were obtained from the fol-
lowing experiments: HNCO, HNCA, HNCACB, CBCACONH and 15N-NOESY experiments were
carried out.
Chemical Shift Perturbations
Chemical shift perturbations were performed with 110 μM 15N-labelled ceSLX4SAP or 15N-labelled
ceMUS81N in a two dimensional 15N-1H- HSQC (heteronuclear single quantum coherence) exper-
iment. In this experimental setup each amino acid residue (except for proline) is described by
one peak in the spectrum. Each peak is defined as amide 15N shift (ω1) and 1H shift (ω2). The
chemical shift of a peak depends on the chemical surrounding of the amino acid amide group.
Furthermore, the side chain amides of glutamate and asparagine are represented in the spectrum.
Ideally, a folded protein will generate a 15N-1H- HSQC spectrum with a broad distribution of
well separated signals. When a ligand binds to the protein, the environment of a spin will change
and this change gives rise to chemical shift changes in the NMR spectrum. Residues involvded
in ligand binding are expected to display a larger chemical shift than residues more far a away.
Through these changes the interface of a protein can be mapped.
Chemical shift perturbations obtained from 1H-15N HSQC titrations were calculated based on
the equation:
∆δ =
√
(∆δ1H)2 +
(
∆δ15N
6
)2
(4.7)
Δδ1H and Δδ15N are the 1H and 15N chemical shift in parts per millions.
4.3.19 Structural Model Calculation
The calculation of the structural model was carried out by Dr. Andre´ Moura˜o at the Helmholtz
Center Munich similar to a an already published approach [332]. A structural model for ceSLX4SAP
was calculated using the Chemical-Shift-ROSETTA (CS-ROSETTA Version 4.8) server from the
Biological Magnetic Resonance Data Bank Rosetta. CS-ROSETTA is a tool for de novo pro-
tein structure generation, using 1H, 15N and 13C chemical shifts as input. CS-ROSETTA em-
ploys SPARTA-based selection of protein fragnents from the PDB, in conjunction with a regular
ROSETTA Monte Carlo assembly and relaxation procedure, to generate structures of minimized
energies. The NMR model was visualized and analyzed using pymol [322].
Structure Alignment
For structural comparison the Dali tool was applied and the ceSLX4SAP NMR model was searched
against all known structures [276, 277]. A DALI search [276] for all 10 models retrieved in total
147 entries with 58 unique entries. Eight entries with Z-scores higher than 3 and similar biological
function were analyzed closer. Structural superimpositions and sequence alignments were carried
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out with Dali [276]. For the molecules 1jeg, 4rec, 1zbh, 2do1 and 4uzw the structural alignment was
further optimized by Pymol using the command align. Molecular representations were generated
using the Pymol software [322]. Electrostatic surface potentials were calculated with PDB2PQR
[317] and APBS [311].
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Abbreviations
53BP1 p53-binding protein 1
A Alanine
aa Amino acid
AEBSF 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride
AEX Anion exchange chromatography
AP Alkaline Phosphatase
APLF Aprataxin and polynucleotide kinase/phosphatase-like factor
ATM Ataxia telangiectasia mutated
ATP Adenosine triphosphate
ATR ATM and Rad3-related
ATRIP ATR interacting protein
BER Base excision repair
BIR Break-induced repair
BLM Boom syndrome RecQ-like helicase
β-ME β-mercaptoethanol
BRCA breast cancer susceptibility protein 1
BSA Bovine serum albumin
BTB Bric a brac, Tramtrack, Broad-complex
BTP 1,3-bis(tris(hydroxymethyl)methylamino)propane
CCD conserved C-terminal domain
Cdc Cell division cycle
CDK Cyclin-dependent kinase
ce Caenorhabditis elegans
C. elegans Caenorhabditi elegans
CHK2 Checkpoint kinase 2
CPD Cysteine protease domain
CtBP CtBP C-terminal binding protein
CtIP CtBP-interacting protein
DDR DNA damage response
D-loop Displacement loop
DNA Deoxyribonucleic acid
dNTP Deoxynucleotide triphosphate
Dpb11 DNA polymerase B II
ds Double-stranded
DSB Double-strand break
DTT Dithiothreitol
E Glutamate
EDTA Ethylenediaminetetraacetic acid
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EME1 Essential meiotic endonuclease 1
EMSA Electrophoretic mobility shift assay
ERCC Excision repair cross complementation group
ESI-TOF MS Electron spray ionization - time of flight mass spectrometry
FA Fanconi anemia
FAAP24 FA-associated protein 24 kDa
FAM Fluorescein amidite
FAN1 FANCD2-associated nuclease 1
FANCD2 Fanconi anemia complementation group D2
FANCM Fanconi anemia complementation group M
Fast-AP Fast alkaline phosphatase
FCS Fetal calf serum
FEN1 Flap endonuclease
FL Full length
GEN Gap endonuclease
GFP Green fluorescent protein
Hepes 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HhH Helix-hairpin-helix
HIM High incidence of males
HR Homologous recombination
ICL Interstrand crosslink
IMAC Immobilized metal ion affinity chromatography
IP Interacting protein
IPTG Isopropyl-β-D-thiogalactopyranoside
ITC Isothermal titration calorimetry
KCl Potassium chloride
KD Dissociation constant
LIC Ligase independent cloning
MEI meiotic protein
MES 2-(N-morpholino)ethanesulfonic acid
MgCl2 Magnesium chloride
MgSO4 Magnesium sulfate
MLR MUS312-MEI9 interaction-like region
MMEJ Microhomologoy mediated end joining
MMR Mismatch Repair
MMS Methyl methane sulfonate
Mms4 methyl methane sulfonate sensitive 4
MPIB Max-Planck Institute for Biochemistry
MRE11 Meiotic recombination 11
MRN MRE11-RAD50-NBS1
MS Mass spectrometry
MSH MutS homolog
MUS81 Methyl methanesulfonate UV sensitive, clone 81
MutS Mutator S
NaCl Sodium chlorid
NBS1 Nijmegen breakage syndrome 1
NER Nucleotide excision repair
NHEJ Non-homologous end joining
Ni Nickel
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NP40 Nonidet P-40, octylphenoxypolyethoxyethanol
nt Nucleotide
NTA Nitrolotriacetic acid
PAGE Polyacrylamide gel electrophoresis
PARP Poly(ADP-ribose) polymerase
RAD Radiation sensitive
RIF1 Replication timing regulator factor 1
RING Really interesting new gene
RPA Replication protein A
PALB2 Partner and localizer of BRCA2
PBS Phosphate buffered saline
PCNA Proliferative cell nuclear antigen
PCR Polymerase chain reaction
PEI Polyethyleneimde
PEG Polyethylene glycol
pI isoelectric point
PKcs Protein kinase catalytic subunit
PLK1 Polo like kinase 1
pol Polymerase
PPT Phosphatase
RAG Recombination activating gene
RF Replication fork
RING Really interesting new gene
RMI RecQ mediated genome instability protein
RPA Replication protein A
rpm Revolutions per minute
RTEL Regulator of telomere length
Rtt107 Regulator of Ty1 transposition protein 107
Ruv Resistance to UV light
SAF Scaffold attachment factor
SAP SAF-A/B, Acinus and PIAS domain
S. cerevisiae Saccharomyces cerevisiae, budding yeast
SDS Sodium dodecyl sulfate
SDSA Synthesis-depedent strand annealing
SEC Size exclusion chromatography
Sgs Slow growth suppressor
SIM SUMO-interacting motif
SLX Synthetic lethal of unknown function
SM SLX4-SLX1-MUS81-EME1
S. pombe Schizosaccharomyces pombe, fission yeast
ss Single-stranded
SSA Single-strand annealing
SSBR Single-strand break repair
SUMO Small ubiquitin modifier
TAE Tris-acetate-EDTA
TLS Translesion synthesis
Top Topoisomerase
TOPBP1 DNA topoisomerase 2 binding protein
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Tris Tris(hydroxymethyl)aminomethane, 2-Amino-2-(hydroxymethyl)-
propane-1,3-diol
TRF Telomeric repeat-binding factor
UBZ Ubiquitin-binding zinc finger domain
UV Ultraviolet
VDJ Variable diverse joining
VPA Valproic acid
WH Winged helix
XLF XRCC4-like factor
XPF Xeroderma pigmentosum complementation group F
XPG Xeroderma pigmentosum complementation group G
X-ray Ro¨ntgen radiation
XRCC X-ray cross complementation chinese hamster gene
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Figure 4.1: See next page for figure legend
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Figure 4.1: See next page for figure legend
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Figure 4.1: Multiple sequence alignment of SLX4 orthologs. Dark blue indicates strictly conserved residues,
white indicates variable residues. The orthologs were aligned with MUSCLE [215] and displayed using Jalview
[216]. Secondary structure elements are indicated by red bars (alpha-helical) and green arrows (beta-sheets) and
were calculated using Jpred [325]. The alignment shows the sequences of Homo sapiens (hs), Mus musculus
(mm), Xenopus leavis (xl), Danio rerio (dr) and Caenorhabditis elegans (ce). Uniprot accession numbers [217]
from top to bottom: Q8IY92, Q6P1D7, A0A068EUV4, F1QPU2 and Q22145.
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Figure 4.2: Multiple sequence alignment of SLX1 orthologs. Dark blue indicates strictly conserved residues,
white indicates variable residues. The black box indicates the GIY-YIG domain. The orthologs were aligned
with MUSCLE [215] and displayed using Jalview [216]. Secondary structure elements are indicated by red bars
(alpha-helical) and green arrows (beta-sheets) and were calculated using Jpred [325]. The alignment shows the
sequences of Homo sapiens (hs), Mus musculus (mm), Xenopus leavis (xl), Danio rerio (dr), Caenorhabditis
elegans (ce), Shizosaccharomyces pombe (sp) and Saccharomyces cerevisiae (sc. Uniprot accession numbers
[217] from top to bottom: Q9BQ83, Q8BX32, Q0IH86, A0A0R4IAZ1, P91351, Q9P7M3 and P38324.
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Figure 4.3: See next page for figure legend
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Figure 4.3: Multiple sequence alignment of MUS81 orthologs. Dark blue indicates strictly conserved
residues, white indicates variable residues. The black box indicates the ERCC4 domain. The orthologs were
aligned with MUSCLE [215] and displayed using Jalview [216]. Secondary structure elements for hsMUS81 are
indicated by red bars (alpha-helical) and green arrows (beta-sheets) and were calculated using Jpred [325]. The
alignment shows the sequences of Homo sapiens (hs), Mus musculus (mm), Xenopus leavis (xl), Danio rerio
(dr), Caenorhabditis elegans (ce), Shizosaccharomyces pombe (sp) and Saccharomyces cerevisiae (sc. Uniprot
accession numbers [217] from top to bottom: Q96NY9, Q91ZJ0, A0A068ER06, Q7SXA9, P91153, P87231
and Q04149.
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Figure 4.4: Multiple sequence alignment of EME1 orthologs. Dark blue indicates strictly conserved
residues, white indicates variable residues. The orthologs were aligned with MUSCLE [215] and displayed using
Jalview [216]. Secondary structure elements are indicated by red bars (alpha-helical) and green arrows (beta-
sheets) and were calculated using Jpred [325]. The alignment shows the sequences of Homo sapiens (hs),
Mus musculus (mm), Xenopus leavis (xl), Danio rerio (dr), Caenorhabditis elegans (ce), Shizosaccharomyces
pombe (sp) and Saccharomyces cerevisiae (sc. Uniprot accession numbers [217] from top to bottom: Q96AY2,
Q8BJW7, A9ULX4, E7F6N8, Q9GZG5, Q9C103 and P38257.
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Figure 4.5: Degradation of hsSLX41300-1834 after IP6 cleavage. hsSLX41300-1834 was expressed with a CPD-
tag in bacterial cells. After induction of CPD-cleavage protein samples of 18 μg were taken every half an hour
(0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 4 h). In Input sample
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Figure 4.6: Possible cleavage sites of the CPD protease on hsSLX41300-1834 The cysteine protease domain
(CPD) is activated upon upon addition of IP6 and undergoes cleavage at the P1 Leu site. As the construct
hsSLX41300-1834 showed degradation bands upon CPD activation, sites of Leu residues were counted to 39 and
analyzed regarding the consensus sequence. The most common residues at P2 position (A, G, S or W [252])
were marked red and sum up to nine sites. The chemically similar residue to W was marked in orange. Residues
which did not correspond the consensus sequence were not marked.
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Figure 4.7: Phosphorylation sites in scSLX4. Phosphorylation site S486 is cell cycle regulated by CDK. The
other phosphorylation sites are induced through DNA damage by Mec1. Adopted from [261].
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Table 4.30: Structural comparison of ceSLX4SAP using Dali server showed 147 entries for other
proteins containing a SAP domain. The entries, which were used for further comparison, are marked in
red. This table resembles the output retrieved from the Dali server. No. refers to the number in the Dali
hit list. PDB and chain gives the protein database number and the chain of the respective molecule. The
Z-score is a measure for the homology of the structures. A Z-score above means that the structures are
definitely homologous, between 8 and 20 the two structures are probably homologous, between 2 and 8
there is a grey area. A Z-score below 2 is not significant [277]. The rmsd gives information about the
root-mean-square deviation of the Cαatoms in superposition. The number of the structurally equivalent
positions is abbreviated by lali. Nres gives the number of total residues in the molecule chain. % id gives
the percentage of amino acid identity in the aligned positions.
No. PDB and Chain Z-
Score
rmsd
(A˚)
lali nres %
id
Description
1 2a8v-C 4.5 3.7 52 118 13 RNA BINDING DOMAIN OF RHO TRANSCRIPTION
2 1xpu-D 4.4 3.7 50 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
3 1pvo-C 4.3 3.7 50 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
4 1xpu-E 4.3 3.7 51 407 14 RHO TRANSCRIPTION TERMINATION FACTOR
5 1xpu-B 4.3 3.8 51 408 14 RHO TRANSCRIPTION TERMINATION FACTOR
6 5jji-C 4.2 3.5 51 417 14 TRANSCRIPTION TERMINATION FACTOR RHO
7 5jjl-C 4.1 3.8 52 415 13 TRANSCRIPTION TERMINATION FACTOR RHO
8 1xpr-E 4.1 3.8 50 407 12 RHO TRANSCRIPTION TERMINATION FACTOR
9 2do1-A 4.0 3.3 46 55 17 NUCLEAR PROTEIN HCC-1
10 1zbh-D 4.0 4.1 47 289 15 3’-5’ EXONUCLEASE ERI1
11 1a62-A 4.0 3.5 52 125 12 RHO
12 1zbh-A 3.9 3.7 47 289 15 3’-5’ EXONUCLEASE ERI1
13 1pv4-A 3.9 3.4 50 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
14 4uzw-A 3.8 5.1 46 50 15 PROTEIN THO1
15 3ice-D 3.8 3.6 48 410 15 TRANSCRIPTION TERMINATION FACTOR RHO
16 1pv4-C 3.8 3.7 50 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
17 1pv4-D 3.7 3.6 50 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
18 1xpu-A 3.7 3.4 50 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
19 3ice-C 3.6 3.6 51 413 10 TRANSCRIPTION TERMINATION FACTOR RHO
20 3ice-B 3.6 3.8 47 408 15 TRANSCRIPTION TERMINATION FACTOR RHO
21 1xpu-C 3.6 3.7 50 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
22 1a63-A 3.6 3.4 51 130 12 RHO
23 2hjq-A 3.4 4.0 49 111 12 HYPOTHETICAL PROTEIN YQBF
24 5jjk-C 3.4 3.9 48 411 15 TRANSCRIPTION TERMINATION FACTOR RHO
25 5jjk-A 3.4 4.0 47 405 15 TRANSCRIPTION TERMINATION FACTOR RHO
26 5jjl-D 3.4 3.9 47 406 15 TRANSCRIPTION TERMINATION FACTOR RHO
27 5jjk-D 3.4 3.8 47 405 15 TRANSCRIPTION TERMINATION FACTOR RHO
28 5jji-D 3.3 3.9 47 406 15 TRANSCRIPTION TERMINATION FACTOR RHO
29 2kw9-A 3.3 4.0 51 75 20 MKL/MYOCARDIN-LIKE PROTEIN 1
30 4rec-A 3.3 2.8 42 593 19 FANCONI-ASSOCIATED NUCLEASE 1
31 1pvo-A 3.2 3.5 51 408 14 MOLECULE: 5’-R(P*UP*C)-3’
32 2kvu-A 3.2 2.5 45 75 22 MKL/MYOCARDIN-LIKE PROTEIN 1
33 4reb-H 3.2 2.7 42 584 19 FANCONI-ASSOCIATED NUCLEASE 1
34 4ria-B 3.2 2.4 43 613 12 FANCONI-ASSOCIATED NUCLEASE 1
35 1v66-A 3.1 1.9 40 65 13 PROTEIN INHIBITOR OF ACTIVATED STAT PRO-
TEIN 1
36 1jeq-A 3.1 2.4 42 548 21 KU70
37 2wqg-A 3.1 2.9 41 51 20 THO1
38 2gwm-A 3.1 2.6 49 200 8 65 KDA VIRULENCE PROTEIN
39 4rea-A 3.1 2.5 41 590 20 FANCONI-ASSOCIATED NUCLEASE 1
40 3nts-A 3.0 2.7 49 185 2 VSDC
41 1xpr-F 3.0 3.9 49 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
42 1xpo-A 3.0 3.9 50 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
43 3d3q-B 3.0 2.4 42 303 7 TRNA DELTA(2)-ISOPENTENYLPYROPHOSPHATE
TRANSFERAS
44 3d3q-A 3.0 2.4 42 307 7 TRNA DELTA(2)-ISOPENTENYLPYROPHOSPHATE
TRANSFERAS
45 2do5-A 2.9 2.4 40 58 15 SPLICING FACTOR 3B SUBUNIT 2
46 4fml-B 2.9 2.6 49 196 2 VSDC
47 5v2o-E 2.9 2.8 42 60 14 TP2
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rmsd
(A˚)
lali nres %
id
Description
48 3c95-A 2.9 2.9 42 446 14 EXODEOXYRIBONUCLEASE I
49 4fml-A 2.8 2.7 49 204 2 VSDC
50 3nts-B 2.8 2.6 49 189 2 VSDC
51 5hy7-D 2.8 3.3 43 55 14 PUTATIVE PRE-MRNA SPLICING PROTEIN
52 2yu0-A 2.8 2.7 47 94 2 INTERFERON-ACTIVABLE PROTEIN 205
53 4ric-B 2.8 2.4 43 628 12 FANCONI-ASSOCIATED NUCLEASE 1
54 4ric-A 2.8 2.4 43 615 12 FANCONI-ASSOCIATED NUCLEASE 1
55 4rid-A 2.8 2.6 40 615 20 FANCONI-ASSOCIATED NUCLEASE 1
56 4js4-A 2.8 2.9 42 468 14 DT16 OLIGONUCLEOTIDE
57 3hp9-A 2.8 2.9 42 452 14 EXODEOXYRIBONUCLEASE I
58 2qxf-A 2.8 2.9 42 433 14 EXODEOXYRIBONUCLEASE I
59 1fxx-A 2.8 3.0 42 459 14 EXONUCLEASE I
60 2gwl-A 2.7 2.5 49 200 8 65 KDA VIRULENCE PROTEIN
61 5hy7-C 2.7 3.3 43 55 14 PUTATIVE PRE-MRNA SPLICING PROTEIN
62 5ue8-A 2.7 2.9 43 847 7 PROTEIN UNC-13 HOMOLOG A
63 1zrj-A 2.7 3.0 40 50 18 E1B-55KDA-ASSOCIATED PROTEIN 5 ISOFORM C
64 1a8v-B 2.7 3.6 52 116 12 TRANSCRIPTION TERMINATION FACTOR RHO
65 2qnc-B 2.7 2.9 40 157 18 T4 ENDONUCLEASE VII
66 1e7d-B 2.7 3.3 44 157 16 RECOMBINATION ENDONUCLEASE VII
67 2qnf-A 2.7 2.9 40 157 18 RECOMBINATION ENDONUCLEASE VII
68 4rib-B 2.7 2.8 40 628 20 FANCONI-ASSOCIATED NUCLEASE 1
69 4rid-B 2.7 2.6 40 628 20 FANCONI-ASSOCIATED NUCLEASE 1
70 3c94-A 2.7 2.9 42 458 14 EXODEOXYRIBONUCLEASE I
71 1gjj-A 2.6 2.3 43 93 9 LAP2
72 1h9e-A 2.6 2.5 46 56 7 LAMINA-ASSOCIATED POLYPEPTIDE 2
73 1pvo-F 2.6 3.8 51 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
74 1pvo-E 2.6 3.6 51 407 12 RHO TRANSCRIPTION TERMINATION FACTOR
75 1xpr-D 2.6 3.7 50 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
76 2a8v-A 2.6 3.7 52 118 13 RNA BINDING DOMAIN OF RHO TRANSCRIPTION
77 1a8v-A 2.6 3.7 52 115 12 TRANSCRIPTION TERMINATION FACTOR RHO
78 1en7-A 2.6 2.8 40 157 18 RECOMBINATION ENDONUCLEASE VII
79 2qnc-A 2.6 2.9 40 157 18 T4 ENDONUCLEASE VII
80 1en7-B 2.6 2.6 39 157 18 RECOMBINATION ENDONUCLEASE VII
81 2qnf-B 2.6 2.9 40 157 18 RECOMBINATION ENDONUCLEASE VII
82 4rib-A 2.6 2.4 43 615 12 FANCONI-ASSOCIATED NUCLEASE 1
83 4jrq-B 2.6 2.4 39 459 15 5CY-DA13
84 1e7d-A 2.5 3.0 41 157 17 RECOMBINATION ENDONUCLEASE VII
85 2ld7-A 2.5 4.2 44 94 11 HISTONE DEACETYLASE COMPLEX SUBUNIT
SAP30
86 5ife-B 2.5 3.2 43 66 16 SPLICING FACTOR 3B SUBUNIT 5
87 1e7l-A 2.5 3.3 42 157 17 RECOMBINATION ENDONUCLEASE VII
88 1e7l-B 2.5 3.4 42 157 17 RECOMBINATION ENDONUCLEASE VII
89 3l0o-A 2.5 3.8 43 413 21 TRANSCRIPTION TERMINATION FACTOR RHO
90 5muu-D 2.5 2.6 40 148 15 MAJOR INNER PROTEIN P1
91 5muu-L 2.5 2.6 40 148 15 MAJOR INNER PROTEIN P1
92 5muu-M 2.5 2.6 40 148 15 MAJOR INNER PROTEIN P1
93 5muu-F 2.5 2.6 40 148 15 MAJOR INNER PROTEIN P1
94 5muu-J 2.5 2.6 40 148 15 MAJOR INNER PROTEIN P1
95 5muu-I 2.5 2.6 40 148 15 MAJOR INNER PROTEIN P1
96 5muu-E 2.5 2.6 40 148 15 MAJOR INNER PROTEIN P1
97 5muu-H 2.5 2.6 40 148 15 MAJOR INNER PROTEIN P1
98 5muu-G 2.5 2.6 40 148 15 MAJOR INNER PROTEIN P1
99 2eap-A 2.4 3.2 45 90 9 LYMPHOCYTE CYTOSOLIC PROTEIN 2;
100 1su8-A 2.4 3.5 42 633 12 CARBON MONOXIDE DEHYDROGENASE 2
101 1jjr-A 2.4 2.3 38 54 18 THYROID AUTOANTIGEN
102 1suf-A 2.4 5.2 44 633 11 CARBON MONOXIDE DEHYDROGENASE 2
103 1pv4-F 2.4 3.7 50 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
104 1pvo-D 2.4 3.8 51 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
105 1jei-A 2.4 2.4 37 53 5 EMERIN
106 2a8v-B 2.4 3.5 52 118 12 RNA BINDING DOMAIN OF RHO TRANSCRIPTION
107 4rea-B 2.4 2.8 42 588 19 FANCONI-ASSOCIATED NUCLEASE 1
108 4ria-A 2.4 3.1 42 613 19 FANCONI-ASSOCIATED NUCLEASE 1
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(A˚)
lali nres %
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Description
109 4ri8-B 2.4 3.1 42 615 19 FANCONI-ASSOCIATED NUCLEASE 1
110 4ri8-A 2.4 3.1 42 615 19 FANCONI-ASSOCIATED NUCLEASE 1
111 4ri9-B 2.4 3.1 42 615 19 FANCONI-ASSOCIATED NUCLEASE 1
112 4ri9-A 2.4 3.1 42 615 19 FANCONI-ASSOCIATED NUCLEASE 1
113 4jrq-A 2.4 3.0 40 460 15 5CY-DA13
114 4xrm-B 2.3 3.2 45 64 7 TRANSCRIPTION FACTOR MEIS1
115 1h1j-S 2.3 2.4 38 44 16 THO1 PROTEIN
116 5v2o-F 2.3 2.5 41 60 15 TP2
117 2ooc-B 2.3 4.3 51 105 6 HISTIDINE PHOSPHOTRANSFERASE
118 4f3l-A 2.3 4.2 40 319 15 BMAL1B
119 4up8-A 2.3 4.9 46 580 7 LYSINE–TRNA LIGASE
120 5uzu-B 2.2 2.7 41 68 10 UNCHARACTERISED PROTEIN OF S. aureus
121 1hwz-A 2.2 4.1 42 501 0 GLUTAMATE DEHYDROGENASE
122 1xpu-F 2.2 3.8 50 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
123 3iz6-Q 2.2 4.3 43 141 7 40S RIBOSOMAL PROTEIN RACK1
124 1xpo-C 2.2 3.6 51 408 12 RHO TRANSCRIPTION TERMINATION FACTOR
125 5sy5-D 2.2 4.1 40 283 25 ARYL HYDROCARBON RECEPTOR NUCLEAR
TRANSLOCATOR
126 1uyr-A 2.2 3.5 42 698 12 ACETYL-COA CARBOXYLASE
127 2xan-A 2.2 3.1 35 414 9 INOSITOL-PENTAKISPHOSPHATE 2-KINASE
128 2hm2-Q 2.2 3.2 42 89 12 PYRIN-ONLY PROTEIN 1
129 4aya-A 2.1 4.2 42 59 10 DNA-BINDING PROTEIN INHIBITOR ID-2
130 2yr4-A 2.1 3.8 41 674 7 PRO-ENZYME OF L-PHENYLALANINE OXIDASE
131 4myz-B 2.1 2.6 32 52 13 CURK, CURL FUSION PROTEIN
132 4ams-A 2.1 2.9 41 367 10 MG662
133 1zs4-A 2.1 3.2 44 82 9 bacteriophage lambda cII protein
134 2bbz-A 2.1 3.3 46 190 11 VIRAL CASP8 AND FADD-LIKE APOPTOSIS REGU-
LATOR
135 2woo-A 2.1 2.6 43 303 5 ATPASE GET3
136 3u5v-A 2.1 4.8 40 62 8 PROTEIN MAX, TRANSCRIPTION FACTOR E2-
ALPHA CHIMER
137 1lyl-A 2.1 3.2 39 482 13 LYSYL-TRNA SYNTHETASE (LYSU)
138 4lk1-F 2.0 3.7 44 542 5 DNA-DIRECTED RNA POLYMERASE SUBUNIT AL-
PHA
139 5jh0-D 2.0 3.2 39 157 5 ARS-BINDING FACTOR 2, MITOCHONDRIAL
140 2rno-A 2.0 3.1 43 110 21 PUTATIVE DNA-BINDING PROTEIN
141 1l6n-A 2.0 3.2 44 288 2 GAG POLYPROTEIN
142 2ko6-A 2.0 2.8 41 89 12 UNCHARACTERIZED PROTEIN YIHD
143 2zm5-A 2.0 2.6 40 306 10 TRNA DELTA(2)-ISOPENTENYLPYROPHOSPHATE
144 2do9-A 2.0 3.1 46 115 13 NACHT-, LRR- AND PYD-CONTAINING PROTEIN 10
145 2dbg-A 2.0 3.5 48 103 4 MYELOID CELL NUCLEAR DIFFERENTIATION
ANTIGEN
146 4o7q-A 2.0 3.3 49 94 8 INTERFERON-INDUCIBLE PROTEIN AIM2
147 5jqe-A 2.0 3.1 43 544 9 SUGAR ABC TRANSPORTER SUBSTRATE-BINDING
PROTEIN
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Figure 4.8: Cleavage activity of ceMUS81 towards DNA substrates. Nuclease activity of ceMUS81
expressed and purified alone was tested with different DNA substrates and Mg2+ or Mn2+ as cofactor. 40 nM
5’FAM labeled substrate was mixed with 640 nM enzyme and incubated for 30 min at 37◦C. The reaction
products were separated on a native 8% TB-PAGE and analyzed with a phosphoimager.
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Figure 4.9: Cleavage activity of ceMUS81-ceEME1-ceSLX4SAP complexes (A) Nuclease activity of
ceMUS81-EME1 in presence and absence of ceSLX4SAP in presence of Mg2+. (B) Quantification of the nuclease
assay carried out with different DNA substrates and Mg2+ as cofactor. (C) Nuclease activity of ceMUS81-EME1
in presence and absence of ceSLX4SAP in presence of Mn2+. (B) Quantification of the nuclease assay carried out
with different DNA substrates and Mn2+ as cofactor. The bar chart shows the percentage of product formation
quantified by using ImageJ. The leftover uncut DA substrate was normalized against the control substrate and
product formation was calculated from the difference. The error bars depict the standard deviation from three
independent experiments.
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